Kit, device, and method for detecting ovarian tumor

Abstract

To provide a kit or a device for detection of ovarian tumor, and a detection method.SOLUTION: The present invention provides a kit or a device for detection of ovarian tumor, comprising a nucleic acid(s) capable of specifically binding to a miRNA(s) in a sample from a subject, and a method for detecting ovarian tumor, comprising measuring the miRNA(s) in vitro.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a kit or device for detecting ovarian tumors, which is used to test whether a subject is affected with ovarian tumors and which comprises a nucleic acid capable of specifically binding to a specific miRNA or its complementary strand, and a method for detecting ovarian tumors, which comprises measuring the expression level of the miRNA using the nucleic acid. [Background technology]

[0002] The ovaries are female-specific reproductive organs that produce eggs, located one on each side of the uterus. The fallopian tubes carry eggs released from the ovaries to the uterus, where they are fertilized and implanted to develop into a fetus. The ovaries also secrete the female hormones estrogen and progesterone. Ovaries are known to be prone to tumor development, and ovarian tumors are broadly classified into superficial epithelial / stromal tumors, sex cord-stromal tumors, and germ cell tumors based on their origin. Ovarian tumors are classified as benign, borderline malignant, or malignant according to their malignancy potential; borderline malignant and malignant ovarian tumors are called ovarian cancer. According to the National Cancer Center's Cancer Control and Information Center, the incidence of ovarian cancer in Japan in 2012 was 9,384, or 1 in 87 Japanese women, and the number of deaths from ovarian cancer reached 4,840 in 2014. In the United States, it is said that one in 75 women will develop ovarian cancer, and the estimated number of women diagnosed with ovarian cancer in 2017 was 22,440, of which approximately 14,080 will die from the disease.

[0003] The stage of ovarian and fallopian tube cancer is determined by factors such as whether the tumor is unilateral or bilateral, and the presence and size of intraperitoneal dissemination, lymph node metastasis, and distant metastasis. Stages are classified as follows: IA, IB, IC (IC1, IC2, IC3), IIA, IIB, IIIA1, IIIA2, IIIB, IIIC, IVA, and IVB. The 5-year relative survival rate for ovarian cancer is highly dependent on the stage of the cancer, with reported rates of 92% for localized cancer, 73% for cancer in the surrounding area, and 29% for distant metastasis. Therefore, because early detection of ovarian cancer leads to improved survival, there is a strong need for methods that enable early detection.

[0004] Ovarian cancer is generally treated with surgery, but drug therapy may also be used depending on the stage of progression, metastasis, overall condition, and classification of the ovarian cancer. In particular, if early-stage ovarian cancer is found in stage I, it may be possible to perform surgery to remove only the ovary and fallopian tube on the side where the cancer was found, rather than the entire uterus, ovaries, and fallopian tube, allowing the woman to maintain her ability to have children in the future.

[0005] In addition, early ovarian cancer and benign ovarian tumors often have no symptoms, and even advanced ovarian cancer often only causes common symptoms such as abdominal bloating and pain, which can also be caused by other factors, making it difficult to detect ovarian tumors based on subjective symptoms. Although much research has been done on ovarian cancer screening tests, no significant results have been achieved, and the only methods that can actually be used are transvaginal ultrasound and the blood marker CA-125 test. Secondary tests for ovarian cancer include imaging tests such as ultrasound, CT scan, MRI, and PET / CT.

[0006] Although still in the research stage, as shown in Patent Documents 1 to 4 and Non-Patent Documents 1 to 3, there are reports that ovarian tumors can be detected based on the expression levels of microRNA (miRNA) in biological samples such as blood.

[0007] Specifically, Patent Document 1 discloses methods for detecting ovarian cancer and predicting the prognosis using miR-191, miR-24, miR-320, miR-328, miR-625-3p, miR-483-5p, miR-92a, miR-1290, etc. in plasma.

[0008] Patent Document 2 indicates that miR-135a-3 in the blood is a biomarker for gynecological cancer.

[0009] Patent Document 3 uses human tissue samples to show that miR-125a-3p, miR-211-3, and the like are biomarkers for ovarian cancer.

[0010] Patent Document 4 discloses a method for distinguishing between endometriosis and endometriosis-derived ovarian cancer or serous ovarian cancer using miR-191-5p, miR-652-5p, miR-744-5p, miR-1246, etc. in plasma.

[0011] Non-Patent Document 1 lists miR-92a, miR-128, miR-191-5p, miR-296-5p, miR-320a, miR-625-3p, and the like in the blood as circulating extracellular miRNAs associated with ovarian cancer.

[0012] Non-Patent Document 2 shows that, as a result of analyzing miRNAs derived from serum samples from patients with ovarian cancer, benign diseases, and healthy individuals using a next-generation sequencer, there are differences in the expression levels of miR-22, miR-45, etc.

[0013] Non-patent document 3 shows that miR-23a / b, miR-92, miR-125a, miR-296-5p, miR-320, miR-422a, miR-663a, etc. are present in the endoplasmic reticulum of body fluids of ovarian cancer patients.

[0014] Non-Patent Document 4 reports that the sensitivity of the blood marker CA-125 for detecting ovarian cancer was 77.4% and the specificity was 70.8%. [Prior art documents] [Patent documents]

[0015] [Patent Document 1] US Patent Application Publication No. 2016 / 0312301 [Patent Document 2] Japanese Patent Application Laid-Open No. 2010-154843 [Patent Document 3] Special Publication No. 2010-538610 [Patent Document 4] International Publication No. 2013 / 148151 [Non-patent literature]

[0016] [Non-Patent Document 1] Nakamura K. et al., 2016, Molecular Cancer. Vol. 15, (1): 48 [Non-patent document 2] Ji T. et al., 2014, Asian Pacific Journal of Cancer Prevention. Vol. 15, (4): 1739 [Non-patent document 3] Giusti I. et al., 2013, BioMed Research International. Vol. 2013, 703048 [Non-patent document 4] Kim YW. et al., 2012, PLoS One. Vol. 7, (9): e44960 Summary of the Invention [Problem to be solved by the invention]

[0017] An object of the present invention is to find a novel ovarian tumor marker and to provide a method for effectively detecting ovarian tumors using nucleic acids for detecting the marker.

[0018] Ovarian tumors are difficult to detect based on subjective symptoms, and only two screening methods for ovarian tumors are known: transvaginal ultrasound and tumor marker CA-125 testing. While transvaginal ultrasound can detect tumors using ultrasound from within the vagina, the ultrasound's range is limited, potentially preventing detection of tumors located far from the vagina. CA-125 is a blood protein that is said to be elevated in patients with ovarian tumors. However, this is often due to reasons unrelated to ovarian tumors, and some patients with ovarian tumors do not experience elevated CA-125 levels, making the CA-125 test an ineffective screening test. As noted above, Non-Patent Document 4 reports that CA-125 has a sensitivity of 77.4% and a specificity of 70.8% for detecting ovarian cancer.

[0019] It has also been found that performing transvaginal ultrasound and tumor marker CA-125 testing does not lead to a reduction in the mortality rate from ovarian cancer.

[0020] Furthermore, although still in the research stage, there have been reports of identifying ovarian tumors using the expression levels of miRNA in biological samples such as blood, as described below, but none of these have yet been put to practical use.

[0021] Patent Document 1 discloses methods for detecting ovarian cancer and predicting prognosis using miRNAs such as miR-191, miR-24, miR-320, miR-328, miR-625-3p, miR-483-5p, miR-92a, and miR-1290 in plasma, but these miRNAs are also expressed in control groups, making them unsuitable for detecting the presence or absence of ovarian cancer. Furthermore, the number of samples tested was limited to only a few dozen cases, making the markers unreliable.

[0022] Patent Document 2 discloses miRNAs such as miR-135a-3 in the blood as biomarkers for gynecological cancer, but only discloses differences in miRNA expression related to uterine cancer and does not describe the detection performance, such as specific accuracy, sensitivity, and specificity, for distinguishing ovarian cancer, making it of little industrial practical use.

[0023] Patent Document 3 uses human tissue samples to show that miRNAs such as miR-125a-3p and miR-211-3 are biomarkers for ovarian cancer, but obtaining tissue samples requires surgical tissue resection, which places a heavy physical burden on patients and is therefore undesirable as a testing method. Furthermore, there is no description of the specific detection performance, such as accuracy, sensitivity, and specificity, for identifying ovarian cancer, making this method of industrial practicality poor.

[0024] Patent Document 4 discloses a method for distinguishing between endometriosis and endometriosis-derived ovarian cancer or serous ovarian cancer using miRNAs such as miR-191-5p, miR-652-5p, miR-744-5p, and miR-1246 in plasma, but does not disclose how to distinguish between ovarian cancer and other cancers, so there is a risk of mistakenly detecting other cancers as ovarian cancer. Furthermore, the number of samples tested was limited to only a few dozen cases, making the markers less reliable.

[0025] Non-Patent Document 1 lists miR-92a, miR-128, miR-191-5p, miR-296-5p, miR-320a, miR-625-3p, and other circulating extracellular miRNAs in the blood that are associated with ovarian cancer. However, the combination of miR-205 and let-7f only achieved a low sensitivity of 62.4% for detecting ovarian epithelial cancer, raising concerns that ovarian cancer cases may be overlooked. Furthermore, while some studies have demonstrated the ability to distinguish between ovarian cancer and healthy individuals using combinations of other miRNAs, the lack of inclusion of patients with other cancers in the study raises the risk of misidentifying other cancers as ovarian cancer, leading to unnecessary additional testing and delays in the detection of the actual cancer, which is undesirable.

[0026] Non-Patent Document 2 shows that there are differences in the expression levels of miRNAs such as miR-22 and miR-45 as a result of analyzing miRNAs derived from serum samples of ovarian cancer patients, benign disease patients, and healthy individuals using a next-generation sequencer. However, there is no description of the detection performance, such as the specific accuracy, sensitivity, and specificity for distinguishing ovarian cancer, and the industrial practicality is poor.

[0027] Non-patent document 3 indicates that miRNAs such as miR-23a / b, miR-92, miR-125a, miR-296-5p, miR-320, miR-422a, and miR-663a are present in the endoplasmic reticulum of body fluids of ovarian cancer patients. However, there is no description of the detection performance, such as the specific accuracy, sensitivity, and specificity for distinguishing ovarian cancer, and the industrial practicality is poor.

[0028] As such, existing tumor markers have poor performance in detecting ovarian tumors, and the performance and detection methods of research-stage markers have not been specifically described. Therefore, their use could result in unnecessary additional testing due to false positives of ovarian tumor patients and missed treatment opportunities due to overlooking ovarian tumor patients. Furthermore, sampling ovarian tissue for tumor marker measurement is highly invasive and undesirable. Therefore, there is a need for highly accurate ovarian cancer markers that can be detected from minimally invasive blood samples and accurately distinguish between ovarian tumor patients and healthy individuals. Early detection and treatment of ovarian cancer can dramatically reduce the risk of recurrence, and partial surgical removal can preserve a woman's future reproductive potential. Therefore, there is a strong need for highly sensitive ovarian cancer markers that can detect even low-stage ovarian cancer. Furthermore, providing a more convenient primary ovarian tumor screening test is expected to increase the rate of secondary screening. [Means for solving the problem]

[0029] As a result of intensive research to solve the above-mentioned problems, the present inventors have discovered a microRNA (miRNA) gene marker that can be used as a detection marker for ovarian tumors from blood, which can be collected minimally invasively, and have found that ovarian tumors can be detected significantly, preferably specifically, by using nucleic acids for detecting this marker, for example, at least one or at least two nucleic acids selected from a probe that can specifically bind to the marker and a primer that amplifies the marker, and have thus completed the present invention.

[0030] <Summary of the Invention> That is, the present invention has the following features. (1) miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-1233-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6798-5p, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-6765-3p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, which are ovarian tumor markersmiR-6887-5p, miR-6742-5p, miR-6729-3p, miR-5090, miR-7975, miR-4505, miR-6889-5p, miR-4708-3p, miR-6131, miR-1225-3p, miR-6132, miR-473 4、miR-3194-3p、miR-638、miR-2467-3p、miR-4728-5p、miR-5572、miR-6789-5p、miR-8063、miR-4429、miR-6840-3p、miR-4476、miR-675-5p、miR-711 miR-6875-5p, miR-3160-5p, miR-1908-5p, miR-6726-5p, miR-1913, miR-8071, miR-3648, miR-4732-5p, miR-4787-5p, miR-3917, miR-619-5p, miR- 1231、miR-342-5p、miR-4433a-5p、miR-6766-5p、miR-4707-5p、miR-7114-5p、miR-6872-3p、miR-6780b-5p、miR-7845-5p、miR-6798-3p、miR-665、miR -6848-5p、miR-5008-5p、miR-4294、miR-6511a-5p、miR-4435、miR-4747-3p、miR-6880-3p、miR-6869-5p、miR-7150、miR-1260a、miR-6877-5p、miR-6 721-5p、miR-4656、miR-1229-5p、miR-4433a-3p、miR-4274、miR-4419b、miR-4674、miR-6893-5p、miR-6763-3p、miR-6762-5p、miR-6738-5p、miR-4513 miR-6746-5p, miR-6880-5p, miR-4736, miR-718, miR-6717-5p, miR-7847-3p, miR-760, miR-1199-5p, miR-6813-5p, miR-6769a-5p, miR-1193, miR- 7108-3p、miR-6741-5p、miR-4298、miR-6796-3p、miR-4750-5p、miR-6785-5p、miR-1292-3p、miR-4749-3p、miR-6800-3p、miR-4722-5p、miR-4746-3p、miR-4450, miR-6795-5p, miR-365a-5p, miR-498, miR-6797-5p, miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR -208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619- 3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR -187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR- 6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-679 4-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, A kit for detecting ovarian tumors, comprising at least one polynucleotide selected from miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p, or a nucleic acid capable of specifically binding to a complementary strand of the polynucleotide.

[0031] (2) miR-4675 is hsa-miR-4675, miR-4783-3p is hsa-miR-4783-3p, miR-1228-5p is hsa-miR-1228-5p, miR-4532 is hsa-miR-4532, miR-6802-5p is hsa-miR-6802-5p, miR-6784-5p is hsa-miR-6784-5p, miR-3940-5p is hsa-miR-3940-5p, miR-1307-3p is hsa-miR-1307-3p, and miR- 8073 is hsa-miR-8073, miR-3184-5p is hsa-miR-3184-5p, miR-1233-5p is hsa-miR-1233-5p, miR-6088 is hsa-miR-6088, miR-5195-3p is hsa-miR-5195-3p, miR-320b is hsa-miR-320b, miR-4649-5p is hsa-miR-4649-5p, miR-6800-5p is hsa-miR-6800-5p, and miR-1343-3p is hsa-miR- miR-1343-3p, miR-4730 is hsa-miR-4730, miR-6885-5p is hsa-miR-6885-5p, miR-5100 is hsa-miR-5100, miR-1203 is hsa-miR-1203, miR-6756-5p is hsa-miR-6756-5p, miR-373-5p is hsa-miR-373-5p, miR-1268a is hsa-miR-1268a, miR-1260b is hsa-miR-1260b, and miR-4258 is hsa-miR-4258, miR-4697-5p is hsa-miR-4697-5p, miR-1469 is hsa-miR-1469, miR-4515 is hsa-miR-4515, miR-6861-5p is hsa-miR-6861-5p, miR-6821-5p is hsa-miR-6821-5p, miR-575 is hsa-miR-575, miR-6805-5p is hsa-miR-6805-5p, miR-4758-5p is hsa-miR-4758-5p,miR-3663-3p is hsa-miR-3663-3p, miR-4530 is hsa-miR-4530, miR-6798-5p is hsa-miR-6798-5p, miR-6781-5p is hsa-miR-6781-5p, miR-885-3p is hsa-miR-885-3p, miR-1273g-3p is hsa-miR-1273g-3p, miR-4787-3p is hsa-miR-4787-3p, miR-4454 is hsa-miR-4454, and miR-47 06 is hsa-miR-4706, miR-1249-3p is hsa-miR-1249-3p, miR-887-3p is hsa-miR-887-3p, miR-6786-5p is hsa-miR-6786-5p, miR-1238-5p is hsa-miR-1238-5p, miR-6749-5p is hsa-miR-6749-5p, miR-6729-5p is hsa-miR-6729-5p, miR-6825-5p is hsa-miR-6825-5p, and miR-663b is hsa-miR-663b, miR-6858-5p, hsa-miR-6858-5p, miR-4690-5p, hsa-miR-4690-5p, miR-6765-5p, hsa-miR-6765-5p, miR-4710, hsa-miR-4710, miR-6775-5p, hsa-miR-6775-5p, miR-371a-5p, hsa-miR-371a-5p, miR-6816-5p, hsa-miR-6816-5p, and miR-296-3p are hsa-miR- miR-296-3p, miR-7977 is hsa-miR-7977, miR-8069 is hsa-miR-8069, miR-6515-3p is hsa-miR-6515-3p, miR-4687-5p is hsa-miR-4687-5p, miR-1343-5p is hsa-miR-1343-5p, miR-7110-5p is hsa-miR-7110-5p, miR-4525 is hsa-miR-4525, miR-3158-5p is hsa-miR-3158-5p,miR-6787-5p is hsa-miR-6787-5p, miR-614 is hsa-miR-614, miR-4689 is hsa-miR-4689, miR-1185-2-3p is hsa-miR-1185-2-3p, miR-1268b is hsa-miR-1268b, miR-1228-3p is hsa-miR-1228-3p, miR-1185-1-3p is hsa-miR-1185-1-3p, miR-940 is hsa-miR-940, and miR-939-5p is hsa- miR-939-5p, miR-6757-5p is hsa-miR-6757-5p, miR-1275 is hsa-miR-1275, miR-5001-5p is hsa-miR-5001-5p, miR-6826-5p is hsa-miR-6826-5p, miR-6765-3p is hsa-miR-6765-3p, miR-3679-3p is hsa-miR-3679-3p, miR-4718 is hsa-miR-4718, miR-4286 is hsa-miR-4286, and mi miR-8059 is hsa-miR-8059, miR-4447 is hsa-miR-4447, miR-4448 is hsa-miR-4448, miR-658 is hsa-miR-658, miR-6766-3p is hsa-miR-6766-3p, miR-197-5p is hsa-miR-197-5p, miR-6887-5p is hsa-miR-6887-5p, miR-6742-5p is hsa-miR-6742-5p, and miR-6729-3p is hsa-miR-6729-3p. miR-5090 is hsa-miR-5090, miR-7975 is hsa-miR-7975, miR-4505 is hsa-miR-4505, miR-6889-5p is hsa-miR-6889-5p, miR-4708-3p is hsa-miR-4708-3p, miR-6131 is hsa-miR-6131, miR-1225-3p is hsa-miR-1225-3p, miR-6132 is hsa-miR-6132, and miR-4734 is hsa-miR-4734;miR-3194-3p is hsa-miR-3194-3p, miR-638 is hsa-miR-638, miR-2467-3p is hsa-miR-2467-3p, miR-4728-5p is hsa-miR-4728-5p, miR-5572 is hsa-miR-5572, miR-6789-5p is hsa-miR-6789-5p, miR-8063 is hsa-miR-8063, miR-4429 is hsa-miR-4429, and miR-6840-3p is hsa-miR-6 miR-840-3p, miR-4476 is hsa-miR-4476, miR-675-5p is hsa-miR-675-5p, miR-711 is hsa-miR-711, miR-6875-5p is hsa-miR-6875-5p, miR-3160-5p is hsa-miR-3160-5p, miR-1908-5p is hsa-miR-1908-5p, miR-6726-5p is hsa-miR-6726-5p, miR-1913 is hsa-miR-1913, and miR-8071 miR-3648 is hsa-miR-3648, miR-4732-5p is hsa-miR-4732-5p, miR-4787-5p is hsa-miR-4787-5p, miR-3917 is hsa-miR-3917, miR-619-5p is hsa-miR-619-5p, miR-1231 is hsa-miR-1231, miR-342-5p is hsa-miR-342-5p, and miR-4433a-5p is hsa-miR-4433a-5p. miR-6766-5p is hsa-miR-6766-5p, miR-4707-5p is hsa-miR-4707-5p, miR-7114-5p is hsa-miR-7114-5p, miR-6872-3p is hsa-miR-6872-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-7845-5p is hsa-miR-7845-5p, miR-6798-3p is hsa-miR-6798-3p, and miR-665 is hsa-miR-665;miR-6848-5p is hsa-miR-6848-5p, miR-5008-5p is hsa-miR-5008-5p, miR-4294 is hsa-miR-4294, miR-6511a-5p is hsa-miR-6511a-5p, miR-4435 is hsa-miR-4435, and miR-4747-3p is hsa-miR-4747-3p. miR-6880-3p is hsa-miR-6880-3p, miR-6869-5p is hsa-miR-6869-5p, miR-7150 is hsa-miR-7150, miR-1260a is hsa-miR-1260a, miR-6877-5p is hsa-miR-6877-5p, and miR-6721-5p is hsa-miR-6721-5p. miR-4656 is hsa-miR-4656, miR-1229-5p is hsa-miR-1229-5p, miR-4433a-3p is hsa-miR-4433a-3p, miR-4274 is hsa-miR-4274, miR-4419b is hsa-miR-4419b, miR-4674 is hsa-miR-4674, and miR-6 893-5p is hsa-miR-6893-5p, miR-6763-3p is hsa-miR-6763-3p, miR-6762-5p is hsa-miR-6762-5p, miR-6738-5p is hsa-miR-6738-5p, miR-4513 is hsa-miR-4513, miR-6746-5p is hsa-miR-6746-5p, miR-6880-5p is hsa-miR-6880-5p, miR-4736 is hsa-miR-4736, miR-718 is hsa-miR-718, miR-6717-5p is hsa-miR-6717-5p, miR-7847-3p is hsa-miR-7847-3p, miR-760 is hsa-miR-760, miR-1199-5p is hsa-miR-1199-5p, miR-6813-5p is hsa-miR-6813-5p, and miR-6769a-5p is hsa-miR-6 769a-5p, miR-1193 is hsa-miR-1193, miR-7108-3p is hsa-miR-7108-3p, miR-6741-5p is hsa-miR-6741-5p, miR-4298 is hsa-miR-4298, miR-6796-3p is hsa-miR-6796-3p, miR-4750-5p is hsa-miR-4750-5p, miR-6785-5p is hsa-miR-6785-5p, miR-1292-3p is hsa-miR-1292-3p, and m miR-4749-3p is hsa-miR-4749-3p, miR-6800-3p is hsa-miR-6800-3p, miR-722-5p is hsa-miR-4722-5p, miR-4746-3p is hsa-miR-4746-3p, miR-4450 is hsa-miR-4450, miR-6795-5p is hsa-miR-6795-5p, miR-365a-5p is hsa-miR-365a-5p, miR-498 is hsa-miR-498, and miR-6797-5p is hsa- miR-6797-5p, miR-1470 is hsa-miR-1470, miR-6851-5p is hsa-miR-6851-5p, miR-1247-3p is hsa-miR-1247-3p, miR-5196-5p is hsa-miR-5196-5p, miR-208a-5p is hsa-miR-208a-5p, miR-6842-5p is hsa-miR-6842-5p, miR-150-3p is hsa-miR-150-3p, and miR-4534 is hsa-miR-4534;miR-3135b is hsa-miR-3135b, miR-3131 is hsa-miR-3131, miR-4792 is hsa-miR-4792, miR-6510-5p is hsa-miR-6510-5p, miR-504-3p is hsa-miR-504-3p, miR-3619-3p is hsa-miR-3619-3p, miR-671-5p is hsa-miR-671-5p, miR-4667-5p is hsa-miR-4667-5p, and miR-4430 is hsa-miR -4430, miR-3195 is hsa-miR-3195, miR-3679-5p is hsa-miR-3679-5p, miR-6076 is hsa-miR-6076, miR-6515-5p is hsa-miR-6515-5p, miR-6820-5p is hsa-miR-6820-5p, miR-4634 is hsa-miR-4634, miR-187-5p is hsa-miR-187-5p, miR-6763-5p is hsa-miR-6763-5p, and miR-190 8-3p is hsa-miR-1908-3p, miR-1181 is hsa-miR-1181, miR-6782-5p is hsa-miR-6782-5p, miR-5010-5p is hsa-miR-5010-5p, miR-6870-5p is hsa-miR-6870-5p, miR-6124 is hsa-miR-6124, miR-1249-5p is hsa-miR-1249-5p, miR-6511b-5p is hsa-miR-6511b-5p, and miR-1254 is hsa- miR-1254, miR-4727-3p is hsa-miR-4727-3p, miR-4259 is hsa-miR-4259, miR-4771 is hsa-miR-4771, miR-3622a-5p is hsa-miR-3622a-5p, miR-4480 is hsa-miR-4480, miR-4740-5p is hsa-miR-4740-5p, miR-6777-5p is hsa-miR-6777-5p, miR-6794-5p is hsa-miR-6794-5p,miR-4687-3p is hsa-miR-4687-3p, miR-6743-5p is hsa-miR-6743-5p, miR-6771-5p is hsa-miR-6771-5p, miR-3141 is hsa-miR-3141, miR-3162-5p is hsa-miR-3162-5p, and miR-42 71 is hsa-miR-4271, miR-1227-5p is hsa-miR-1227-5p, miR-4257 is hsa-miR-4257, miR-4270 is hsa-miR-4270, miR-4516 is hsa-miR-4516, miR-4651 is hsa-miR-4651, and miR-4 725-3p is hsa-miR-4725-3p, miR-6125 is hsa-miR-6125, miR-6732-5p is hsa-miR-6732-5p, miR-6791-5p is hsa-miR-6791-5p, miR-6819-5p is hsa-miR-6819-5p, and miR-6891-5p is hsa-miR-6891-5p, miR-7108-5p is hsa-miR-7108-5p, miR-7109-5p is hsa-miR-7109-5p, miR-642b-3p is hsa-miR-642b-3p, and miR-642a-3p is hsa-miR-642a-3p.

[0032] (3) The nucleic acid is a polynucleotide represented by any one of the following (a) to (e): (a) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 1 to 247, 251, and 268, or a base sequence in which u is t in the base sequence, or a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 247, 251, and 268; (c) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 1 to 247, 251, and 268, or a base sequence complementary to the base sequence in which u is t in the base sequence, or a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (d) a polynucleotide comprising a base sequence complementary to any of the base sequences represented by SEQ ID NOs: 1 to 247, 251, and 268, or the base sequence in which u is t; and (e) a polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (a) to (d) above; The kit according to (1) or (2), wherein the polynucleotide is selected from the group consisting of:

[0033] (4) The above kit does not detect other ovarian tumor markers, such as miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3p, and miR-140a-3p. The kit according to any one of (1) to (3), further comprising at least one polynucleotide selected from miR-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3p, and miR-22-3p, or a nucleic acid capable of specifically binding to a complementary strand of the polynucleotide.

[0034] (5) miR-320a is hsa-miR-320a, miR-663a is hsa-miR-663a, miR-328-5p is hsa-miR-328-5p, miR-128-2-5p is hsa-miR-128-2-5p, miR-125a-3p is hsa-miR-125a-3p, miR-191-5p is hsa-miR-191-5p, and miR-92b-5p is hsa -miR-92b-5p, miR-296-5p is hsa-miR-296-5p, miR-1246 is hsa-miR-1246, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-128-1-5p is hsa-miR-128-1-5p, miR-1290 is hsa-miR-1290, miR-211-3p is hsa-miR-211-3p; miR-744-5p is hsa-miR-744-5p, miR-135a-3p is hsa-miR-135a-3p, miR-451a is hsa-miR-451a, miR-625-3p is hsa-miR-625-3p, miR-92a-3p is hsa-miR-92a-3p, miR-422a is hsa-miR-422a, and miR-483-5p is hsa-miR-48 3-5p, miR-652-5p is hsa-miR-652-5p, miR-24-3p is hsa-miR-24-3p, miR-23b-3p is hsa-miR-23b-3p, miR-23a-3p is hsa-miR-23a-3p, miR-92b-3p is hsa-miR-92b-3p, and miR-22-3p is hsa-miR-22-3p. (4) The kit according to claim 3, wherein the miR-92b-3p is hsa-miR-92b-3p, and the miR-22-3p is hsa-miR-22-3p.

[0035] (6) The nucleic acid is a polynucleotide represented by any one of the following (f) to (j): (f) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275, or a base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (g) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275; (h) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275, or a base sequence complementary to the base sequence in which u is t in the base sequence, or a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (i) a polynucleotide comprising a base sequence complementary to any one of SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275, or the base sequence in which u is t; and (j) a polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (f) to (i) above; The kit according to (4) or (5), wherein the polynucleotide is selected from the group consisting of:

[0036] (7) A kit described in any one of (1) to (6), comprising at least two polynucleotides selected from all of the ovarian tumor markers described in (1) or (2), or at least two nucleic acids capable of specifically binding to each of the complementary strands of the polynucleotides.

[0037] (8) miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-1233-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6798-5p, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-6765-3p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, which are ovarian tumor markersmiR-6887-5p, miR-6742-5p, miR-6729-3p, miR-5090, miR-7975, miR-4505, miR-6889-5p, miR-4708-3p, miR-6131, miR-1225-3p, miR-6132, miR-473 4、miR-3194-3p、miR-638、miR-2467-3p、miR-4728-5p、miR-5572、miR-6789-5p、miR-8063、miR-4429、miR-6840-3p、miR-4476、miR-675-5p、miR-711 miR-6875-5p, miR-3160-5p, miR-1908-5p, miR-6726-5p, miR-1913, miR-8071, miR-3648, miR-4732-5p, miR-4787-5p, miR-3917, miR-619-5p, miR- 1231、miR-342-5p、miR-4433a-5p、miR-6766-5p、miR-4707-5p、miR-7114-5p、miR-6872-3p、miR-6780b-5p、miR-7845-5p、miR-6798-3p、miR-665、miR -6848-5p、miR-5008-5p、miR-4294、miR-6511a-5p、miR-4435、miR-4747-3p、miR-6880-3p、miR-6869-5p、miR-7150、miR-1260a、miR-6877-5p、miR-6 721-5p、miR-4656、miR-1229-5p、miR-4433a-3p、miR-4274、miR-4419b、miR-4674、miR-6893-5p、miR-6763-3p、miR-6762-5p、miR-6738-5p、miR-4513 miR-6746-5p, miR-6880-5p, miR-4736, miR-718, miR-6717-5p, miR-7847-3p, miR-760, miR-1199-5p, miR-6813-5p, miR-6769a-5p, miR-1193, miR- 7108-3p、miR-6741-5p、miR-4298、miR-6796-3p、miR-4750-5p、miR-6785-5p、miR-1292-3p、miR-4749-3p、miR-6800-3p、miR-4722-5p、miR-4746-3p、miR-4450, miR-6795-5p, miR-365a-5p, miR-498, miR-6797-5p, miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR -208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619- 3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR -187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR- 6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-679 4-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, A device for detecting ovarian tumors, comprising at least one polynucleotide selected from miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p, or a nucleic acid capable of specifically binding to a complementary strand of the polynucleotide.

[0038] (9) miR-4675 is hsa-miR-4675, miR-4783-3p is hsa-miR-4783-3p, miR-1228-5p is hsa-miR-1228-5p, miR-4532 is hsa-miR-4532, miR-6802-5p is hsa-miR-6802-5p, miR-6784-5p is hsa-miR-6784-5p, miR-3940-5p is hsa-miR-3940-5p, miR-1307-3p is hsa-miR-1307-3p, and miR- 8073 is hsa-miR-8073, miR-3184-5p is hsa-miR-3184-5p, miR-1233-5p is hsa-miR-1233-5p, miR-6088 is hsa-miR-6088, miR-5195-3p is hsa-miR-5195-3p, miR-320b is hsa-miR-320b, miR-4649-5p is hsa-miR-4649-5p, miR-6800-5p is hsa-miR-6800-5p, and miR-1343-3p is hsa-miR- miR-1343-3p, miR-4730 is hsa-miR-4730, miR-6885-5p is hsa-miR-6885-5p, miR-5100 is hsa-miR-5100, miR-1203 is hsa-miR-1203, miR-6756-5p is hsa-miR-6756-5p, miR-373-5p is hsa-miR-373-5p, miR-1268a is hsa-miR-1268a, miR-1260b is hsa-miR-1260b, and miR-4258 is hsa-miR-4258, miR-4697-5p is hsa-miR-4697-5p, miR-1469 is hsa-miR-1469, miR-4515 is hsa-miR-4515, miR-6861-5p is hsa-miR-6861-5p, miR-6821-5p is hsa-miR-6821-5p, miR-575 is hsa-miR-575, miR-6805-5p is hsa-miR-6805-5p, miR-4758-5p is hsa-miR-4758-5p,miR-3663-3p is hsa-miR-3663-3p, miR-4530 is hsa-miR-4530, miR-6798-5p is hsa-miR-6798-5p, miR-6781-5p is hsa-miR-6781-5p, miR-885-3p is hsa-miR-885-3p, miR-1273g-3p is hsa-miR-1273g-3p, miR-4787-3p is hsa-miR-4787-3p, miR-4454 is hsa-miR-4454, and miR-47 06 is hsa-miR-4706, miR-1249-3p is hsa-miR-1249-3p, miR-887-3p is hsa-miR-887-3p, miR-6786-5p is hsa-miR-6786-5p, miR-1238-5p is hsa-miR-1238-5p, miR-6749-5p is hsa-miR-6749-5p, miR-6729-5p is hsa-miR-6729-5p, miR-6825-5p is hsa-miR-6825-5p, and miR-663b is hsa-miR-663b, miR-6858-5p, hsa-miR-6858-5p, miR-4690-5p, hsa-miR-4690-5p, miR-6765-5p, hsa-miR-6765-5p, miR-4710, hsa-miR-4710, miR-6775-5p, hsa-miR-6775-5p, miR-371a-5p, hsa-miR-371a-5p, miR-6816-5p, hsa-miR-6816-5p, and miR-296-3p are hsa-miR- miR-296-3p, miR-7977 is hsa-miR-7977, miR-8069 is hsa-miR-8069, miR-6515-3p is hsa-miR-6515-3p, miR-4687-5p is hsa-miR-4687-5p, miR-1343-5p is hsa-miR-1343-5p, miR-7110-5p is hsa-miR-7110-5p, miR-4525 is hsa-miR-4525, miR-3158-5p is hsa-miR-3158-5p,miR-6787-5p is hsa-miR-6787-5p, miR-614 is hsa-miR-614, miR-4689 is hsa-miR-4689, miR-1185-2-3p is hsa-miR-1185-2-3p, miR-1268b is hsa-miR-1268b, miR-1228-3p is hsa-miR-1228-3p, miR-1185-1-3p is hsa-miR-1185-1-3p, miR-940 is hsa-miR-940, and miR-939-5p is hsa- miR-939-5p, miR-6757-5p is hsa-miR-6757-5p, miR-1275 is hsa-miR-1275, miR-5001-5p is hsa-miR-5001-5p, miR-6826-5p is hsa-miR-6826-5p, miR-6765-3p is hsa-miR-6765-3p, miR-3679-3p is hsa-miR-3679-3p, miR-4718 is hsa-miR-4718, miR-4286 is hsa-miR-4286, and mi miR-8059 is hsa-miR-8059, miR-4447 is hsa-miR-4447, miR-4448 is hsa-miR-4448, miR-658 is hsa-miR-658, miR-6766-3p is hsa-miR-6766-3p, miR-197-5p is hsa-miR-197-5p, miR-6887-5p is hsa-miR-6887-5p, miR-6742-5p is hsa-miR-6742-5p, and miR-6729-3p is hsa-miR-6729-3p. miR-5090 is hsa-miR-5090, miR-7975 is hsa-miR-7975, miR-4505 is hsa-miR-4505, miR-6889-5p is hsa-miR-6889-5p, miR-4708-3p is hsa-miR-4708-3p, miR-6131 is hsa-miR-6131, miR-1225-3p is hsa-miR-1225-3p, miR-6132 is hsa-miR-6132, and miR-4734 is hsa-miR-4734;miR-3194-3p is hsa-miR-3194-3p, miR-638 is hsa-miR-638, miR-2467-3p is hsa-miR-2467-3p, miR-4728-5p is hsa-miR-4728-5p, miR-5572 is hsa-miR-5572, miR-6789-5p is hsa-miR-6789-5p, miR-8063 is hsa-miR-8063, miR-4429 is hsa-miR-4429, and miR-6840-3p is hsa-miR-6 miR-840-3p, miR-4476 is hsa-miR-4476, miR-675-5p is hsa-miR-675-5p, miR-711 is hsa-miR-711, miR-6875-5p is hsa-miR-6875-5p, miR-3160-5p is hsa-miR-3160-5p, miR-1908-5p is hsa-miR-1908-5p, miR-6726-5p is hsa-miR-6726-5p, miR-1913 is hsa-miR-1913, and miR-8071 miR-3648 is hsa-miR-3648, miR-4732-5p is hsa-miR-4732-5p, miR-4787-5p is hsa-miR-4787-5p, miR-3917 is hsa-miR-3917, miR-619-5p is hsa-miR-619-5p, miR-1231 is hsa-miR-1231, miR-342-5p is hsa-miR-342-5p, and miR-4433a-5p is hsa-miR-4433a-5p. miR-6766-5p is hsa-miR-6766-5p, miR-4707-5p is hsa-miR-4707-5p, miR-7114-5p is hsa-miR-7114-5p, miR-6872-3p is hsa-miR-6872-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-7845-5p is hsa-miR-7845-5p, miR-6798-3p is hsa-miR-6798-3p, and miR-665 is hsa-miR-665;miR-6848-5p is hsa-miR-6848-5p, miR-5008-5p is hsa-miR-5008-5p, miR-4294 is hsa-miR-4294, miR-6511a-5p is hsa-miR-6511a-5p, miR-4435 is hsa-miR-4435, and miR-4747-3p is hsa-miR-4747-3p. miR-6880-3p is hsa-miR-6880-3p, miR-6869-5p is hsa-miR-6869-5p, miR-7150 is hsa-miR-7150, miR-1260a is hsa-miR-1260a, miR-6877-5p is hsa-miR-6877-5p, and miR-6721-5p is hsa-miR-6721-5p. miR-4656 is hsa-miR-4656, miR-1229-5p is hsa-miR-1229-5p, miR-4433a-3p is hsa-miR-4433a-3p, miR-4274 is hsa-miR-4274, miR-4419b is hsa-miR-4419b, miR-4674 is hsa-miR-4674, and miR-6 893-5p is hsa-miR-6893-5p, miR-6763-3p is hsa-miR-6763-3p, miR-6762-5p is hsa-miR-6762-5p, miR-6738-5p is hsa-miR-6738-5p, miR-4513 is hsa-miR-4513, miR-6746-5p is hsa-miR-6746-5p, miR-6880-5p is hsa-miR-6880-5p, miR-4736 is hsa-miR-4736, miR-718 is hsa-miR-718, miR-6717-5p is hsa-miR-6717-5p, miR-7847-3p is hsa-miR-7847-3p, miR-760 is hsa-miR-760, miR-1199-5p is hsa-miR-1199-5p, miR-6813-5p is hsa-miR-6813-5p, and miR-6769a-5p is hsa-miR-67 69a-5p, miR-1193 is hsa-miR-1193, miR-7108-3p is hsa-miR-7108-3p, miR-6741-5p is hsa-miR-6741-5p, miR-4298 is hsa-miR-4298, miR-6796-3p is hsa-miR-6796-3p, miR-4750-5p is hsa-miR-4750-5p, miR-6785-5p is hsa-miR-6785-5p, miR-1292-3p is hsa-miR-1292-3p, and miR- 4749-3p is hsa-miR-4749-3p, miR-6800-3p is hsa-miR-6800-3p, miR-722-5p is hsa-miR-4722-5p, miR-4746-3p is hsa-miR-4746-3p, miR-4450 is hsa-miR-4450, miR-6795-5p is hsa-miR-6795-5p, miR-365a-5p is hsa-miR-365a-5p, miR-498 is hsa-miR-498, and miR-6797-5p is hs a-miR-6797-5p, miR-1470 is hsa-miR-1470, miR-6851-5p is hsa-miR-6851-5p, miR-1247-3p is hsa-miR-1247-3p, miR-5196-5p is hsa-miR-5196-5p, miR-208a-5p is hsa-miR-208a-5p, miR-6842-5p is hsa-miR-6842-5p, miR-150-3p is hsa-miR-150-3p, and miR-4534 is hsa-miR-4 534, miR-3135b is hsa-miR-3135b, miR-3131 is hsa-miR-3131, miR-4792 is hsa-miR-4792, miR-6510-5p is hsa-miR-6510-5p, miR-504-3p is hsa-miR-504-3p, miR-3619-3p is hsa-miR-3619-3p, miR-671-5p is hsa-miR-671-5p, miR-4667-5p is hsa-miR-4667-5p, and miR-4430 is hsa-miR-4430, miR-3195 is hsa-miR-3195, miR-3679-5p is hsa-miR-3679-5p, miR-6076 is hsa-miR-6076, miR-6515-5p is hsa-miR-6515-5p, miR-6820-5p is hsa-miR-6820-5p, miR-4634 is hsa-miR-4634, miR-187-5p is hsa-miR-187-5p, miR-6763-5p is hsa-miR-6763-5p,miR-1908-3p is hsa-miR-1908-3p, miR-1181 is hsa-miR-1181, miR-6782-5p is hsa-miR-6782-5p, miR-5010-5p is hsa-miR-5010-5p, miR-6870-5p is hsa-miR-6870-5p, miR-6124 is hsa-miR-6124, miR-1249-5p is hsa-miR-1249-5p, miR-6511b-5p is hsa-miR-6511b-5p, and miR-125 4 is hsa-miR-1254, miR-4727-3p is hsa-miR-4727-3p, miR-4259 is hsa-miR-4259, miR-4771 is hsa-miR-4771, miR-3622a-5p is hsa-miR-3622a-5p, miR-4480 is hsa-miR-4480, miR-4740-5p is hsa-miR-4740-5p, miR-6777-5p is hsa-miR-6777-5p, and miR-6794-5p is hsa-miR-6794-5p. p, miR-4687-3p is hsa-miR-4687-3p, miR-6743-5p is hsa-miR-6743-5p, miR-6771-5p is hsa-miR-6771-5p, miR-3141 is hsa-miR-3141, miR-3162-5p is hsa-miR-3162-5p, miR-4271 is hsa-miR-4271, miR-1227-5p is hsa-miR-1227-5p, miR-4257 is hsa-miR-4257, and miR-4270 is hsa-miR-4271. miR-4270 is hsa-miR-4516, miR-4651 is hsa-miR-4651, miR-4725-3p is hsa-miR-4725-3p, miR-6125 is hsa-miR-6125, miR-6732-5p is hsa-miR-6732-5p, miR-6791-5p is hsa-miR-6791-5p, miR-6819-5p is hsa-miR-6819-5p, miR-6891-5p is hsa-miR-6891-5p,The device according to (8), wherein miR-7108-5p is hsa-miR-7108-5p, miR-7109-5p is hsa-miR-7109-5p, miR-642b-3p is hsa-miR-642b-3p, and miR-642a-3p is hsa-miR-642a-3p.

[0039] (10) The nucleic acid is a polynucleotide represented by any one of the following (a) to (e): (a) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 1 to 247, 251, and 268, or a base sequence in which u is t in the base sequence, or a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 247, 251, and 268; (c) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 1 to 247, 251, and 268, or a base sequence complementary to the base sequence in which u is t in the base sequence, or a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (d) a polynucleotide comprising a base sequence complementary to any of the base sequences represented by SEQ ID NOs: 1 to 247, 251, and 268, or the base sequence in which u is t; and (e) a polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (a) to (d) above; The device according to (8) or (9), wherein the polynucleotide is selected from the group consisting of:

[0040] (11) The above device detects other ovarian tumor markers, miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3p, miR-140a-3p, miR-150a-3p, miR-160a-3p, miR-170a-3p, miR-180a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3p, miR-180a-3p, miR-191-5p, miR-291-5p, miR-21 ... The device according to any one of (8) to (10), further comprising at least one polynucleotide selected from iR-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3p, and miR-22-3p, or a nucleic acid capable of specifically binding to a complementary strand of the polynucleotide.

[0041] (12) miR-320a is hsa-miR-320a, miR-663a is hsa-miR-663a, miR-328-5p is hsa-miR-328-5p, miR-128-2-5p is hsa-miR-128-2-5p, miR-125a-3p is hsa-miR-125a-3p, miR-191-5p is hsa-miR-191-5p, and miR-92b-5p is hsa-miR-191-5p. a-miR-92b-5p, miR-296-5p is hsa-miR-296-5p, miR-1246 is hsa-miR-1246, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-128-1-5p is hsa-miR-128-1-5p, miR-1290 is hsa-miR-1290, miR-211-3p is hsa-miR-211-3p, miR-744-5p is hsa-miR-744-5p, miR-135a-3p is hsa-miR-135a-3p, miR-451a is hsa-miR-451a, miR-625-3p is hsa-miR-625-3p, miR-92a-3p is hsa-miR-92a-3p, miR-422a is hsa-miR-422a, and miR-483-5p is hsa-miR-483 -5p, miR-652-5p is hsa-miR-652-5p, miR-24-3p is hsa-miR-24-3p, miR-23b-3p is hsa-miR-23b-3p, miR-23a-3p is hsa-miR-23a-3p, miR-92b-3p is hsa-miR-92b-3p, and miR-22-3p is hsa-miR-22-3p.

[0042] (13) The nucleic acid is a polynucleotide represented by any one of the following (f) to (j): (f) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275, or a base sequence in which u is t in the base sequence, a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (g) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275; (h) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275, or a base sequence complementary to the base sequence in which u is t in the base sequence, or a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (i) a polynucleotide comprising a base sequence complementary to any one of SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275, or the base sequence in which u is t; and (j) a polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (f) to (i) above; The device according to (11) or (12), wherein the polynucleotide is selected from the group consisting of:

[0043] (14) The device according to any one of (8) to (13), which is a device for measurement by hybridization technology.

[0044] (15) The device according to (14), wherein the hybridization technology is a nucleic acid array technology.

[0045] (16) A device described in any one of (8) to (15), which comprises at least two polynucleotides selected from all of the ovarian tumor markers described in (8) or (9), or at least two nucleic acids capable of specifically binding to each of the complementary strands of the polynucleotides.

[0046] (17) R-4532、miR-6802-5p、miR-6784-5p、miR-3940-5p、miR-1307-3p、miR-807 3、miR-3184-5p、miR-1233-5p、miR-6088、miR-5195-3p、miR-320b、miR-46 49-5p、miR-6800-5p、miR-1343-3p、miR-4730、miR-6885-5p、miR-5100、mi R-1203、miR-6756-5p、miR-373-5p、miR-1268a、miR-1260b、miR-4258、miR -4697-5p、miR-1469、miR-4515、miR-6861-5p、miR-6821-5p、miR-575、miR -6805-5p、miR-4758-5p、miR-3663-3p、miR-4530、miR-6798-5p、miR-6781 -5p、miR-885-3p、miR-1273g-3p、miR-4787-3p、miR-4454、miR-4706、miR-1 249-3p、miR-887-3p、miR-6786-5p、miR-1238-5p、miR-6749-5p、miR-6729 -5p、miR-6825-5p、miR-663b、miR-6858-5p、miR-4690-5p、miR-6765-5p、m iR-4710、miR-6775-5p、miR-371a-5p、miR-6816-5p、miR-296-3p、miR-797 7、miR-8069、miR-6515-3p、miR-4687-5p、miR-1343-5p、miR-7110-5p、miR- 4525、miR-3158-5p、miR-6787-5p、miR-614、miR-4689、miR-1185-2-3p、mi R-1268b、miR-1228-3p、miR-1185-1-3p、miR-940、miR-939-5p、miR-6757- 5p、miR-1275、miR-5001-5p、miR-6826-5p、miR-6765-3p、miR-3679-3p、mi R-4718、miR-4286、miR-8059、miR-4447、miR-4448、miR-658、miR-6766-3p、miR-197-5p, miR-6887-5p, miR-6742-5p, miR-6729-3p, miR-5090, miR-7975, miR-4505, miR-6889-5p, miR-4708-3p, miR-6131, miR-1225-3p, miR-6 132, miR-4734, miR-3194-3p, miR-638, miR-2467-3p, miR-4728-5p, miR-5572, miR-6789-5p, miR-8063, miR-4429, miR-6840-3p, miR-4476, miR-675 -5p、miR-711、miR-6875-5p、miR-3160-5p、miR-1908-5p、miR-6726-5p、miR-1913、miR-8071、miR-3648、miR-4732-5p、miR-4787-5p、miR-3917、miR- 619-5p、miR-1231、miR-342-5p、miR-4433a-5p、miR-6766-5p、miR-4707-5p、miR-7114-5p、miR-6872-3p、miR-6780b-5p、miR-7845-5p、miR-6798-3p、 miR-665, miR-6848-5p, miR-5008-5p, miR-4294, miR-6511a-5p, miR-4435, miR-4747-3p, miR-6880-3p, miR-6869-5p, miR-7150, miR-1260a, miR-68 77-5p、miR-6721-5p、miR-4656、miR-1229-5p、miR-4433a-3p、miR-4274、miR-4419b、miR-4674、miR-6893-5p、miR-6763-3p、miR-6762-5p、miR-6738 -5p、miR-4513、miR-6746-5p、miR-6880-5p、miR-4736、miR-718、miR-6717-5p、miR-7847-3p、miR-760、miR-1199-5p、miR-6813-5p、miR-6769a-5p、m iR-1193, miR-7108-3p, miR-6741-5p, miR-4298, miR-6796-3p, miR-4750-5p, miR-6785-5p, miR-1292-3p, miR-4749-3p, miR-6800-3p, miR-4722-5pmiR-4746-3p, miR-4450, miR-6795-5p, miR-365a-5p, miR-498, miR-6797-5p, miR-1470, miR-6851-5p, miR-1247-3p, miR-51 96-5p, miR-208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR -3619-3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR- 6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-6794-5 p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, miR-451 6. A method for detecting ovarian tumors, comprising measuring the expression level of at least one polynucleotide selected from miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p, and using the measured expression level to evaluate in vitro whether a subject is affected by an ovarian tumor or not.

[0047] (18) miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-1233-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6798-5p, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-6765-3p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, which are ovarian tumor markersmiR-6887-5p, miR-6742-5p, miR-6729-3p, miR-5090, miR-7975, miR-4505, miR-6889-5p, miR-4708-3p, miR-6131, miR-1225-3p, miR-6132, miR-473 4、miR-3194-3p、miR-638、miR-2467-3p、miR-4728-5p、miR-5572、miR-6789-5p、miR-8063、miR-4429、miR-6840-3p、miR-4476、miR-675-5p、miR-711 miR-6875-5p, miR-3160-5p, miR-1908-5p, miR-6726-5p, miR-1913, miR-8071, miR-3648, miR-4732-5p, miR-4787-5p, miR-3917, miR-619-5p, miR- 1231、miR-342-5p、miR-4433a-5p、miR-6766-5p、miR-4707-5p、miR-7114-5p、miR-6872-3p、miR-6780b-5p、miR-7845-5p、miR-6798-3p、miR-665、miR -6848-5p、miR-5008-5p、miR-4294、miR-6511a-5p、miR-4435、miR-4747-3p、miR-6880-3p、miR-6869-5p、miR-7150、miR-1260a、miR-6877-5p、miR-6 721-5p、miR-4656、miR-1229-5p、miR-4433a-3p、miR-4274、miR-4419b、miR-4674、miR-6893-5p、miR-6763-3p、miR-6762-5p、miR-6738-5p、miR-4513 miR-6746-5p, miR-6880-5p, miR-4736, miR-718, miR-6717-5p, miR-7847-3p, miR-760, miR-1199-5p, miR-6813-5p, miR-6769a-5p, miR-1193, miR- 7108-3p、miR-6741-5p、miR-4298、miR-6796-3p、miR-4750-5p、miR-6785-5p、miR-1292-3p、miR-4749-3p、miR-6800-3p、miR-4722-5p、miR-4746-3p、miR-4450, miR-6795-5p, miR-365a-5p, miR-498, miR-6797-5p, miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR-208a-5p, miR-6842- 5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619-3p, miR-671-5p, miR-4667-5p, miR-4430, m iR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, m iR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR-6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, m iR-4740-5p, miR-6777-5p, miR-6794-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-42 57, miR-4270, miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109 a method for detecting an ovarian tumor, the method comprising measuring the expression level of a target nucleic acid in a specimen from a subject using the kit according to any one of (1) to (7) or the device according to any one of (8) to (16), the kit comprising at least one or at least two polynucleotides selected from miR-642b-3p, miR-642a-3p, and miR-642b-5p, or a nucleic acid capable of specifically binding to each of the complementary strands of the polynucleotides; and evaluating in vitro whether the subject is affected with an ovarian tumor or not, using the measured expression level and a control expression level similarly measured in a healthy subject.

[0048] (19) miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-1233-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6798-5p, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-6765-3p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, which are ovarian tumor markersmiR-6887-5p, miR-6742-5p, miR-6729-3p, miR-5090, miR-7975, miR-4505, miR-6889-5p, miR-4708-3p, miR-6131, miR-1225-3p, miR-6132, miR-473 4、miR-3194-3p、miR-638、miR-2467-3p、miR-4728-5p、miR-5572、miR-6789-5p、miR-8063、miR-4429、miR-6840-3p、miR-4476、miR-675-5p、miR-711 miR-6875-5p, miR-3160-5p, miR-1908-5p, miR-6726-5p, miR-1913, miR-8071, miR-3648, miR-4732-5p, miR-4787-5p, miR-3917, miR-619-5p, miR- 1231、miR-342-5p、miR-4433a-5p、miR-6766-5p、miR-4707-5p、miR-7114-5p、miR-6872-3p、miR-6780b-5p、miR-7845-5p、miR-6798-3p、miR-665、miR -6848-5p、miR-5008-5p、miR-4294、miR-6511a-5p、miR-4435、miR-4747-3p、miR-6880-3p、miR-6869-5p、miR-7150、miR-1260a、miR-6877-5p、miR-6 721-5p、miR-4656、miR-1229-5p、miR-4433a-3p、miR-4274、miR-4419b、miR-4674、miR-6893-5p、miR-6763-3p、miR-6762-5p、miR-6738-5p、miR-4513 miR-6746-5p, miR-6880-5p, miR-4736, miR-718, miR-6717-5p, miR-7847-3p, miR-760, miR-1199-5p, miR-6813-5p, miR-6769a-5p, miR-1193, miR- 7108-3p、miR-6741-5p、miR-4298、miR-6796-3p、miR-4750-5p、miR-6785-5p、miR-1292-3p、miR-4749-3p、miR-6800-3p、miR-4722-5p、miR-4746-3p、miR-4450, miR-6795-5p, miR-365a-5p, miR-498, miR-6797-5p, miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR-208a-5p, miR-6842-5p, mi R-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619-3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, mi R-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR- 6870-5p, miR-6124, miR-1249-5p, miR-6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777- 5p, miR-6794-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, miR-4516, miR- Select from 4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, miR-642a-3p. The kit according to any one of (1) to (7) or the device according to any one of (8) to (16) contains at least one or at least two polynucleotides selected from the above, or nucleic acids capable of specifically binding to each of the complementary strands of the polynucleotides, and a discriminant that can distinguish between the presence and absence of an ovarian tumor is prepared using the gene expression levels of a sample derived from a subject known to have an ovarian tumor and the gene expression levels of a sample derived from a subject not affected by an ovarian tumor as teacher samples.A method for detecting ovarian tumors, comprising assigning the expression level of a target gene in a sample derived from the subject, thereby evaluating the presence or absence of ovarian tumors in vitro.

[0049] (20) miR-4675 is hsa-miR-4675, miR-4783-3p is hsa-miR-4783-3p, miR-1228-5p is hsa-miR-1228-5p, miR-4532 is hsa-miR-4532, miR-6802-5p is hsa-miR-6802-5p, miR-6784-5p is hsa-miR-6784-5p, miR-3940-5p is hsa-miR-3940-5p, miR-1307-3p is hsa-miR-1307-3p, and miR -8073 is hsa-miR-8073, miR-3184-5p is hsa-miR-3184-5p, miR-1233-5p is hsa-miR-1233-5p, miR-6088 is hsa-miR-6088, miR-5195-3p is hsa-miR-5195-3p, miR-320b is hsa-miR-320b, miR-4649-5p is hsa-miR-4649-5p, miR-6800-5p is hsa-miR-6800-5p, and miR-1343-3p is hsa-miR- miR-1343-3p, miR-4730 is hsa-miR-4730, miR-6885-5p is hsa-miR-6885-5p, miR-5100 is hsa-miR-5100, miR-1203 is hsa-miR-1203, miR-6756-5p is hsa-miR-6756-5p, miR-373-5p is hsa-miR-373-5p, miR-1268a is hsa-miR-1268a, miR-1260b is hsa-miR-1260b, and miR-4258 is hsa-miR-4258, miR-4697-5p is hsa-miR-4697-5p, miR-1469 is hsa-miR-1469, miR-4515 is hsa-miR-4515, miR-6861-5p is hsa-miR-6861-5p, miR-6821-5p is hsa-miR-6821-5p, miR-575 is hsa-miR-575, miR-6805-5p is hsa-miR-6805-5p, miR-4758-5p is hsa-miR-4758-5p,miR-3663-3p is hsa-miR-3663-3p, miR-4530 is hsa-miR-4530, miR-6798-5p is hsa-miR-6798-5p, miR-6781-5p is hsa-miR-6781-5p, miR-885-3p is hsa-miR-885-3p, miR-1273g-3p is hsa-miR-1273g-3p, miR-4787-3p is hsa-miR-4787-3p, miR-4454 is hsa-miR-4454, and miR-47 06 is hsa-miR-4706, miR-1249-3p is hsa-miR-1249-3p, miR-887-3p is hsa-miR-887-3p, miR-6786-5p is hsa-miR-6786-5p, miR-1238-5p is hsa-miR-1238-5p, miR-6749-5p is hsa-miR-6749-5p, miR-6729-5p is hsa-miR-6729-5p, miR-6825-5p is hsa-miR-6825-5p, and miR-663b is hsa-miR-663b, miR-6858-5p, hsa-miR-6858-5p, miR-4690-5p, hsa-miR-4690-5p, miR-6765-5p, hsa-miR-6765-5p, miR-4710, hsa-miR-4710, miR-6775-5p, hsa-miR-6775-5p, miR-371a-5p, hsa-miR-371a-5p, miR-6816-5p, hsa-miR-6816-5p, and miR-296-3p are hsa-miR- miR-296-3p, miR-7977 is hsa-miR-7977, miR-8069 is hsa-miR-8069, miR-6515-3p is hsa-miR-6515-3p, miR-4687-5p is hsa-miR-4687-5p, miR-1343-5p is hsa-miR-1343-5p, miR-7110-5p is hsa-miR-7110-5p, miR-4525 is hsa-miR-4525, miR-3158-5p is hsa-miR-3158-5p,miR-6787-5p is hsa-miR-6787-5p, miR-614 is hsa-miR-614, miR-4689 is hsa-miR-4689, miR-1185-2-3p is hsa-miR-1185-2-3p, miR-1268b is hsa-miR-1268b, miR-1228-3p is hsa-miR-1228-3p, miR-1185-1-3p is hsa-miR-1185-1-3p, miR-940 is hsa-miR-940, and miR-939-5p is hsa- miR-939-5p, miR-6757-5p is hsa-miR-6757-5p, miR-1275 is hsa-miR-1275, miR-5001-5p is hsa-miR-5001-5p, miR-6826-5p is hsa-miR-6826-5p, miR-6765-3p is hsa-miR-6765-3p, miR-3679-3p is hsa-miR-3679-3p, miR-4718 is hsa-miR-4718, miR-4286 is hsa-miR-4286, and mi miR-8059 is hsa-miR-8059, miR-4447 is hsa-miR-4447, miR-4448 is hsa-miR-4448, miR-658 is hsa-miR-658, miR-6766-3p is hsa-miR-6766-3p, miR-197-5p is hsa-miR-197-5p, miR-6887-5p is hsa-miR-6887-5p, miR-6742-5p is hsa-miR-6742-5p, and miR-6729-3p is hsa-miR-6729-3p. miR-5090 is hsa-miR-5090, miR-7975 is hsa-miR-7975, miR-4505 is hsa-miR-4505, miR-6889-5p is hsa-miR-6889-5p, miR-4708-3p is hsa-miR-4708-3p, miR-6131 is hsa-miR-6131, miR-1225-3p is hsa-miR-1225-3p, miR-6132 is hsa-miR-6132, and miR-4734 is hsa-miR-4734;miR-3194-3p is hsa-miR-3194-3p, miR-638 is hsa-miR-638, miR-2467-3p is hsa-miR-2467-3p, miR-4728-5p is hsa-miR-4728-5p, miR-5572 is hsa-miR-5572, miR-6789-5p is hsa-miR-6789-5p, miR-8063 is hsa-miR-8063, miR-4429 is hsa-miR-4429, and miR-6840-3p is hsa-miR-6 miR-840-3p, miR-4476 is hsa-miR-4476, miR-675-5p is hsa-miR-675-5p, miR-711 is hsa-miR-711, miR-6875-5p is hsa-miR-6875-5p, miR-3160-5p is hsa-miR-3160-5p, miR-1908-5p is hsa-miR-1908-5p, miR-6726-5p is hsa-miR-6726-5p, miR-1913 is hsa-miR-1913, and miR-8071 miR-3648 is hsa-miR-3648, miR-4732-5p is hsa-miR-4732-5p, miR-4787-5p is hsa-miR-4787-5p, miR-3917 is hsa-miR-3917, miR-619-5p is hsa-miR-619-5p, miR-1231 is hsa-miR-1231, miR-342-5p is hsa-miR-342-5p, and miR-4433a-5p is hsa-miR-4433a-5p. miR-6766-5p is hsa-miR-6766-5p, miR-4707-5p is hsa-miR-4707-5p, miR-7114-5p is hsa-miR-7114-5p, miR-6872-3p is hsa-miR-6872-3p, miR-6780b-5p is hsa-miR-6780b-5p, miR-7845-5p is hsa-miR-7845-5p, miR-6798-3p is hsa-miR-6798-3p, and miR-665 is hsa-miR-665;miR-6848-5p is hsa-miR-6848-5p, miR-5008-5p is hsa-miR-5008-5p, miR-4294 is hsa-miR-4294, miR-6511a-5p is hsa-miR-6511a-5p, miR-4435 is hsa-miR-4435, miR-4747-3p is hsa-miR-4747-3p, miR-6880-3p is hsa-miR-6880-3p, miR-6869-5p is hsa-miR-6869-5p, and miR-715 0 is hsa-miR-7150, miR-1260a is hsa-miR-1260a, miR-6877-5p is hsa-miR-6877-5p, miR-6721-5p is hsa-miR-6721-5p, miR-4656 is hsa-miR-4656, miR-1229-5p is hsa-miR-1229-5p, miR-4433a-3p is hsa-miR-4433a-3p, miR-4274 is hsa-miR-4274, and miR-4419b is hsa-miR-4419b. miR-4674 is hsa-miR-4674, miR-6893-5p is hsa-miR-6893-5p, miR-6763-3p is hsa-miR-6763-3p, miR-6762-5p is hsa-miR-6762-5p, miR-6738-5p is hsa-miR-6738-5p, miR-4513 is hsa-miR-4513, miR-6746-5p is hsa-miR-6746-5p, miR-6880-5p is hsa-miR-6880-5p, and miR-473 6 is hsa-miR-4736, miR-718 is hsa-miR-718, miR-6717-5p is hsa-miR-6717-5p, miR-7847-3p is hsa-miR-7847-3p, miR-760 is hsa-miR-760, miR-1199-5p is hsa-miR-1199-5p, miR-6813-5p is hsa-miR-6813-5p, miR-6769a-5p is hsa-miR-6769a-5p, miR-1193 is hsa-miR-1193;miR-7108-3p is hsa-miR-7108-3p, miR-6741-5p is hsa-miR-6741-5p, miR-4298 is hsa-miR-4298, miR-6796-3p is hsa-miR-6796-3p, miR-4750-5p is hsa-miR-4750-5p, miR-6785-5p is hsa-miR-6785-5p, miR-1292-3p is hsa-miR-1292-3p, miR-4749-3p is hsa-miR-4749-, 3p, miR-6800-3p is hsa-miR-6800-3p, miR-722-5p is hsa-miR-4722-5p, miR-4746-3p is hsa-miR-4746-3p, miR-4450 is hsa-miR-4450, miR-6795-5p is hsa-miR-6795-5p, miR-365a-5p is hsa-miR-365a-5p, miR-498 is hsa-miR-498, miR-6797-5p is hsa-miR-6797-5p, and miR-147 0 is hsa-miR-1470, miR-6851-5p is hsa-miR-6851-5p, miR-1247-3p is hsa-miR-1247-3p, miR-5196-5p is hsa-miR-5196-5p, miR-208a-5p is hsa-miR-208a-5p, miR-6842-5p is hsa-miR-6842-5p, miR-150-3p is hsa-miR-150-3p, miR-4534 is hsa-miR-4534, and miR-3135b is hsa-miR-3 135b, miR-3131 is hsa-miR-3131, miR-4792 is hsa-miR-4792, miR-6510-5p is hsa-miR-6510-5p, miR-504-3p is hsa-miR-504-3p, miR-3619-3p is hsa-miR-3619-3p, miR-671-5p is hsa-miR-671-5p, miR-4667-5p is hsa-miR-4667-5p, miR-4430 is hsa-miR-4430, and miR-3195 is hsa -miR-3195, miR-3679-5p is hsa-miR-3679-5p, miR-6076 is hsa-miR-6076, miR-6515-5p is hsa-miR-6515-5p, miR-6820-5p is hsa-miR-6820-5p, miR-4634 is hsa-miR-4634, miR-187-5p is hsa-miR-187-5p, miR-6763-5p is hsa-miR-6763-5p, miR-1908-3p is hsa-miR-1908-3p,miR-1181 is hsa-miR-1181, miR-6782-5p is hsa-miR-6782-5p, miR-5010-5p is hsa-miR-5010-5p, miR-6870-5p is hsa-miR-6870-5p, miR-6124 is hsa-miR-6124, miR-1249-5p is hsa-miR-1249-5p, miR-6511b-5p is hsa-miR-6511b-5p, miR-1254 is hsa-miR-1254, and miR-4727-3p is hsa-miR-1254. miR-4727-3p is hsa-miR-4727-3p, miR-4259 is hsa-miR-4259, miR-4771 is hsa-miR-4771, miR-3622a-5p is hsa-miR-3622a-5p, miR-4480 is hsa-miR-4480, miR-4740-5p is hsa-miR-4740-5p, miR-6777-5p is hsa-miR-6777-5p, miR-6794-5p is hsa-miR-6794-5p, and miR-4687-3p is hsa-miR-4687-3p. p, miR-6743-5p is hsa-miR-6743-5p, miR-6771-5p is hsa-miR-6771-5p, miR-3141 is hsa-miR-3141, miR-3162-5p is hsa-miR-3162-5p, miR-4271 is hsa-miR-4271, miR-1227-5p is hsa-miR-1227-5p, miR-4257 is hsa-miR-4257, miR-4270 is hsa-miR-4270, and miR-4516 is hsa-miR -4516, miR-4651 is hsa-miR-4651, miR-4725-3p is hsa-miR-4725-3p, miR-6125 is hsa-miR-6125, miR-6732-5p is hsa-miR-6732-5p, miR-6791-5p is hsa-miR-6791-5p, miR-6819-5p is hsa-miR-6819-5p, miR-6891-5p is hsa-miR-6891-5p, and miR-7108-5p is hsa-miR-7108-5p;The method according to any one of (17) to (19), wherein miR-7109-5p is hsa-miR-7109-5p, miR-642b-3p is hsa-miR-642b-3p, and miR-642a-3p is hsa-miR-642a-3p.

[0050] (21) The nucleic acid is a polynucleotide represented by any one of the following (a) to (e): (a) a polynucleotide consisting of a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 247, 251, and 268, or a nucleotide sequence in which u is t in the nucleotide sequence, or a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive nucleotides; (b) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 1 to 247, 251, and 268; (c) a polynucleotide consisting of a base sequence complementary to any of the base sequences represented by SEQ ID NOs: 1 to 247, 251, and 268, or the base sequence in which u is t, or a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (d) a polynucleotide comprising a base sequence complementary to a base sequence represented by any one of SEQ ID NOs: 1 to 247, 251, and 268, or a base sequence in which u is t in the base sequence; and (e) a polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (a) to (d) above; The method according to any one of (17) to (19), wherein the polynucleotide is selected from the group consisting of:

[0051] (22) The kit or device is capable of detecting another ovarian tumor marker, miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, or miR-135a-3p. The method according to any one of (17) to (21), further comprising at least one polynucleotide selected from miR-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3p, and miR-22-3p, or a nucleic acid capable of specifically binding to a complementary strand of the polynucleotide.

[0052] (23) miR-320a is hsa-miR-320a, miR-663a is hsa-miR-663a, miR-328-5p is hsa-miR-328-5p, miR-128-2-5p is hsa-miR-128-2-5p, miR-125a-3p is hsa-miR-125a-3p, miR-191-5p is hsa-miR-191-5p, and miR-92b-5p is hsa-miR-191-5p. a-miR-92b-5p, miR-296-5p is hsa-miR-296-5p, miR-1246 is hsa-miR-1246, miR-92a-2-5p is hsa-miR-92a-2-5p, miR-128-1-5p is hsa-miR-128-1-5p, miR-1290 is hsa-miR-1290, and miR-211-3p is hsa-miR-211-3p. , miR-744-5p is hsa-miR-744-5p, miR-135a-3p is hsa-miR-135a-3p, miR-451a is hsa-miR-451a, miR-625-3p is hsa-miR-625-3p, miR-92a-3p is hsa-miR-92a-3p, miR-422a is hsa-miR-422a, and miR-483-5p is hsa-miR-4 83-5p, miR-652-5p is hsa-miR-652-5p, miR-24-3p is hsa-miR-24-3p, miR-23b-3p is hsa-miR-23b-3p, miR-23a-3p is hsa-miR-23a-3p, miR-92b-3p is hsa-miR-92b-3p, and miR-22-3p is hsa-miR-22-3p.

[0053] (24) The nucleic acid is a polynucleotide represented by any one of the following (f) to (j): (f) a polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275, or a base sequence in which u is t in the base sequence, or a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (g) a polynucleotide comprising a nucleotide sequence represented by any one of SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275; (h) a polynucleotide consisting of a base sequence complementary to any of the base sequences represented by SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275, or the base sequence in which u is t, or a variant thereof, a derivative thereof, or a fragment thereof containing 15 or more consecutive bases; (i) a polynucleotide comprising a base sequence complementary to any of the base sequences represented by SEQ ID NOs: 248 to 250, 252 to 267, and 269 to 275, or the base sequence in which u is t; and (j) a polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (f) to (i) above; The method according to (22) or (23), wherein the polynucleotide is selected from the group consisting of:

[0054] (25) The method according to any one of (17) to (24), wherein the subject is a human.

[0055] (26) The method according to any one of (17) to (25), wherein the sample is blood, serum, or plasma.

[0056] <Terminology> Terms used herein have the following definitions. The abbreviations for nucleotide, polynucleotide, DNA, RNA, etc. shall be in accordance with the "Guidelines for the Preparation of Specifications Including Nucleotide Sequences or Amino Acid Sequences" (edited by the Japan Patent Office) and common practice in the technical field.

[0057] As used herein, the term "polynucleotide" refers to nucleic acids, including RNA, DNA, and RNA / DNA chimeras. DNA includes cDNA, genomic DNA, and synthetic DNA. RNA includes total RNA, mRNA, rRNA, miRNA, siRNA, snoRNA, snRNA, non-coding RNA, and synthetic RNA. As used herein, "synthetic DNA" and "synthetic RNA" refer to DNA and RNA artificially produced using, for example, an automated nucleic acid synthesizer, based on a predetermined base sequence (which may be either a natural or non-natural sequence). As used herein, the term "non-natural sequence" is intended to be used in a broad sense and encompasses sequences that differ from a natural sequence, such as sequences containing one or more nucleotide substitutions, deletions, insertions, and / or additions (i.e., mutant sequences), sequences containing one or more modified nucleotides (i.e., modified sequences), and the like. As used herein, the term "polynucleotide" is used interchangeably with the term "nucleic acid."

[0058] As used herein, a "fragment" refers to a polynucleotide having a continuous partial base sequence of a polynucleotide, and desirably has a length of 15 bases or more, preferably 17 bases or more, and more preferably 19 bases or more.

[0059] As used herein, the term "gene" is intended to encompass not only RNA and double-stranded DNA, but also each of the single-stranded DNAs that make up the RNA, such as the positive strand (or sense strand) or complementary strand (or antisense strand). Furthermore, it is not particularly limited by its length. Therefore, unless otherwise specified, the term "gene" as used herein includes double-stranded DNA, including human genomic DNA, single-stranded DNA (positive strand), single-stranded DNA (complementary strand) having a sequence complementary to the positive strand, cDNA, microRNA (miRNA), and fragments thereof, the human genome, and transcription products thereof. Furthermore, the term "gene" does not only encompass "genes" represented by a specific nucleotide sequence (or SEQ ID NO:), but also "nucleic acids" that encode RNAs that have biological functions equivalent to the RNAs encoded by these, such as homologs (i.e., homologs or orthologs), mutants such as genetic polymorphisms, and derivatives. Specific examples of "nucleic acids" encoding such homologs, variants, or derivatives include "nucleic acids" having a nucleotide sequence that hybridizes under stringent conditions described below with a nucleotide sequence represented by any of SEQ ID NOs: 1 to 842, or a complementary sequence of the nucleotide sequence in which u is replaced by t. The term "gene" refers to any functional region, and may include, for example, an expression control region, a coding region, an exon, or an intron. Furthermore, a "gene" may be contained within a cell, released outside the cell and present alone, or encapsulated in a vesicle known as an exosome.

[0060] As used herein, "exosomes" or "exosomes" refer to vesicles enclosed in a lipid bilayer membrane that are secreted from cells. Exosomes are derived from multivesicular endosomes and, when released into the extracellular environment, may contain biological substances such as RNA, DNA, and other "genes" and proteins. Exosomes are known to be contained in body fluids such as blood, serum, plasma, serum, and lymph.

[0061] As used herein, the term "transcription product" refers to RNA synthesized using the DNA sequence of a gene as a template. RNA polymerase binds to a site called the promoter located upstream of the gene, and RNA is synthesized by attaching ribonucleotides to the 3' end so that the sequence is complementary to the DNA base sequence. This RNA includes not only the gene itself, but also the entire sequence from the transcription start point to the end of the poly(A) sequence, including expression control regions, coding regions, exons, and introns.

[0062] Furthermore, unless otherwise specified, the term "microRNA (miRNA)" as used herein refers to a 15-25 base non-coding RNA that is transcribed as a hairpin-like RNA precursor, cleaved by a dsRNA cleaving enzyme with RNase III cleavage activity, incorporated into a protein complex called RISC, and involved in the translational repression of mRNA. Furthermore, the term "miRNA" as used herein not only refers to a "miRNA" represented by a specific base sequence (or SEQ ID NO:), but also encompasses "miRNA" that contains a precursor of the "miRNA" (pre-miRNA, pri-miRNA) and has biological functions equivalent to those of the miRNA encoded by these, such as homologs (i.e., homologs or orthologs), variants such as genetic polymorphisms, and derivatives. Specific examples of "miRNAs" encoding such precursors, homologs, variants, or derivatives can be identified using miRBase release 21 (http: / / www.mirbase.org / ), and include "miRNAs" having a nucleotide sequence that hybridizes under stringent conditions described below with the complementary sequence of any of the specific nucleotide sequences represented by SEQ ID NOs: 1 to 842. Furthermore, as used herein, "miRNA" may refer to the gene product of a miR gene, and such gene products include mature miRNAs (e.g., non-coding RNAs of 15 to 25 bases or 19 to 25 bases involved in translational repression of mRNA as described above) or miRNA precursors (e.g., pre-miRNAs or pri-miRNAs as described above).

[0063] As used herein, the term "probe" encompasses a polynucleotide used to specifically detect RNA produced by gene expression or a polynucleotide derived therefrom, and / or a polynucleotide complementary thereto.

[0064] As used herein, the term "primer" encompasses consecutive polynucleotides and / or polynucleotides complementary thereto that specifically recognize and amplify RNA produced by gene expression or a polynucleotide derived therefrom.

[0065] Here, a complementary polynucleotide (complementary strand, reverse strand) refers to a polynucleotide that is base-complementary to the full-length polynucleotide sequence consisting of a base sequence defined by any one of SEQ ID NOS: 1 to 842, or a base sequence in which u is replaced with t, or a partial sequence thereof (herein referred to as the normal strand for convenience). However, such a complementary strand is not limited to a sequence that forms a completely complementary sequence with the base sequence of the target normal strand, but may also have a complementary relationship to the extent that it can hybridize with the target normal strand under stringent conditions.

[0066] As used herein, "stringent conditions" refers to conditions under which a nucleic acid probe hybridizes to its target sequence to a detectably greater extent (e.g., a measurement value of at least the mean of background measurements plus twice the standard error of the background measurement) than to other sequences. Stringent conditions are sequence-dependent and vary depending on the environment in which hybridization occurs. By controlling the stringency of hybridization and / or washing conditions, a target sequence that is 100% complementary to a nucleic acid probe can be identified. Specific examples of "stringent conditions" are described below. As used herein, the term "Tm value" refers to the temperature at which the double-stranded portion of a polynucleotide is denatured into a single strand, and the double strand and single strand exist in a 1:1 ratio.

[0067] As used herein, the term "variant" refers to, in the case of nucleic acids, natural variants resulting from polymorphism, mutation, etc., or variants comprising a deletion, substitution, addition, or insertion of one, two, three, or more (e.g., one to several) bases in a base sequence represented by a SEQ ID NO:, or a base sequence in which u is replaced by t in said base sequence, or a partial sequence thereof; or a variant comprising a deletion, substitution, addition, or insertion of one, two, three, or more (e.g., one to several) bases in a base sequence of a precursor RNA (premature miRNA) of any of SEQ ID NOs: 1 to 275, or a base sequence in which u is replaced by t in said base sequence, or a partial sequence thereof; or a variant showing about 90% or more, about 95% or more, about 97% or more, about 98% or more, or about 99% or more percent identity with each of said base sequences or a partial sequence thereof; or a nucleic acid that hybridizes to a polynucleotide or oligonucleotide comprising said base sequence or a partial sequence thereof under stringent conditions as defined above.

[0068] As used herein, "several" means an integer of about 10, 9, 8, 7, 6, 5, 4, 3, or 2.

[0069] As used herein, mutants can be prepared using well-known techniques such as site-directed mutagenesis and PCR-based mutagenesis.

[0070] As used herein, "% identity" can be determined using a protein or gene search system such as BLAST (https: / / blast.ncbi.nlm.nih.gov / Blast.cgi) or FASTA (http: / / www.genome.jp / tools / fasta / ), with or without introducing gaps (Zheng Zhang et al., 2000, J. Comput. Biol., Vol. 7, pp. 203-214; Altschul, S. F. et al., 1990, Journal of Molecular Biology, Vol. 215, pp. 403-410; Pearson, W. R. et al., 1988, Proc. Natl. Acad. Sci. USA, Vol. 85, pp. 2444-2448).

[0071] As used herein, the term "derivative" refers to modified nucleic acids, including, but not limited to, derivatives labeled with a fluorophore or the like, derivatives containing modified nucleotides (e.g., nucleotides containing groups such as halogen, alkyl such as methyl, alkoxy such as methoxy, thio, and carboxymethyl, and nucleotides that have undergone base rearrangement, double bond saturation, deamination, or substitution of oxygen molecules with sulfur molecules), PNA (peptide nucleic acid; Nielsen, P.E. et al., 1991, Science, Vol. 254, pp. 1497-500), LNA (locked nucleic acid; Obika, S. et al., 1998, Tetrahedron Lett., Vol. 39, pp. 5401-5404), and the like.

[0072] As used herein, a polynucleotide selected from the miRNAs that are ovarian tumor markers, or a "nucleic acid" capable of specifically binding to the complementary strand of such a polynucleotide, or a "nucleic acid" capable of detecting such a polynucleotide, refers to a synthetic or prepared nucleic acid, including, for example, a "nucleic acid probe" or "primer," which is used directly or indirectly to detect the presence or absence of ovarian tumor in a subject, to diagnose the presence or absence of ovarian tumor disease, the degree of ovarian tumor disease, the presence or degree of improvement of ovarian tumor, or sensitivity to ovarian tumor treatment, or to screen for candidate substances useful for the prevention, amelioration, or treatment of ovarian tumor. These include nucleotides, oligonucleotides, and polynucleotides that can specifically recognize and bind to a transcription product represented by any of SEQ ID NOs: 1 to 842 or a cDNA synthetic nucleic acid thereof in a biological sample, particularly in a biological sample such as blood or urine, in relation to ovarian tumor disease. Based on the above-described properties, these nucleotides, oligonucleotides, and polynucleotides can be effectively used as probes for detecting the gene expressed in vivo, in tissues, cells, etc., or as primers for amplifying the gene expressed in vivo.

[0073] The term "detection" as used herein may be replaced with the terms "test," "measurement," "detection," or "assistance in diagnosis." Furthermore, the term "evaluation" as used herein is used to include the support of diagnosis or assessment based on test results or measurement results.

[0074] As used herein, "subject" refers to mammals such as humans, primates including chimpanzees, pet animals such as dogs and cats, livestock animals such as cows, horses, sheep and goats, rodents such as mice and rats, and animals kept in zoos. A preferred subject is a human. As used herein, "subject" may also be referred to as "test subject." A "healthy subject" also refers to such a mammal, an animal or subject not suffering from the cancer to be detected. A preferred healthy subject is a human.

[0075] As used herein, "ovarian cancer" refers to a malignant tumor that occurs in the ovary, and includes, for example, epithelial ovarian cancer that arises from the mucosal epithelium and germ cell stromal ovarian cancer.

[0076] As used herein, a "benign ovarian tumor" is a benign tumor that occurs in the ovary, and includes, for example, mucinous cystadenoma, serous cystadenoma, mature teratoma, and fibroma.

[0077] As used herein, "ovarian tumor" is a term that encompasses the above-mentioned "ovarian cancer" and "benign ovarian tumor."

[0078] As used herein, "P" or "P value" indicates the probability that a statistical value that is more extreme than the statistical value actually calculated from data under the null hypothesis will be observed in a statistical test. Therefore, the smaller the "P" or "P value," the more significant the difference between the compared subjects.

[0079] As used herein, "sensitivity" refers to the value of (the number of true positives) / (the number of true positives + the number of false negatives). High sensitivity enables early detection of ovarian cancer, leading to complete removal of cancerous tissue and a reduced recurrence rate.

[0080] As used herein, "specificity" means (number of true negatives) / (number of true negatives + number of false positives). High specificity prevents unnecessary additional testing due to misidentification of healthy individuals as ovarian cancer patients, reducing the burden on patients and medical costs.

[0081] In this specification, "accuracy" means the value of (number of true positives + number of true negatives) / (total number of cases). Accuracy indicates the proportion of correct discrimination results for all samples, and is the primary index for evaluating detection performance.

[0082] As used herein, the term "specimen" to be assessed, detected, or diagnosed refers to tissues and biological materials in which the expression of the gene of the present invention changes with the onset, progression, and therapeutic effects of ovarian cancer. Specifically, this refers to ovarian tissues and fallopian tubes, lymph nodes and surrounding organs, organs suspected of metastasis, skin, and bodily fluids such as blood, urine, saliva, sweat, and tissue exudates, as well as serum and plasma prepared from blood, feces, and hair. It also refers to biological samples extracted from these, specifically genes such as RNA and miRNA.

[0083] As used herein, the term "hsa-miR-4675 gene" or "hsa-miR-4675" encompasses the hsa-miR-4675 gene set forth in SEQ ID NO: 1 (miRBase Accession No. MIMAT0019757) as well as homologs or orthologs from other biological species. The hsa-miR-4675 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4675" is "hsa-mir-4675" (miRBase Accession No. MI0017306, SEQ ID NO: 276), which has a hairpin-like structure.

[0084] As used herein, the terms "hsa-miR-4783-3p gene" or "hsa-miR-4783-3p" encompass the hsa-miR-4783-3p gene set forth in SEQ ID NO: 2 (miRBase Accession No. MIMAT0019947) as well as homologs or orthologs from other organisms. The hsa-miR-4783-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4783-3p" is known to be "hsa-mir-4783" (miRBase Accession No. MI0017428, SEQ ID NO: 277), which has a hairpin-like structure.

[0085] As used herein, the terms "hsa-miR-1228-5p gene" or "hsa-miR-1228-5p" encompass the hsa-miR-1228-5p gene set forth in SEQ ID NO: 3 (miRBase Accession No. MIMAT0005582) and homologs or orthologs from other biological species. The hsa-miR-1228-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, pp. 328-336. Furthermore, the precursor of "hsa-miR-1228-5p" is known to be "hsa-mir-1228" (miRBase Accession No. MI0006318, SEQ ID NO: 278), which has a hairpin-like structure.

[0086] As used herein, the term "hsa-miR-4532 gene" or "hsa-miR-4532" encompasses the hsa-miR-4532 gene set forth in SEQ ID NO: 4 (miRBase Accession No. MIMAT0019071) and homologs or orthologs from other biological species. The hsa-miR-4532 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4532" is "hsa-mir-4532" (miRBase Accession No. MI0016899, SEQ ID NO: 279), which has a hairpin-like structure.

[0087] As used herein, the terms "hsa-miR-6802-5p gene" or "hsa-miR-6802-5p" encompass the hsa-miR-6802-5p gene set forth in SEQ ID NO: 5 (miRBase Accession No. MIMAT0027504) and homologs or orthologs from other biological species. The hsa-miR-6802-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6802-5p" is known to be "hsa-mir-6802" (miRBase Accession No. MI0022647, SEQ ID NO: 280), which has a hairpin-like structure.

[0088] As used herein, the terms "hsa-miR-6784-5p gene" or "hsa-miR-6784-5p" encompass the hsa-miR-6784-5p gene set forth in SEQ ID NO: 6 (miRBase Accession No. MIMAT0027468) and homologs or orthologs from other biological species. The hsa-miR-6784-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6784-5p" is known to be "hsa-mir-6784" (miRBase Accession No. MI0022629, SEQ ID NO: 281), which has a hairpin-like structure.

[0089] As used herein, the terms "hsa-miR-3940-5p gene" or "hsa-miR-3940-5p" encompass the hsa-miR-3940-5p gene set forth in SEQ ID NO: 7 (miRBase Accession No. MIMAT0019229) as well as homologs or orthologs from other biological species. The hsa-miR-3940-5p gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, Vol. 5, e10563. Furthermore, the precursor of "hsa-miR-3940-5p" is known to be "hsa-mir-3940" (miRBase Accession No. MI0016597, SEQ ID NO: 282), which has a hairpin-like structure. As used herein, the terms "hsa-miR-1307-3p gene" or "hsa-miR-1307-3p" encompass the hsa-miR-1307-3p gene set forth in SEQ ID NO: 8 (miRBase Accession No. MIMAT0005951) and homologs or orthologs from other organisms. The hsa-miR-1307-3p gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, vol. 18, pp. 610-621. Furthermore, the precursor of "hsa-miR-1307-3p" is known to be "hsa-mir-1307" (miRBase Accession No. MI0006444, SEQ ID NO: 283), which has a hairpin-like structure.

[0090] As used herein, the term "hsa-miR-8073 gene" or "hsa-miR-8073" encompasses the hsa-miR-8073 gene set forth in SEQ ID NO: 9 (miRBase Accession No. MIMAT0031000) and homologs or orthologs from other biological species. The hsa-miR-8073 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, vol. 39, pp. 480-487. Furthermore, a known precursor of "hsa-miR-8073" is "hsa-mir-8073" (miRBase Accession No. MI0025909, SEQ ID NO: 284), which has a hairpin-like structure.

[0091] As used herein, the terms "hsa-miR-3184-5p gene" or "hsa-miR-3184-5p" encompass the hsa-miR-3184-5p gene set forth in SEQ ID NO: 10 (miRBase Accession No. MIMAT0015064) and homologs or orthologs from other biological species. The hsa-miR-3184-5p gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, vol. 5, e9685. It is also known that the precursor of "hsa-miR-3184-5p" is "hsa-mir-3184" (miRBase Accession No. MI0014226, SEQ ID NO: 285), which has a hairpin-like structure.

[0092] As used herein, the terms "hsa-miR-1233-5p gene" or "hsa-miR-1233-5p" encompass the hsa-miR-1233-5p gene set forth in SEQ ID NO: 11 (miRBase Accession No. MIMAT0022943) as well as homologs or orthologs from other biological species. The hsa-miR-1233-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, pp. 328-336. Furthermore, "hsa-miR-1233-5p" is known to have precursors with hairpin-like structures, "hsa-mir-1233-1" and "hsa-mir-1233-2" (miRBase Accession Nos. MI0006323 and MI0015973, SEQ ID NOs: 286 and 287).

[0093] As used herein, the term "hsa-miR-6088 gene" or "hsa-miR-6088" encompasses the hsa-miR-6088 gene set forth in SEQ ID NO: 12 (miRBase Accession No. MIMAT0023713) and homologs or orthologs from other biological species. The hsa-miR-6088 gene can be obtained by the method described in Yoo JK et al., 2012, Stem Cells Dev, vol. 21, pp. 2049-2057. Furthermore, a known precursor of "hsa-miR-6088" is "hsa-mir-6088" (miRBase Accession No. MI0020365, SEQ ID NO: 288), which has a hairpin-like structure.

[0094] As used herein, the terms "hsa-miR-5195-3p gene" or "hsa-miR-5195-3p" encompass the hsa-miR-5195-3p gene set forth in SEQ ID NO: 13 (miRBase Accession No. MIMAT0021127) as well as homologs or orthologs from other organisms. The hsa-miR-5195-3p gene can be obtained by the method described in Schotte D et al., 2011, Leukemia, Vol. 25, pp. 1389-1399. Furthermore, the precursor of "hsa-miR-5195-3p" is known to be "hsa-mir-5195" (miRBase Accession No. MI0018174, SEQ ID NO: 289), which has a hairpin-like structure.

[0095] As used herein, the term "hsa-miR-320b gene" or "hsa-miR-320b" encompasses the hsa-miR-320b gene set forth in SEQ ID NO: 14 (miRBase Accession No. MIMAT0005792) and homologs or orthologs from other organisms. The hsa-miR-320b gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, vol. 16, pp. 1289-1298. Furthermore, "hsa-miR-320b" is known to have precursors with hairpin-like structures, such as "hsa-mir-320b-1" and "hsa-mir-320b-2" (miRBase Accession Nos. MI0003776 and MI0003839, SEQ ID NOs: 290 and 291).

[0096] As used herein, the terms "hsa-miR-4649-5p gene" or "hsa-miR-4649-5p" encompass the hsa-miR-4649-5p gene set forth in SEQ ID NO: 15 (miRBase Accession No. MIMAT0019711) and homologs or orthologs from other biological species. The hsa-miR-4649-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4649-5p" is known to be "hsa-mir-4649" (miRBase Accession No. MI0017276, SEQ ID NO: 292), which has a hairpin-like structure.

[0097] As used herein, the terms "hsa-miR-6800-5p gene" or "hsa-miR-6800-5p" encompass the hsa-miR-6800-5p gene set forth in SEQ ID NO: 16 (miRBase Accession No. MIMAT0027500) and homologs or orthologs from other biological species. The hsa-miR-6800-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6800-5p" is known to be "hsa-mir-6800" (miRBase Accession No. MI0022645, SEQ ID NO: 293), which has a hairpin-like structure.

[0098] As used herein, the terms "hsa-miR-1343-3p gene" or "hsa-miR-1343-3p" encompass the hsa-miR-1343-3p gene set forth in SEQ ID NO: 17 (miRBase Accession No. MIMAT0019776) as well as homologs or orthologs from other organisms. The hsa-miR-1343-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-1343-3p" is known to be "hsa-mir-1343" (miRBase Accession No. MI0017320, SEQ ID NO: 294), which has a hairpin-like structure.

[0099] As used herein, the term "hsa-miR-4730 gene" or "hsa-miR-4730" encompasses the hsa-miR-4730 gene set forth in SEQ ID NO: 18 (miRBase Accession No. MIMAT0019852) and homologs or orthologs from other biological species. The hsa-miR-4730 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4730" is "hsa-mir-4730" (miRBase Accession No. MI0017367, SEQ ID NO: 295), which has a hairpin-like structure.

[0100] As used herein, the terms "hsa-miR-6885-5p gene" or "hsa-miR-6885-5p" encompass the hsa-miR-6885-5p gene set forth in SEQ ID NO: 19 (miRBase Accession No. MIMAT0027670) and homologs or orthologs from other organisms. The hsa-miR-6885-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6885-5p" is known to have a precursor, "hsa-mir-6885" (miRBase Accession No. MI0022732, SEQ ID NO: 296), which has a hairpin-like structure.

[0101] As used herein, the term "hsa-miR-5100 gene" or "hsa-miR-5100" encompasses the hsa-miR-5100 gene set forth in SEQ ID NO: 20 (miRBase Accession No. MIMAT0022259) and homologs or orthologs from other biological species. The hsa-miR-5100 gene can be obtained by the method described in Tandon M et al., 2012, Oral Dis, Vol. 18, pp. 127-131. Furthermore, a known precursor of "hsa-miR-5100" is "hsa-mir-5100" (miRBase Accession No. MI0019116, SEQ ID NO: 297), which has a hairpin-like structure.

[0102] As used herein, the term "hsa-miR-1203 gene" or "hsa-miR-1203" encompasses the hsa-miR-1203 gene set forth in SEQ ID NO: 21 (miRBase Accession No. MIMAT0005866) as well as homologs or orthologs from other organisms. The hsa-miR-1203 gene can be obtained by the method described in Marton S et al., 2008, Leukemia, vol. 22, pp. 330-338. Furthermore, a known precursor of "hsa-miR-1203" is "hsa-mir-1203" (miRBase Accession No. MI0006335, SEQ ID NO: 298), which has a hairpin-like structure.

[0103] As used herein, the terms "hsa-miR-6756-5p gene" or "hsa-miR-6756-5p" encompass the hsa-miR-6756-5p gene set forth in SEQ ID NO: 22 (miRBase Accession No. MIMAT0027412) and homologs or orthologs from other biological species. The hsa-miR-6756-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6756-5p" is known to be "hsa-mir-6756" (miRBase Accession No. MI0022601, SEQ ID NO: 299), which has a hairpin-like structure.

[0104] As used herein, the term "hsa-miR-373-5p gene" or "hsa-miR-373-5p" encompasses the hsa-miR-373-5p gene set forth in SEQ ID NO: 23 (miRBase Accession No. MIMAT0000725) and homologs or orthologs from other organisms. The hsa-miR-373-5p gene can be obtained by the method described in Suh MR et al., 2004, Dev Biol, vol. 270, pp. 488-498. Furthermore, the precursor of "hsa-miR-373-5p" is known to be "hsa-mir-373" (miRBase Accession No. MI0000781, SEQ ID NO: 300), which has a hairpin-like structure.

[0105] As used herein, the term "hsa-miR-1268a gene" or "hsa-miR-1268a" encompasses the hsa-miR-1268a gene set forth in SEQ ID NO: 24 (miRBase Accession No. MIMAT0005922) and homologs or orthologs from other organisms. The hsa-miR-1268a gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, vol. 18, pp. 610-621. Furthermore, a known precursor of "hsa-miR-1268a" is "hsa-mir-1268a" (miRBase Accession No. MI0006405, SEQ ID NO: 301), which has a hairpin-like structure.

[0106] As used herein, the term "hsa-miR-1260b gene" or "hsa-miR-1260b" encompasses the hsa-miR-1260b gene set forth in SEQ ID NO: 25 (miRBase Accession No. MIMAT0015041) as well as homologs or orthologs from other biological species. The hsa-miR-1260b gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, vol. 5, e9685. Furthermore, a known precursor of "hsa-miR-1260b" is "hsa-mir-1260b" (miRBase Accession No. MI0014197, SEQ ID NO: 302), which has a hairpin-like structure.

[0107] As used herein, the term "hsa-miR-4258 gene" or "hsa-miR-4258" encompasses the hsa-miR-4258 gene set forth in SEQ ID NO: 26 (miRBase Accession No. MIMAT0016879) as well as homologs or orthologs from other biological species. The hsa-miR-4258 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, vol. 4, e7192. Furthermore, a known precursor of "hsa-miR-4258" is "hsa-mir-4258" (miRBase Accession No. MI0015857, SEQ ID NO: 303), which has a hairpin-like structure.

[0108] As used herein, the terms "hsa-miR-4697-5p gene" or "hsa-miR-4697-5p" encompass the hsa-miR-4697-5p gene set forth in SEQ ID NO: 27 (miRBase Accession No. MIMAT0019791) and homologs or orthologs from other organisms. The hsa-miR-4697-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4697-5p" is known to be "hsa-mir-4697" (miRBase Accession No. MI0017330, SEQ ID NO: 304), which has a hairpin-like structure.

[0109] As used herein, the term "hsa-miR-1469 gene" or "hsa-miR-1469" encompasses the hsa-miR-1469 gene set forth in SEQ ID NO: 28 (miRBase Accession No. MIMAT0007347) as well as homologs or orthologs from other organisms. The hsa-miR-1469 gene can be obtained by the method described in Kawaji H et al., 2008, BMC Genomics, Vol. 9, p. 157. Furthermore, a known precursor of "hsa-miR-1469" is "hsa-mir-1469" (miRBase Accession No. MI0007074, SEQ ID NO: 305), which has a hairpin-like structure.

[0110] As used herein, the term "hsa-miR-4515 gene" or "hsa-miR-4515" encompasses the hsa-miR-4515 gene set forth in SEQ ID NO: 29 (miRBase Accession No. MIMAT0019052) and homologs or orthologs from other biological species. The hsa-miR-4515 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4515" is "hsa-mir-4515" (miRBase Accession No. MI0016881, SEQ ID NO: 306), which has a hairpin-like structure.

[0111] As used herein, the terms "hsa-miR-6861-5p gene" or "hsa-miR-6861-5p" encompass the hsa-miR-6861-5p gene set forth in SEQ ID NO: 30 (miRBase Accession No. MIMAT0027623) and homologs or orthologs from other organisms. The hsa-miR-6861-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6861-5p" is known to be "hsa-mir-6861" (miRBase Accession No. MI0022708, SEQ ID NO: 307), which has a hairpin-like structure.

[0112] As used herein, the terms "hsa-miR-6821-5p gene" or "hsa-miR-6821-5p" encompass the hsa-miR-6821-5p gene set forth in SEQ ID NO: 31 (miRBase Accession No. MIMAT0027542) and homologs or orthologs from other organisms. The hsa-miR-6821-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6821-5p" is known to have a precursor, "hsa-mir-6821" (miRBase Accession No. MI0022666, SEQ ID NO: 308), which has a hairpin-like structure.

[0113] As used herein, the term "hsa-miR-575 gene" or "hsa-miR-575" encompasses the hsa-miR-575 gene set forth in SEQ ID NO: 32 (miRBase Accession No. MIMAT0003240) and homologs or orthologs from other organisms. The hsa-miR-575 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, pp. 3687-3692. Furthermore, a known precursor of "hsa-miR-575" is "hsa-mir-575" (miRBase Accession No. MI0003582, SEQ ID NO: 309), which has a hairpin-like structure.

[0114] As used herein, the terms "hsa-miR-6805-5p gene" or "hsa-miR-6805-5p" encompass the hsa-miR-6805-5p gene set forth in SEQ ID NO: 33 (miRBase Accession No. MIMAT0027510) and homologs or orthologs from other organisms. The hsa-miR-6805-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6805-5p" is known to have a precursor, "hsa-mir-6805" (miRBase Accession No. MI0022650, SEQ ID NO: 310), which has a hairpin-like structure.

[0115] As used herein, the terms "hsa-miR-4758-5p gene" or "hsa-miR-4758-5p" encompass the hsa-miR-4758-5p gene set forth in SEQ ID NO: 34 (miRBase Accession No. MIMAT0019903) as well as homologs or orthologs from other organisms. The hsa-miR-4758-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4758-5p" is known to be "hsa-mir-4758" (miRBase Accession No. MI0017399, SEQ ID NO: 311), which has a hairpin-like structure.

[0116] As used herein, the terms "hsa-miR-3663-3p gene" or "hsa-miR-3663-3p" encompass the hsa-miR-3663-3p gene set forth in SEQ ID NO: 35 (miRBase Accession No. MIMAT0018085) and homologs or orthologs from other organisms. The hsa-miR-3663-3p gene can be obtained by the method described in Liao JY et al., 2010, PLoS One, Vol. 5, e10563. Furthermore, the precursor of "hsa-miR-3663-3p" is known to be "hsa-mir-3663" (miRBase Accession No. MI0016064, SEQ ID NO: 312), which has a hairpin-like structure.

[0117] As used herein, the term "hsa-miR-4530 gene" or "hsa-miR-4530" encompasses the hsa-miR-4530 gene set forth in SEQ ID NO: 36 (miRBase Accession No. MIMAT0019069) and homologs or orthologs from other biological species. The hsa-miR-4530 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4530" is "hsa-mir-4530" (miRBase Accession No. MI0016897, SEQ ID NO: 313), which has a hairpin-like structure.

[0118] As used herein, the term "hsa-miR-6798-5p gene" or "hsa-miR-6798-5p" encompasses the hsa-miR-6798-5p gene set forth in SEQ ID NO: 37 (miRBase Accession No. MIMAT0027496) and homologs or orthologs from other biological species. The hsa-miR-6798-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6798-5p" is known to be "hsa-mir-6798" (miRBase Accession No. MI0022643, SEQ ID NO: 314), which has a hairpin-like structure.

[0119] As used herein, the term "hsa-miR-6781-5p gene" or "hsa-miR-6781-5p" encompasses the hsa-miR-6781-5p gene set forth in SEQ ID NO: 38 (miRBase Accession No. MIMAT0027462) and homologs or orthologs from other organisms. The hsa-miR-6781-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6781-5p" is known to be "hsa-mir-6781" (miRBase Accession No. MI0022626, SEQ ID NO: 315), which has a hairpin-like structure.

[0120] As used herein, the terms "hsa-miR-885-3p gene" or "hsa-miR-885-3p" encompass the hsa-miR-885-3p gene set forth in SEQ ID NO: 39 (miRBase Accession No. MIMAT0004948) and homologs or orthologs from other organisms. The hsa-miR-885-3p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, vol. 16, pp. 1289-1298. Furthermore, the precursor of "hsa-miR-885-3p" is known to be "hsa-mir-885" (miRBase Accession No. MI0005560, SEQ ID NO: 316), which has a hairpin-like structure.

[0121] As used herein, the terms "hsa-miR-1273g-3p gene" or "hsa-miR-1273g-3p" encompass the hsa-miR-1273g-3p gene set forth in SEQ ID NO: 40 (miRBase Accession No. MIMAT0022742) and homologs or orthologs from other biological species. The hsa-miR-1273g-3p gene can be obtained by the method described in Reshmi G et al., 2011, Genomics, Vol. 97, pp. 333-340. Furthermore, the precursor of "hsa-miR-1273g-3p" is known to be "hsa-mir-1273g" (miRBase Accession No. MI0018003, SEQ ID NO: 317), which has a hairpin-like structure.

[0122] As used herein, the terms "hsa-miR-4787-3p gene" or "hsa-miR-4787-3p" encompass the hsa-miR-4787-3p gene set forth in SEQ ID NO: 41 (miRBase Accession No. MIMAT0019957) as well as homologs or orthologs from other biological species. The hsa-miR-4787-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4787-3p" is known to be "hsa-mir-4787" (miRBase Accession No. MI0017434, SEQ ID NO: 318), which has a hairpin-like structure.

[0123] As used herein, the term "hsa-miR-4454 gene" or "hsa-miR-4454" encompasses the hsa-miR-4454 gene set forth in SEQ ID NO: 42 (miRBase Accession No. MIMAT0018976) as well as homologs or orthologs from other biological species. The hsa-miR-4454 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4454" is "hsa-mir-4454" (miRBase Accession No. MI0016800, SEQ ID NO: 319), which has a hairpin-like structure.

[0124] As used herein, the term "hsa-miR-4706 gene" or "hsa-miR-4706" encompasses the hsa-miR-4706 gene set forth in SEQ ID NO: 43 (miRBase Accession No. MIMAT0019806) as well as homologs or orthologs from other organisms. The hsa-miR-4706 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4706" is "hsa-mir-4706" (miRBase Accession No. MI0017339, SEQ ID NO: 320), which has a hairpin-like structure.

[0125] As used herein, the terms "hsa-miR-1249-3p gene" or "hsa-miR-1249-3p" encompass the hsa-miR-1249-3p gene set forth in SEQ ID NO: 44 (miRBase Accession No. MIMAT0005901) and homologs or orthologs from other organisms. The hsa-miR-1249-3p gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, vol. 18, pp. 610-621. Furthermore, the precursor of "hsa-miR-1249-3p" is known to be "hsa-mir-1249" (miRBase Accession No. MI0006384, SEQ ID NO: 321), which has a hairpin-like structure.

[0126] As used herein, the term "hsa-miR-887-3p gene" or "hsa-miR-887-3p" encompasses the hsa-miR-887-3p gene set forth in SEQ ID NO: 45 (miRBase Accession No. MIMAT0004951) and homologs or orthologs from other organisms. The hsa-miR-887-3p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, vol. 16, pp. 1289-1298. Furthermore, the precursor of "hsa-miR-887-3p" is known to be "hsa-mir-887" (miRBase Accession No. MI0005562, SEQ ID NO: 322), which has a hairpin-like structure.

[0127] As used herein, the term "hsa-miR-6786-5p gene" or "hsa-miR-6786-5p" encompasses the hsa-miR-6786-5p gene set forth in SEQ ID NO: 46 (miRBase Accession No. MIMAT0027472) and homologs or orthologs from other organisms. The hsa-miR-6786-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6786-5p" is known to be "hsa-mir-6786" (miRBase Accession No. MI0022631, SEQ ID NO: 323), which has a hairpin-like structure.

[0128] As used herein, the terms "hsa-miR-1238-5p gene" or "hsa-miR-1238-5p" encompass the hsa-miR-1238-5p gene set forth in SEQ ID NO: 47 (miRBase Accession No. MIMAT0022947) as well as homologs or orthologs from other organisms. The hsa-miR-1238-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, pp. 328-336. Furthermore, "hsa-miR-1238-5p" is known to have a precursor, "hsa-mir-1238" (miRBase Accession No. MI0006328, SEQ ID NO: 324), which has a hairpin-like structure.

[0129] As used herein, the term "hsa-miR-6749-5p gene" or "hsa-miR-6749-5p" encompasses the hsa-miR-6749-5p gene set forth in SEQ ID NO: 48 (miRBase Accession No. MIMAT0027398) and homologs or orthologs from other organisms. The hsa-miR-6749-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6749-5p" is known to be "hsa-mir-6749" (miRBase Accession No. MI0022594, SEQ ID NO: 325), which has a hairpin-like structure.

[0130] As used herein, the term "hsa-miR-6729-5p gene" or "hsa-miR-6729-5p" encompasses the hsa-miR-6729-5p gene set forth in SEQ ID NO: 49 (miRBase Accession No. MIMAT0027359) and homologs or orthologs from other biological species. The hsa-miR-6729-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6729-5p" is known to be "hsa-mir-6729" (miRBase Accession No. MI0022574, SEQ ID NO: 326), which has a hairpin-like structure.

[0131] As used herein, the terms "hsa-miR-6825-5p gene" or "hsa-miR-6825-5p" encompass the hsa-miR-6825-5p gene set forth in SEQ ID NO: 50 (miRBase Accession No. MIMAT0027550) and homologs or orthologs from other biological species. The hsa-miR-6825-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6825-5p" is known to be "hsa-mir-6825" (miRBase Accession No. MI0022670, SEQ ID NO: 327), which has a hairpin-like structure.

[0132] As used herein, the term "hsa-miR-663b gene" or "hsa-miR-663b" encompasses the hsa-miR-663b gene set forth in SEQ ID NO: 51 (miRBase Accession No. MIMAT0005867) and homologs or orthologs from other organisms. The hsa-miR-663b gene can be obtained by the method described in Takada S et al., 2008, Leukemia, Vol. 22, pp. 1274-1278. Furthermore, a known precursor of "hsa-miR-663b" is "hsa-mir-663b" (miRBase Accession No. MI0006336, SEQ ID NO: 328), which has a hairpin-like structure.

[0133] As used herein, the terms "hsa-miR-6858-5p gene" or "hsa-miR-6858-5p" encompass the hsa-miR-6858-5p gene set forth in SEQ ID NO: 52 (miRBase Accession No. MIMAT0027616) and homologs or orthologs from other organisms. The hsa-miR-6858-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6858-5p" is known to be "hsa-mir-6858" (miRBase Accession No. MI0022704, SEQ ID NO: 329), which has a hairpin-like structure.

[0134] As used herein, the terms "hsa-miR-4690-5p gene" or "hsa-miR-4690-5p" encompass the hsa-miR-4690-5p gene set forth in SEQ ID NO: 53 (miRBase Accession No. MIMAT0019779) as well as homologs or orthologs from other biological species. The hsa-miR-4690-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4690-5p" is known to be "hsa-mir-4690" (miRBase Accession No. MI0017323, SEQ ID NO: 330), which has a hairpin-like structure.

[0135] As used herein, the term "hsa-miR-6765-5p gene" or "hsa-miR-6765-5p" encompasses the hsa-miR-6765-5p gene set forth in SEQ ID NO: 54 (miRBase Accession No. MIMAT0027430) and homologs or orthologs from other organisms. The hsa-miR-6765-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6765-5p" is known to have a precursor, "hsa-mir-6765" (miRBase Accession No. MI0022610, SEQ ID NO: 331), which has a hairpin-like structure.

[0136] As used herein, the term "hsa-miR-4710 gene" or "hsa-miR-4710" encompasses the hsa-miR-4710 gene set forth in SEQ ID NO: 55 (miRBase Accession No. MIMAT0019815) and homologs or orthologs from other biological species. The hsa-miR-4710 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4710" is "hsa-mir-4710" (miRBase Accession No. MI0017344, SEQ ID NO: 332), which has a hairpin-like structure.

[0137] As used herein, the term "hsa-miR-6775-5p gene" or "hsa-miR-6775-5p" encompasses the hsa-miR-6775-5p gene set forth in SEQ ID NO: 56 (miRBase Accession No. MIMAT0027450) and homologs or orthologs from other biological species. The hsa-miR-6775-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6775-5p" is known to have a precursor, "hsa-mir-6775" (miRBase Accession No. MI0022620, SEQ ID NO: 333), which has a hairpin-like structure.

[0138] As used herein, the terms "hsa-miR-371a-5p gene" or "hsa-miR-371a-5p" encompass the hsa-miR-371a-5p gene set forth in SEQ ID NO: 57 (miRBase Accession No. MIMAT0004687) and homologs or orthologs from other organisms. The hsa-miR-371a-5p gene can be obtained by the method described in Suh MR et al., 2004, Dev Biol, vol. 270, pp. 488-498. Furthermore, the precursor of "hsa-miR-371a-5p" is known to be "hsa-mir-371a" (miRBase Accession No. MI0000779, SEQ ID NO: 334), which has a hairpin-like structure.

[0139] As used herein, the term "hsa-miR-6816-5p gene" or "hsa-miR-6816-5p" encompasses the hsa-miR-6816-5p gene set forth in SEQ ID NO: 58 (miRBase Accession No. MIMAT0027532) and homologs or orthologs from other biological species. The hsa-miR-6816-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6816-5p" is known to be "hsa-mir-6816" (miRBase Accession No. MI0022661, SEQ ID NO: 335), which has a hairpin-like structure.

[0140] As used herein, the terms "hsa-miR-296-3p gene" or "hsa-miR-296-3p" encompass the hsa-miR-296-3p gene set forth in SEQ ID NO: 59 (miRBase Accession No. MIMAT0004679) and homologs or orthologs from other organisms. The hsa-miR-296-3p gene can be obtained by the method described in Houbaviy HB et al., 2003, Dev Cell, vol. 5, pp. 351-358. Furthermore, the precursor of "hsa-miR-296-3p" is known to be "hsa-mir-296" (miRBase Accession No. MI0000747, SEQ ID NO: 336), which has a hairpin-like structure.

[0141] As used herein, the term "hsa-miR-7977 gene" or "hsa-miR-7977" encompasses the hsa-miR-7977 gene set forth in SEQ ID NO: 60 (miRBase Accession No. MIMAT0031180) and homologs or orthologs from other biological species. The hsa-miR-7977 gene can be obtained by the method described in Velthut-Meikas A et al., 2013, Mol Endocrinol, Vol. 27, pp. 1128-1141. Furthermore, a known precursor of "hsa-miR-7977" is "hsa-mir-7977" (miRBase Accession No. MI0025753, SEQ ID NO: 337), which has a hairpin-like structure.

[0142] As used herein, the term "hsa-miR-8069 gene" or "hsa-miR-8069" encompasses the hsa-miR-8069 gene set forth in SEQ ID NO: 61 (miRBase Accession No. MIMAT0030996) as well as homologs or orthologs from other biological species. The hsa-miR-8069 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, vol. 39, pp. 480-487. Furthermore, "hsa-miR-8069" is known to have precursors with hairpin-like structures, "hsa-mir-8069-1" and "hsa-mir-8069-2" (miRBase Accession Nos. MI0025905 and MI0031519, SEQ ID NOs: 338 and 339).

[0143] As used herein, the terms "hsa-miR-6515-3p gene" or "hsa-miR-6515-3p" encompass the hsa-miR-6515-3p gene set forth in SEQ ID NO: 62 (miRBase Accession No. MIMAT0025487) as well as homologs or orthologs from other biological species. The hsa-miR-6515-3p gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet, vol. 20, pp. 4025-4040. Furthermore, the precursor of "hsa-miR-6515-3p" is known to be "hsa-mir-6515" (miRBase Accession No. MI0022227, SEQ ID NO: 340), which has a hairpin-like structure.

[0144] As used herein, the terms "hsa-miR-4687-5p gene" or "hsa-miR-4687-5p" encompass the hsa-miR-4687-5p gene set forth in SEQ ID NO: 63 (miRBase Accession No. MIMAT0019774) as well as homologs or orthologs from other biological species. The hsa-miR-4687-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4687-5p" is known to be "hsa-mir-4687" (miRBase Accession No. MI0017319, SEQ ID NO: 341), which has a hairpin-like structure.

[0145] As used herein, the terms "hsa-miR-1343-5p gene" or "hsa-miR-1343-5p" encompass the hsa-miR-1343-5p gene set forth in SEQ ID NO: 64 (miRBase Accession No. MIMAT0027038) and homologs or orthologs from other organisms. The hsa-miR-1343-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-1343-5p" is known to be "hsa-mir-1343" (miRBase Accession No. MI0017320, SEQ ID NO: 294), which has a hairpin-like structure.

[0146] As used herein, the terms "hsa-miR-7110-5p gene" or "hsa-miR-7110-5p" encompass the hsa-miR-7110-5p gene set forth in SEQ ID NO: 65 (miRBase Accession No. MIMAT0028117) and homologs or orthologs from other biological species. The hsa-miR-7110-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-7110-5p" is known to be "hsa-mir-7110" (miRBase Accession No. MI0022961, SEQ ID NO: 342), which has a hairpin-like structure.

[0147] As used herein, the term "hsa-miR-4525 gene" or "hsa-miR-4525" encompasses the hsa-miR-4525 gene set forth in SEQ ID NO: 66 (miRBase Accession No. MIMAT0019064) and homologs or orthologs from other biological species. The hsa-miR-4525 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4525" is "hsa-mir-4525" (miRBase Accession No. MI0016892, SEQ ID NO: 343), which has a hairpin-like structure.

[0148] As used herein, the terms "hsa-miR-3158-5p gene" or "hsa-miR-3158-5p" encompass the hsa-miR-3158-5p gene set forth in SEQ ID NO: 67 (miRBase Accession No. MIMAT0019211) and homologs or orthologs from other biological species. The hsa-miR-3158-5p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, vol. 5, e9637. Furthermore, "hsa-miR-3158-5p" is known to have precursors with hairpin-like structures, "hsa-mir-3158-1" and "hsa-mir-3158-2" (miRBase Accession Nos. MI0014186 and MI0014187, SEQ ID NOs: 344 and 345).

[0149] As used herein, the terms "hsa-miR-6787-5p gene" or "hsa-miR-6787-5p" encompass the hsa-miR-6787-5p gene set forth in SEQ ID NO: 68 (miRBase Accession No. MIMAT0027474) and homologs or orthologs from other biological species. The hsa-miR-6787-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6787-5p" is known to be "hsa-mir-6787" (miRBase Accession No. MI0022632, SEQ ID NO: 346), which has a hairpin-like structure.

[0150] As used herein, the term "hsa-miR-614 gene" or "hsa-miR-614" encompasses the hsa-miR-614 gene set forth in SEQ ID NO: 69 (miRBase Accession No. MIMAT0003282) and homologs or orthologs from other organisms. The hsa-miR-614 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, pp. 3687-3692. Furthermore, a known precursor of "hsa-miR-614" is "hsa-mir-614" (miRBase Accession No. MI0003627, SEQ ID NO: 347), which has a hairpin-like structure.

[0151] As used herein, the term "hsa-miR-4689 gene" or "hsa-miR-4689" encompasses the hsa-miR-4689 gene set forth in SEQ ID NO: 70 (miRBase Accession No. MIMAT0019778) as well as homologs or orthologs from other organisms. The hsa-miR-4689 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4689" is "hsa-mir-4689" (miRBase Accession No. MI0017322, SEQ ID NO: 348), which has a hairpin-like structure.

[0152] As used herein, the term "hsa-miR-1185-2-3p gene" or "hsa-miR-1185-2-3p" encompasses the hsa-miR-1185-2-3p gene set forth in SEQ ID NO: 71 (miRBase Accession No. MIMAT0022713) and homologs or orthologs from other organisms. The hsa-miR-1185-2-3p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, vol. 16, pp. 1289-1298. Furthermore, the precursor of "hsa-miR-1185-2-3p" is known to be "hsa-mir-1185-2" (miRBase Accession No. MI0003821, SEQ ID NO: 349), which has a hairpin-like structure.

[0153] As used herein, the term "hsa-miR-1268b gene" or "hsa-miR-1268b" encompasses the hsa-miR-1268b gene set forth in SEQ ID NO: 72 (miRBase Accession No. MIMAT0018925) as well as homologs or orthologs from other biological species. The hsa-miR-1268b gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, "hsa-miR-1268b" is known to have a precursor, "hsa-mir-1268b" (miRBase Accession No. MI0016748, SEQ ID NO: 350), which has a hairpin-like structure.

[0154] As used herein, the terms "hsa-miR-1228-3p gene" or "hsa-miR-1228-3p" encompass the hsa-miR-1228-3p gene set forth in SEQ ID NO: 73 (miRBase Accession No. MIMAT0005583) as well as homologs or orthologs from other organisms. The hsa-miR-1228-3p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, pp. 328-336. Furthermore, the precursor of "hsa-miR-1228-3p" is known to be "hsa-mir-1228" (miRBase Accession No. MI0006318, SEQ ID NO: 278), which has a hairpin-like structure.

[0155] As used herein, the term "hsa-miR-1185-1-3p gene" or "hsa-miR-1185-1-3p" encompasses the hsa-miR-1185-1-3p gene set forth in SEQ ID NO: 74 (miRBase Accession No. MIMAT0022838) and homologs or orthologs from other organisms. The hsa-miR-1185-1-3p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, vol. 16, pp. 1289-1298. Furthermore, the precursor of "hsa-miR-1185-1-3p" is known to be "hsa-mir-1185-1" (miRBase Accession No. MI0003844, SEQ ID NO: 351), which has a hairpin-like structure.

[0156] As used herein, the term "hsa-miR-940 gene" or "hsa-miR-940" encompasses the hsa-miR-940 gene set forth in SEQ ID NO: 75 (miRBase Accession No. MIMAT0004983) as well as homologs or orthologs from other biological species. The hsa-miR-940 gene can be obtained by the method described in Lui WO et al., 2007, Cancer Res, Vol. 67, pp. 6031-6043. Furthermore, a known precursor of "hsa-miR-940" is "hsa-mir-940" (miRBase Accession No. MI0005762, SEQ ID NO: 352), which has a hairpin-like structure.

[0157] As used herein, the terms "hsa-miR-939-5p gene" or "hsa-miR-939-5p" encompass the hsa-miR-939-5p gene set forth in SEQ ID NO: 76 (miRBase Accession No. MIMAT0004982) and homologs or orthologs from other species. The hsa-miR-939-5p gene can be obtained by the method described in Lui WO et al., 2007, Cancer Res, Vol. 67, pp. 6031-6043. Furthermore, the precursor of "hsa-miR-939-5p" is known to be "hsa-mir-939" (miRBase Accession No. MI0005761, SEQ ID NO: 353), which has a hairpin-like structure.

[0158] As used herein, the term "hsa-miR-6757-5p gene" or "hsa-miR-6757-5p" encompasses the hsa-miR-6757-5p gene set forth in SEQ ID NO: 77 (miRBase Accession No. MIMAT0027414) and homologs or orthologs from other biological species. The hsa-miR-6757-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6757-5p" is known to be "hsa-mir-6757" (miRBase Accession No. MI0022602, SEQ ID NO: 354), which has a hairpin-like structure.

[0159] As used herein, the term "hsa-miR-1275 gene" or "hsa-miR-1275" encompasses the hsa-miR-1275 gene set forth in SEQ ID NO: 78 (miRBase Accession No. MIMAT0005929) as well as homologs or orthologs from other organisms. The hsa-miR-1275 gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, vol. 18, pp. 610-621. Furthermore, a known precursor of "hsa-miR-1275" is "hsa-mir-1275" (miRBase Accession No. MI0006415, SEQ ID NO: 355), which has a hairpin-like structure.

[0160] As used herein, the terms "hsa-miR-5001-5p gene" or "hsa-miR-5001-5p" encompass the hsa-miR-5001-5p gene set forth in SEQ ID NO: 79 (miRBase Accession No. MIMAT0021021) and homologs or orthologs from other organisms. The hsa-miR-5001-5p gene can be obtained by the method described in Hansen TB et al., 2011, RNA Biol, Vol. 8, pp. 378-383. Furthermore, "hsa-miR-5001-5p" is known to have a precursor, "hsa-mir-5001" (miRBase Accession No. MI0017867, SEQ ID NO: 356), which has a hairpin-like structure.

[0161] As used herein, the term "hsa-miR-6826-5p gene" or "hsa-miR-6826-5p" encompasses the hsa-miR-6826-5p gene set forth in SEQ ID NO: 80 (miRBase Accession No. MIMAT0027552) and homologs or orthologs from other biological species. The hsa-miR-6826-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6826-5p" is known to be "hsa-mir-6826" (miRBase Accession No. MI0022671, SEQ ID NO: 357), which has a hairpin-like structure.

[0162] As used herein, the term "hsa-miR-6765-3p gene" or "hsa-miR-6765-3p" encompasses the hsa-miR-6765-3p gene set forth in SEQ ID NO: 81 (miRBase Accession No. MIMAT0027431) and homologs or orthologs from other biological species. The hsa-miR-6765-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6765-3p" is known to be "hsa-mir-6765" (miRBase Accession No. MI0022610, SEQ ID NO: 331), which has a hairpin-like structure.

[0163] As used herein, the terms "hsa-miR-3679-3p gene" or "hsa-miR-3679-3p" encompass the hsa-miR-3679-3p gene set forth in SEQ ID NO: 82 (miRBase Accession No. MIMAT0018105) as well as homologs or orthologs from other organisms. The hsa-miR-3679-3p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, vol. 5, e9637. Furthermore, the precursor of "hsa-miR-3679-3p" is known to be "hsa-mir-3679" (miRBase Accession No. MI0016080, SEQ ID NO: 358), which has a hairpin-like structure.

[0164] As used herein, the term "hsa-miR-4718 gene" or "hsa-miR-4718" encompasses the hsa-miR-4718 gene set forth in SEQ ID NO: 83 (miRBase Accession No. MIMAT0019831) and homologs or orthologs from other species. The hsa-miR-4718 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4718" is "hsa-mir-4718" (miRBase Accession No. MI0017353, SEQ ID NO: 359), which has a hairpin-like structure.

[0165] As used herein, the term "hsa-miR-4286 gene" or "hsa-miR-4286" encompasses the hsa-miR-4286 gene set forth in SEQ ID NO: 84 (miRBase Accession No. MIMAT0016916) as well as homologs or orthologs from other organisms. The hsa-miR-4286 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, vol. 4, e7192. Furthermore, "hsa-miR-4286" is known to have a precursor, "hsa-mir-4286" (miRBase Accession No. MI0015894, SEQ ID NO: 360), which has a hairpin-like structure.

[0166] As used herein, the term "hsa-miR-8059 gene" or "hsa-miR-8059" encompasses the hsa-miR-8059 gene set forth in SEQ ID NO: 85 (miRBase Accession No. MIMAT0030986) and homologs or orthologs from other biological species. The hsa-miR-8059 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, vol. 39, pp. 480-487. Furthermore, "hsa-miR-8059" is known to have a precursor, "hsa-mir-8059" (miRBase Accession No. MI0025895, SEQ ID NO: 361), which has a hairpin-like structure.

[0167] As used herein, the term "hsa-miR-4447 gene" or "hsa-miR-4447" encompasses the hsa-miR-4447 gene set forth in SEQ ID NO: 86 (miRBase Accession No. MIMAT0018966) as well as homologs or orthologs from other biological species. The hsa-miR-4447 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4447" is "hsa-mir-4447" (miRBase Accession No. MI0016790, SEQ ID NO: 362), which has a hairpin-like structure.

[0168] As used herein, the term "hsa-miR-4448 gene" or "hsa-miR-4448" encompasses the hsa-miR-4448 gene set forth in SEQ ID NO: 87 (miRBase Accession No. MIMAT0018967) as well as homologs or orthologs from other biological species. The hsa-miR-4448 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4448" is "hsa-mir-4448" (miRBase Accession No. MI0016791, SEQ ID NO: 363), which has a hairpin-like structure.

[0169] As used herein, the term "hsa-miR-658 gene" or "hsa-miR-658" encompasses the hsa-miR-658 gene set forth in SEQ ID NO: 88 (miRBase Accession No. MIMAT0003336) as well as homologs or orthologs from other organisms. The hsa-miR-658 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, pp. 3687-3692. Furthermore, a known precursor of "hsa-miR-658" is "hsa-mir-658" (miRBase Accession No. MI0003682, SEQ ID NO: 364), which has a hairpin-like structure.

[0170] As used herein, the term "hsa-miR-6766-3p gene" or "hsa-miR-6766-3p" encompasses the hsa-miR-6766-3p gene set forth in SEQ ID NO: 89 (miRBase Accession No. MIMAT0027433) and homologs or orthologs from other organisms. The hsa-miR-6766-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6766-3p" is known to be "hsa-mir-6766" (miRBase Accession No. MI0022611, SEQ ID NO: 365), which has a hairpin-like structure.

[0171] As used herein, the terms "hsa-miR-197-5p gene" or "hsa-miR-197-5p" encompass the hsa-miR-197-5p gene set forth in SEQ ID NO: 90 (miRBase Accession No. MIMAT0022691) and homologs or orthologs from other organisms. The hsa-miR-197-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2003, RNA, vol. 9, pp. 175-179. Furthermore, the precursor of "hsa-miR-197-5p" is known to be "hsa-mir-197" (miRBase Accession No. MI0000239, SEQ ID NO: 366), which has a hairpin-like structure.

[0172] As used herein, the terms "hsa-miR-6887-5p gene" or "hsa-miR-6887-5p" encompass the hsa-miR-6887-5p gene set forth in SEQ ID NO: 91 (miRBase Accession No. MIMAT0027674) and homologs or orthologs from other biological species. The hsa-miR-6887-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6887-5p" is known to have a precursor, "hsa-mir-6887" (miRBase Accession No. MI0022734, SEQ ID NO: 367), which has a hairpin-like structure.

[0173] As used herein, the term "hsa-miR-6742-5p gene" or "hsa-miR-6742-5p" encompasses the hsa-miR-6742-5p gene set forth in SEQ ID NO: 92 (miRBase Accession No. MIMAT0027385) and homologs or orthologs from other organisms. The hsa-miR-6742-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6742-5p" is known to be "hsa-mir-6742" (miRBase Accession No. MI0022587, SEQ ID NO: 368), which has a hairpin-like structure.

[0174] As used herein, the term "hsa-miR-6729-3p gene" or "hsa-miR-6729-3p" encompasses the hsa-miR-6729-3p gene set forth in SEQ ID NO: 93 (miRBase Accession No. MIMAT0027360) and homologs or orthologs from other biological species. The hsa-miR-6729-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6729-3p" is known to be "hsa-mir-6729" (miRBase Accession No. MI0022574, SEQ ID NO: 326), which has a hairpin-like structure.

[0175] As used herein, the term "hsa-miR-5090 gene" or "hsa-miR-5090" encompasses the hsa-miR-5090 gene set forth in SEQ ID NO: 94 (miRBase Accession No. MIMAT0021082) and homologs or orthologs from other biological species. The hsa-miR-5090 gene can be obtained by the method described in Ding N et al., 2011, J Radiat Res, vol. 52, pp. 425-432. Furthermore, a known precursor of "hsa-miR-5090" is "hsa-mir-5090" (miRBase Accession No. MI0017979, SEQ ID NO: 369), which has a hairpin-like structure.

[0176] As used herein, the term "hsa-miR-7975 gene" or "hsa-miR-7975" encompasses the hsa-miR-7975 gene set forth in SEQ ID NO: 95 (miRBase Accession No. MIMAT0031178) and homologs or orthologs from other biological species. The hsa-miR-7975 gene can be obtained by the method described in Velthut-Meikas A et al., 2013, Mol Endocrinol, Vol. 27, pp. 1128-1141. Furthermore, a known precursor of "hsa-miR-7975" is "hsa-mir-7975" (miRBase Accession No. MI0025751, SEQ ID NO: 370), which has a hairpin-like structure.

[0177] As used herein, the term "hsa-miR-4505 gene" or "hsa-miR-4505" encompasses the hsa-miR-4505 gene set forth in SEQ ID NO: 96 (miRBase Accession No. MIMAT0019041) and homologs or orthologs from other biological species. The hsa-miR-4505 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4505" is "hsa-mir-4505" (miRBase Accession No. MI0016868, SEQ ID NO: 371), which has a hairpin-like structure.

[0178] As used herein, the term "hsa-miR-6889-5p gene" or "hsa-miR-6889-5p" encompasses the hsa-miR-6889-5p gene set forth in SEQ ID NO: 97 (miRBase Accession No. MIMAT0027678) and homologs or orthologs from other biological species. The hsa-miR-6889-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6889-5p" is known to have a precursor, "hsa-mir-6889" (miRBase Accession No. MI0022736, SEQ ID NO: 372), which has a hairpin-like structure.

[0179] As used herein, the terms "hsa-miR-4708-3p gene" or "hsa-miR-4708-3p" encompass the hsa-miR-4708-3p gene set forth in SEQ ID NO: 98 (miRBase Accession No. MIMAT0019810) and homologs or orthologs from other organisms. The hsa-miR-4708-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4708-3p" is known to be "hsa-mir-4708" (miRBase Accession No. MI0017341, SEQ ID NO: 373), which has a hairpin-like structure.

[0180] As used herein, the term "hsa-miR-6131 gene" or "hsa-miR-6131" encompasses the hsa-miR-6131 gene set forth in SEQ ID NO: 99 (miRBase Accession No. MIMAT0024615) and homologs or orthologs from other biological species. The hsa-miR-6131 gene can be obtained by the method described in Dannemann M et al., 2012, Genome Biol Evol, vol. 4, pp. 552-564. Furthermore, a known precursor of "hsa-miR-6131" is "hsa-mir-6131" (miRBase Accession No. MI0021276, SEQ ID NO: 374), which has a hairpin-like structure.

[0181] As used herein, the terms "hsa-miR-1225-3p gene" or "hsa-miR-1225-3p" encompass the hsa-miR-1225-3p gene set forth in SEQ ID NO: 100 (miRBase Accession No. MIMAT0005573) as well as homologs or orthologs from other organisms. The hsa-miR-1225-3p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, pp. 328-336. Furthermore, the precursor of "hsa-miR-1225-3p" is known to be "hsa-mir-1225" (miRBase Accession No. MI0006311, SEQ ID NO: 375), which has a hairpin-like structure.

[0182] As used herein, the term "hsa-miR-6132 gene" or "hsa-miR-6132" encompasses the hsa-miR-6132 gene set forth in SEQ ID NO: 101 (miRBase Accession No. MIMAT0024616) and homologs or orthologs from other biological species. The hsa-miR-6132 gene can be obtained by the method described in Dannemann M et al., 2012, Genome Biol Evol, Vol. 4, pp. 552-564. Furthermore, a known precursor of "hsa-miR-6132" is "hsa-mir-6132" (miRBase Accession No. MI0021277, SEQ ID NO: 376), which has a hairpin-like structure.

[0183] As used herein, the term "hsa-miR-4734 gene" or "hsa-miR-4734" encompasses the hsa-miR-4734 gene set forth in SEQ ID NO: 102 (miRBase Accession No. MIMAT0019859) as well as homologs or orthologs from other species. The hsa-miR-4734 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4734" is "hsa-mir-4734" (miRBase Accession No. MI0017371, SEQ ID NO: 377), which has a hairpin-like structure.

[0184] As used herein, the terms "hsa-miR-3194-3p gene" or "hsa-miR-3194-3p" encompass the hsa-miR-3194-3p gene set forth in SEQ ID NO: 103 (miRBase Accession No. MIMAT0019218) and homologs or orthologs from other organisms. The hsa-miR-3194-3p gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, vol. 5, e9685. Furthermore, the precursor of "hsa-miR-3194-3p" is known to be "hsa-mir-3194" (miRBase Accession No. MI0014239, SEQ ID NO: 378), which has a hairpin-like structure.

[0185] As used herein, the term "hsa-miR-638 gene" or "hsa-miR-638" encompasses the hsa-miR-638 gene set forth in SEQ ID NO: 104 (miRBase Accession No. MIMAT0003308) as well as homologs or orthologs from other organisms. The hsa-miR-638 gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, pp. 3687-3692. Furthermore, a known precursor of "hsa-miR-638" is "hsa-mir-638" (miRBase Accession No. MI0003653, SEQ ID NO: 379), which has a hairpin-like structure.

[0186] As used herein, the terms "hsa-miR-2467-3p gene" or "hsa-miR-2467-3p" encompass the hsa-miR-2467-3p gene set forth in SEQ ID NO: 105 (miRBase Accession No. MIMAT0019953) as well as homologs or orthologs from other organisms. The hsa-miR-2467-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-2467-3p" is known to be "hsa-mir-2467" (miRBase Accession No. MI0017432, SEQ ID NO: 380), which has a hairpin-like structure.

[0187] As used herein, the terms "hsa-miR-4728-5p gene" or "hsa-miR-4728-5p" encompass the hsa-miR-4728-5p gene set forth in SEQ ID NO: 106 (miRBase Accession No. MIMAT0019849) as well as homologs or orthologs from other biological species. The hsa-miR-4728-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4728-5p" is known to be "hsa-mir-4728" (miRBase Accession No. MI0017365, SEQ ID NO: 381), which has a hairpin-like structure.

[0188] As used herein, the term "hsa-miR-5572 gene" or "hsa-miR-5572" encompasses the hsa-miR-5572 gene set forth in SEQ ID NO: 107 (miRBase Accession No. MIMAT0022260) and homologs or orthologs from other biological species. The hsa-miR-5572 gene can be obtained by the method described in Tandon M et al., 2012, Oral Dis, vol. 18, pp. 127-131. Furthermore, a known precursor of "hsa-miR-5572" is "hsa-mir-5572" (miRBase Accession No. MI0019117, SEQ ID NO: 382), which has a hairpin-like structure.

[0189] As used herein, the term "hsa-miR-6789-5p gene" or "hsa-miR-6789-5p" encompasses the hsa-miR-6789-5p gene set forth in SEQ ID NO: 108 (miRBase Accession No. MIMAT0027478) and homologs or orthologs from other biological species. The hsa-miR-6789-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6789-5p" is known to be "hsa-mir-6789" (miRBase Accession No. MI0022634, SEQ ID NO: 383), which has a hairpin-like structure.

[0190] As used herein, the term "hsa-miR-8063 gene" or "hsa-miR-8063" encompasses the hsa-miR-8063 gene set forth in SEQ ID NO: 109 (miRBase Accession No. MIMAT0030990) and homologs or orthologs from other biological species. The hsa-miR-8063 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, vol. 39, pp. 480-487. Furthermore, a known precursor of "hsa-miR-8063" is "hsa-mir-8063" (miRBase Accession No. MI0025899, SEQ ID NO: 384), which has a hairpin-like structure.

[0191] As used herein, the term "hsa-miR-4429 gene" or "hsa-miR-4429" encompasses the hsa-miR-4429 gene set forth in SEQ ID NO: 110 (miRBase Accession No. MIMAT0018944) as well as homologs or orthologs from other biological species. The hsa-miR-4429 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4429" is "hsa-mir-4429" (miRBase Accession No. MI0016768, SEQ ID NO: 385), which has a hairpin-like structure.

[0192] As used herein, the terms "hsa-miR-6840-3p gene" or "hsa-miR-6840-3p" encompass the hsa-miR-6840-3p gene set forth in SEQ ID NO: 111 (miRBase Accession No. MIMAT0027583) and homologs or orthologs from other organisms. The hsa-miR-6840-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6840-3p" is known to be "hsa-mir-6840" (miRBase Accession No. MI0022686, SEQ ID NO: 386), which has a hairpin-like structure.

[0193] As used herein, the term "hsa-miR-4476 gene" or "hsa-miR-4476" encompasses the hsa-miR-4476 gene set forth in SEQ ID NO: 112 (miRBase Accession No. MIMAT0019003) and homologs or orthologs from other biological species. The hsa-miR-4476 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4476" is "hsa-mir-4476" (miRBase Accession No. MI0016828, SEQ ID NO: 387), which has a hairpin-like structure.

[0194] As used herein, the terms "hsa-miR-675-5p gene" or "hsa-miR-675-5p" encompass the hsa-miR-675-5p gene set forth in SEQ ID NO: 113 (miRBase Accession No. MIMAT0004284) and homologs or orthologs from other organisms. The hsa-miR-675-5p gene can be obtained by the method described in Cai X et al., 2007, RNA, Vol. 13, pp. 313-316. Furthermore, the precursor of "hsa-miR-675-5p" is known to be "hsa-mir-675" (miRBase Accession No. MI0005416, SEQ ID NO: 388), which has a hairpin-like structure.

[0195] As used herein, the term "hsa-miR-711 gene" or "hsa-miR-711" encompasses the hsa-miR-711 gene set forth in SEQ ID NO: 114 (miRBase Accession No. MIMAT0012734) and homologs or orthologs from other biological species. The hsa-miR-711 gene can be obtained by the method described in Artzi S et al., 2008, BMC Bioinformatics, Vol. 9, p. 39. Furthermore, "hsa-miR-711" is known to have a precursor, "hsa-mir-711" (miRBase Accession No. MI0012488, SEQ ID NO: 389), which has a hairpin-like structure.

[0196] As used herein, the term "hsa-miR-6875-5p gene" or "hsa-miR-6875-5p" encompasses the hsa-miR-6875-5p gene set forth in SEQ ID NO: 115 (miRBase Accession No. MIMAT0027650) and homologs or orthologs from other biological species. The hsa-miR-6875-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6875-5p" is known to have a precursor, "hsa-mir-6875" (miRBase Accession No. MI0022722, SEQ ID NO: 390), which has a hairpin-like structure.

[0197] As used herein, the terms "hsa-miR-3160-5p gene" or "hsa-miR-3160-5p" encompass the hsa-miR-3160-5p gene set forth in SEQ ID NO: 116 (miRBase Accession No. MIMAT0019212) and homologs or orthologs from other biological species. The hsa-miR-3160-5p gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, vol. 5, e9685. Furthermore, "hsa-miR-3160-5p" is known to have precursors with hairpin-like structures, "hsa-mir-3160-1" and "hsa-mir-3160-2" (miRBase Accession Nos. MI0014189 and MI0014190, SEQ ID NOs: 391 and 392).

[0198] As used herein, the terms "hsa-miR-1908-5p gene" or "hsa-miR-1908-5p" encompass the hsa-miR-1908-5p gene set forth in SEQ ID NO: 117 (miRBase Accession No. MIMAT0007881) and homologs or orthologs from other organisms. The hsa-miR-1908-5p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. Furthermore, the precursor of "hsa-miR-1908-5p" is known to be "hsa-mir-1908" (miRBase Accession No. MI0008329, SEQ ID NO: 393), which has a hairpin-like structure.

[0199] As used herein, the term "hsa-miR-6726-5p gene" or "hsa-miR-6726-5p" encompasses the hsa-miR-6726-5p gene set forth in SEQ ID NO: 118 (miRBase Accession No. MIMAT0027353) and homologs or orthologs from other organisms. The hsa-miR-6726-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6726-5p" is known to be "hsa-mir-6726" (miRBase Accession No. MI0022571, SEQ ID NO: 394), which has a hairpin-like structure.

[0200] As used herein, the term "hsa-miR-1913 gene" or "hsa-miR-1913" encompasses the hsa-miR-1913 gene set forth in SEQ ID NO: 119 (miRBase Accession No. MIMAT0007888) as well as homologs or orthologs from other biological species. The hsa-miR-1913 gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. Furthermore, a known precursor of "hsa-miR-1913" is "hsa-mir-1913" (miRBase Accession No. MI0008334, SEQ ID NO: 395), which has a hairpin-like structure.

[0201] As used herein, the term "hsa-miR-8071 gene" or "hsa-miR-8071" encompasses the hsa-miR-8071 gene set forth in SEQ ID NO: 120 (miRBase Accession No. MIMAT0030998) and homologs or orthologs from other biological species. The hsa-miR-8071 gene can be obtained by the method described in Wang HJ et al., 2013, Shock, vol. 39, pp. 480-487. Furthermore, "hsa-miR-8071" is known to have precursors with hairpin-like structures, "hsa-mir-8071-1" and "hsa-mir-8071-2" (miRBase Accession Nos. MI0025907 and MI0026417, SEQ ID NOs: 396 and 397).

[0202] As used herein, the term "hsa-miR-3648 gene" or "hsa-miR-3648" encompasses the hsa-miR-3648 gene set forth in SEQ ID NO: 121 (miRBase Accession No. MIMAT0018068) as well as homologs or orthologs from other organisms. The hsa-miR-3648 gene can be obtained by the method described in Meiri E et al., 2010, Nucleic Acids Res, 38, pp. 6234-6246. Furthermore, "hsa-miR-3648" is known to have precursors with hairpin-like structures, "hsa-mir-3648-1" and "hsa-mir-3648-2" (miRBase Accession Nos. MI0016048 and MI0031512, SEQ ID NOs: 398 and 399).

[0203] As used herein, the terms "hsa-miR-4732-5p gene" or "hsa-miR-4732-5p" encompass the hsa-miR-4732-5p gene set forth in SEQ ID NO: 122 (miRBase Accession No. MIMAT0019855) as well as homologs or orthologs from other species. The hsa-miR-4732-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4732-5p" is known to be "hsa-mir-4732" (miRBase Accession No. MI0017369, SEQ ID NO: 400), which has a hairpin-like structure.

[0204] As used herein, the terms "hsa-miR-4787-5p gene" or "hsa-miR-4787-5p" encompass the hsa-miR-4787-5p gene set forth in SEQ ID NO: 123 (miRBase Accession No. MIMAT0019956) as well as homologs or orthologs from other organisms. The hsa-miR-4787-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4787-5p" is known to be "hsa-mir-4787" (miRBase Accession No. MI0017434, SEQ ID NO: 318), which has a hairpin-like structure.

[0205] As used herein, the term "hsa-miR-3917 gene" or "hsa-miR-3917" encompasses the hsa-miR-3917 gene set forth in SEQ ID NO: 124 (miRBase Accession No. MIMAT0018191) and homologs or orthologs from other biological species. The hsa-miR-3917 gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, vol. 5, e9637. Furthermore, a known precursor of "hsa-miR-3917" is "hsa-mir-3917" (miRBase Accession No. MI0016423, SEQ ID NO: 401), which has a hairpin-like structure.

[0206] As used herein, the terms "hsa-miR-619-5p gene" or "hsa-miR-619-5p" encompass the hsa-miR-619-5p gene set forth in SEQ ID NO: 125 (miRBase Accession No. MIMAT0026622) and homologs or orthologs from other organisms. The hsa-miR-619-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, pp. 3687-3692. Furthermore, the precursor of "hsa-miR-619-5p" is known to be "hsa-mir-619" (miRBase Accession No. MI0003633, SEQ ID NO: 402), which has a hairpin-like structure.

[0207] As used herein, the term "hsa-miR-1231 gene" or "hsa-miR-1231" encompasses the hsa-miR-1231 gene set forth in SEQ ID NO: 126 (miRBase Accession No. MIMAT0005586) as well as homologs or orthologs from other organisms. The hsa-miR-1231 gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, pp. 328-336. Furthermore, a known precursor of "hsa-miR-1231" is "hsa-mir-1231" (miRBase Accession No. MI0006321, SEQ ID NO: 403), which has a hairpin-like structure.

[0208] As used herein, the terms "hsa-miR-342-5p gene" or "hsa-miR-342-5p" encompass the hsa-miR-342-5p gene set forth in SEQ ID NO: 127 (miRBase Accession No. MIMAT0004694) and homologs or orthologs from other organisms. The hsa-miR-342-5p gene can be obtained by the method described in Kim J et al., 2004, Proc Natl Acad Sci USA, vol. 101, pp. 360-365. Furthermore, the precursor of "hsa-miR-342-5p" is known to be "hsa-mir-342" (miRBase Accession No. MI0000805, SEQ ID NO: 404), which has a hairpin-like structure.

[0209] As used herein, the terms "hsa-miR-4433a-5p gene" or "hsa-miR-4433a-5p" encompass the hsa-miR-4433a-5p gene set forth in SEQ ID NO: 128 (miRBase Accession No. MIMAT0020956) and homologs or orthologs from other biological species. The hsa-miR-4433a-5p gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, the precursor of "hsa-miR-4433a-5p" is known to be "hsa-mir-4433a" (miRBase Accession No. MI0016773, SEQ ID NO: 405), which has a hairpin-like structure.

[0210] As used herein, the term "hsa-miR-6766-5p gene" or "hsa-miR-6766-5p" encompasses the hsa-miR-6766-5p gene set forth in SEQ ID NO: 129 (miRBase Accession No. MIMAT0027432) and homologs or orthologs from other organisms. The hsa-miR-6766-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6766-5p" is known to be "hsa-mir-6766" (miRBase Accession No. MI0022611, SEQ ID NO: 365), which has a hairpin-like structure.

[0211] As used herein, the terms "hsa-miR-4707-5p gene" or "hsa-miR-4707-5p" encompass the hsa-miR-4707-5p gene set forth in SEQ ID NO: 130 (miRBase Accession No. MIMAT0019807) as well as homologs or orthologs from other organisms. The hsa-miR-4707-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4707-5p" is known to be "hsa-mir-4707" (miRBase Accession No. MI0017340, SEQ ID NO: 406), which has a hairpin-like structure.

[0212] As used herein, the terms "hsa-miR-7114-5p gene" or "hsa-miR-7114-5p" encompass the hsa-miR-7114-5p gene set forth in SEQ ID NO: 131 (miRBase Accession No. MIMAT0028125) and homologs or orthologs from other biological species. The hsa-miR-7114-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-7114-5p" is known to be "hsa-mir-7114" (miRBase Accession No. MI0022965, SEQ ID NO: 407), which has a hairpin-like structure.

[0213] As used herein, the terms "hsa-miR-6872-3p gene" or "hsa-miR-6872-3p" encompass the hsa-miR-6872-3p gene set forth in SEQ ID NO: 132 (miRBase Accession No. MIMAT0027645) and homologs or orthologs from other biological species. The hsa-miR-6872-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6872-3p" is known to be "hsa-mir-6872" (miRBase Accession No. MI0022719, SEQ ID NO: 408), which has a hairpin-like structure.

[0214] As used herein, the term "hsa-miR-6780b-5p gene" or "hsa-miR-6780b-5p" encompasses the hsa-miR-6780b-5p gene set forth in SEQ ID NO: 133 (miRBase Accession No. MIMAT0027572) and homologs or orthologs from other biological species. The hsa-miR-6780b-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6780b-5p" is known to be "hsa-mir-6780b" (miRBase Accession No. MI0022681, SEQ ID NO: 409), which has a hairpin-like structure.

[0215] As used herein, the terms "hsa-miR-7845-5p gene" or "hsa-miR-7845-5p" encompass the hsa-miR-7845-5p gene set forth in SEQ ID NO: 134 (miRBase Accession No. MIMAT0030420) and homologs or orthologs from other biological species. The hsa-miR-7845-5p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. Furthermore, "hsa-miR-7845-5p" is known to have a precursor, "hsa-mir-7845" (miRBase Accession No. MI0025515, SEQ ID NO: 410), which has a hairpin-like structure.

[0216] As used herein, the term "hsa-miR-6798-3p gene" or "hsa-miR-6798-3p" encompasses the hsa-miR-6798-3p gene set forth in SEQ ID NO: 135 (miRBase Accession No. MIMAT0027497) and homologs or orthologs from other biological species. The hsa-miR-6798-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6798-3p" is known to be "hsa-mir-6798" (miRBase Accession No. MI0022643, SEQ ID NO: 314), which has a hairpin-like structure.

[0217] As used herein, the term "hsa-miR-665 gene" or "hsa-miR-665" encompasses the hsa-miR-665 gene set forth in SEQ ID NO: 136 (miRBase Accession No. MIMAT0004952) and homologs or orthologs from other organisms. The hsa-miR-665 gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, vol. 16, pp. 1289-1298. Furthermore, a known precursor of "hsa-miR-665" is "hsa-mir-665" (miRBase Accession No. MI0005563, SEQ ID NO: 411), which has a hairpin-like structure.

[0218] As used herein, the terms "hsa-miR-6848-5p gene" or "hsa-miR-6848-5p" encompass the hsa-miR-6848-5p gene set forth in SEQ ID NO: 137 (miRBase Accession No. MIMAT0027596) and homologs or orthologs from other organisms. The hsa-miR-6848-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6848-5p" is known to be "hsa-mir-6848" (miRBase Accession No. MI0022694, SEQ ID NO: 412), which has a hairpin-like structure.

[0219] As used herein, the terms "hsa-miR-5008-5p gene" or "hsa-miR-5008-5p" encompass the hsa-miR-5008-5p gene set forth in SEQ ID NO: 138 (miRBase Accession No. MIMAT0021039) and homologs or orthologs from other organisms. The hsa-miR-5008-5p gene can be obtained by the method described in Hansen TB et al., 2011, RNA Biol, Vol. 8, pp. 378-383. Furthermore, "hsa-miR-5008-5p" is known to have a precursor, "hsa-mir-5008" (miRBase Accession No. MI0017876, SEQ ID NO: 413), which has a hairpin-like structure.

[0220] As used herein, the term "hsa-miR-4294 gene" or "hsa-miR-4294" encompasses the hsa-miR-4294 gene set forth in SEQ ID NO: 139 (miRBase Accession No. MIMAT0016849) as well as homologs or orthologs from other biological species. The hsa-miR-4294 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, vol. 4, e7192. Furthermore, a known precursor of "hsa-miR-4294" is "hsa-mir-4294" (miRBase Accession No. MI0015827, SEQ ID NO: 414), which has a hairpin-like structure.

[0221] As used herein, the term "hsa-miR-6511a-5p gene" or "hsa-miR-6511a-5p" encompasses the hsa-miR-6511a-5p gene set forth in SEQ ID NO: 140 (miRBase Accession No. MIMAT0025478) and homologs or orthologs from other organisms. The hsa-miR-6511a-5p gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet, 20, pp. 4025-4040. In addition, "hsa-miR-6511a-5p" is known to have precursors that have hairpin-like structures: "hsa-mir-6511a-1, hsa-mir-6511a-2, hsa-mir-6511a-3, hsa-mir-6511a-4" (miRBase Accession Nos. MI0022223, MI0023564, MI0023565, MI0023566, SEQ ID NOs: 415, 416, 417, 418).

[0222] As used herein, the term "hsa-miR-4435 gene" or "hsa-miR-4435" encompasses the hsa-miR-4435 gene set forth in SEQ ID NO: 141 (miRBase Accession No. MIMAT0018951) and homologs or orthologs from other biological species. The hsa-miR-4435 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, "hsa-miR-4435" is known to have precursors with hairpin-like structures, "hsa-mir-4435-1" and "hsa-mir-4435-2" (miRBase Accession Nos. MI0016775 and MI0016777, SEQ ID NOs: 419 and 420).

[0223] As used herein, the terms "hsa-miR-4747-3p gene" or "hsa-miR-4747-3p" encompass the hsa-miR-4747-3p gene set forth in SEQ ID NO: 142 (miRBase Accession No. MIMAT0019883) and homologs or orthologs from other biological species. The hsa-miR-4747-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4747-3p" is known to be "hsa-mir-4747" (miRBase Accession No. MI0017386, SEQ ID NO: 421), which has a hairpin-like structure.

[0224] As used herein, the terms "hsa-miR-6880-3p gene" or "hsa-miR-6880-3p" encompass the hsa-miR-6880-3p gene set forth in SEQ ID NO: 143 (miRBase Accession No. MIMAT0027661) and homologs or orthologs from other biological species. The hsa-miR-6880-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6880-3p" is known to be "hsa-mir-6880" (miRBase Accession No. MI0022727, SEQ ID NO: 422), which has a hairpin-like structure.

[0225] As used herein, the term "hsa-miR-6869-5p gene" or "hsa-miR-6869-5p" encompasses the hsa-miR-6869-5p gene set forth in SEQ ID NO: 144 (miRBase Accession No. MIMAT0027638) and homologs or orthologs from other organisms. The hsa-miR-6869-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6869-5p" is known to be "hsa-mir-6869" (miRBase Accession No. MI0022716, SEQ ID NO: 423), which has a hairpin-like structure.

[0226] As used herein, the term "hsa-miR-7150 gene" or "hsa-miR-7150" encompasses the hsa-miR-7150 gene set forth in SEQ ID NO: 145 (miRBase Accession No. MIMAT0028211) and homologs or orthologs from other biological species. The hsa-miR-7150 gene can be obtained by the method described in Oulas A et al., 2009, Nucleic Acids Res, Vol. 37, pp. 3276-3287. Furthermore, a known precursor of "hsa-miR-7150" is "hsa-mir-7150" (miRBase Accession No. MI0023610, SEQ ID NO: 424), which has a hairpin-like structure.

[0227] As used herein, the term "hsa-miR-1260a gene" or "hsa-miR-1260a" encompasses the hsa-miR-1260a gene set forth in SEQ ID NO: 146 (miRBase Accession No. MIMAT0005911) and homologs or orthologs from other biological species. The hsa-miR-1260a gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, vol. 18, pp. 610-621. Furthermore, a known precursor of "hsa-miR-1260a" is "hsa-mir-1260a" (miRBase Accession No. MI0006394, SEQ ID NO: 425), which has a hairpin-like structure.

[0228] As used herein, the terms "hsa-miR-6877-5p gene" or "hsa-miR-6877-5p" encompass the hsa-miR-6877-5p gene set forth in SEQ ID NO: 147 (miRBase Accession No. MIMAT0027654) and homologs or orthologs from other organisms. The hsa-miR-6877-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6877-5p" is known to be "hsa-mir-6877" (miRBase Accession No. MI0022724, SEQ ID NO: 426), which has a hairpin-like structure.

[0229] As used herein, the terms "hsa-miR-6721-5p gene" or "hsa-miR-6721-5p" encompass the hsa-miR-6721-5p gene set forth in SEQ ID NO: 148 (miRBase Accession No. MIMAT0025852) and homologs or orthologs from other biological species. The hsa-miR-6721-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, vol. 497, pp. 330-335. Furthermore, the precursor of "hsa-miR-6721-5p" is known to be "hsa-mir-6721" (miRBase Accession No. MI0022556, SEQ ID NO: 427), which has a hairpin-like structure.

[0230] As used herein, the term "hsa-miR-4656 gene" or "hsa-miR-4656" encompasses the hsa-miR-4656 gene set forth in SEQ ID NO: 149 (miRBase Accession No. MIMAT0019723) as well as homologs or orthologs from other organisms. The hsa-miR-4656 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4656" is "hsa-mir-4656" (miRBase Accession No. MI0017284, SEQ ID NO: 428), which has a hairpin-like structure.

[0231] As used herein, the terms "hsa-miR-1229-5p gene" or "hsa-miR-1229-5p" encompass the hsa-miR-1229-5p gene set forth in SEQ ID NO: 150 (miRBase Accession No. MIMAT0022942) and homologs or orthologs from other organisms. The hsa-miR-1229-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, pp. 328-336. Furthermore, "hsa-miR-1229-5p" is known to have a precursor, "hsa-mir-1229" (miRBase Accession No. MI0006319, SEQ ID NO: 429), which has a hairpin-like structure.

[0232] As used herein, the terms "hsa-miR-4433a-3p gene" or "hsa-miR-4433a-3p" encompass the hsa-miR-4433a-3p gene set forth in SEQ ID NO: 151 (miRBase Accession No. MIMAT0018949) and homologs or orthologs from other biological species. The hsa-miR-4433a-3p gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, the precursor of "hsa-miR-4433a-3p" is known to be "hsa-mir-4433a" (miRBase Accession No. MI0016773, SEQ ID NO: 405), which has a hairpin-like structure.

[0233] As used herein, the term "hsa-miR-4274 gene" or "hsa-miR-4274" encompasses the hsa-miR-4274 gene set forth in SEQ ID NO: 152 (miRBase Accession No. MIMAT0016906) as well as homologs or orthologs from other organisms. The hsa-miR-4274 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, vol. 4, e7192. Furthermore, a known precursor of "hsa-miR-4274" is "hsa-mir-4274" (miRBase Accession No. MI0015884, SEQ ID NO: 430), which has a hairpin-like structure.

[0234] As used herein, the term "hsa-miR-4419b gene" or "hsa-miR-4419b" encompasses the hsa-miR-4419b gene set forth in SEQ ID NO: 153 (miRBase Accession No. MIMAT0019034) and homologs or orthologs from other biological species. The hsa-miR-4419b gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4419b" is "hsa-mir-4419b" (miRBase Accession No. MI0016861, SEQ ID NO: 431), which has a hairpin-like structure.

[0235] As used herein, the term "hsa-miR-4674 gene" or "hsa-miR-4674" encompasses the hsa-miR-4674 gene set forth in SEQ ID NO: 154 (miRBase Accession No. MIMAT0019756) as well as homologs or orthologs from other biological species. The hsa-miR-4674 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4674" is "hsa-mir-4674" (miRBase Accession No. MI0017305, SEQ ID NO: 432), which has a hairpin-like structure.

[0236] As used herein, the term "hsa-miR-6893-5p gene" or "hsa-miR-6893-5p" encompasses the hsa-miR-6893-5p gene set forth in SEQ ID NO: 155 (miRBase Accession No. MIMAT0027686) and homologs or orthologs from other biological species. The hsa-miR-6893-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6893-5p" is known to be "hsa-mir-6893" (miRBase Accession No. MI0022740, SEQ ID NO: 433), which has a hairpin-like structure.

[0237] As used herein, the term "hsa-miR-6763-3p gene" or "hsa-miR-6763-3p" encompasses the hsa-miR-6763-3p gene set forth in SEQ ID NO: 156 (miRBase Accession No. MIMAT0027427) and homologs or orthologs from other biological species. The hsa-miR-6763-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6763-3p" is known to be "hsa-mir-6763" (miRBase Accession No. MI0022608, SEQ ID NO: 434), which has a hairpin-like structure.

[0238] As used herein, the term "hsa-miR-6762-5p gene" or "hsa-miR-6762-5p" encompasses the hsa-miR-6762-5p gene set forth in SEQ ID NO: 157 (miRBase Accession No. MIMAT0027424) and homologs or orthologs from other organisms. The hsa-miR-6762-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6762-5p" is known to be "hsa-mir-6762" (miRBase Accession No. MI0022607, SEQ ID NO: 435), which has a hairpin-like structure.

[0239] As used herein, the term "hsa-miR-6738-5p gene" or "hsa-miR-6738-5p" encompasses the hsa-miR-6738-5p gene set forth in SEQ ID NO: 158 (miRBase Accession No. MIMAT0027377) and homologs or orthologs from other biological species. The hsa-miR-6738-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6738-5p" is known to be "hsa-mir-6738" (miRBase Accession No. MI0022583, SEQ ID NO: 436), which has a hairpin-like structure.

[0240] As used herein, the term "hsa-miR-4513 gene" or "hsa-miR-4513" encompasses the hsa-miR-4513 gene set forth in SEQ ID NO: 159 (miRBase Accession No. MIMAT0019050) and homologs or orthologs from other biological species. The hsa-miR-4513 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4513" is "hsa-mir-4513" (miRBase Accession No. MI0016879, SEQ ID NO: 437), which has a hairpin-like structure.

[0241] As used herein, the term "hsa-miR-6746-5p gene" or "hsa-miR-6746-5p" encompasses the hsa-miR-6746-5p gene set forth in SEQ ID NO: 160 (miRBase Accession No. MIMAT0027392) and homologs or orthologs from other organisms. The hsa-miR-6746-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6746-5p" is known to be "hsa-mir-6746" (miRBase Accession No. MI0022591, SEQ ID NO: 438), which has a hairpin-like structure.

[0242] As used herein, the terms "hsa-miR-6880-5p gene" or "hsa-miR-6880-5p" encompass the hsa-miR-6880-5p gene set forth in SEQ ID NO: 161 (miRBase Accession No. MIMAT0027660) and homologs or orthologs from other biological species. The hsa-miR-6880-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6880-5p" is known to be "hsa-mir-6880" (miRBase Accession No. MI0022727, SEQ ID NO: 422), which has a hairpin-like structure.

[0243] As used herein, the term "hsa-miR-4736 gene" or "hsa-miR-4736" encompasses the hsa-miR-4736 gene set forth in SEQ ID NO: 162 (miRBase Accession No. MIMAT0019862) and homologs or orthologs from other species. The hsa-miR-4736 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4736" is "hsa-mir-4736" (miRBase Accession No. MI0017373, SEQ ID NO: 439), which has a hairpin-like structure.

[0244] As used herein, the term "hsa-miR-718 gene" or "hsa-miR-718" encompasses the hsa-miR-718 gene set forth in SEQ ID NO: 163 (miRBase Accession No. MIMAT0012735) and homologs or orthologs from other biological species. The hsa-miR-718 gene can be obtained by the method described in Artzi S et al., 2008, BMC Bioinformatics, Vol. 9, p. 39. Furthermore, "hsa-miR-718" is known to have a precursor, "hsa-mir-718" (miRBase Accession No. MI0012489, SEQ ID NO: 440), which has a hairpin-like structure.

[0245] As used herein, the terms "hsa-miR-6717-5p gene" or "hsa-miR-6717-5p" encompass the hsa-miR-6717-5p gene set forth in SEQ ID NO: 164 (miRBase Accession No. MIMAT0025846) and homologs or orthologs from other biological species. The hsa-miR-6717-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, vol. 497, pp. 330-335. Furthermore, the precursor of "hsa-miR-6717-5p" is known to be "hsa-mir-6717" (miRBase Accession No. MI0022551, SEQ ID NO: 441), which has a hairpin-like structure.

[0246] As used herein, the terms "hsa-miR-7847-3p gene" or "hsa-miR-7847-3p" encompass the hsa-miR-7847-3p gene set forth in SEQ ID NO: 165 (miRBase Accession No. MIMAT0030422) and homologs or orthologs from other biological species. The hsa-miR-7847-3p gene can be obtained by the method described in Ple H et al., 2012, PLoS One, Vol. 7, e50746. Furthermore, the precursor of "hsa-miR-7847-3p" is known to be "hsa-mir-7847" (miRBase Accession No. MI0025517, SEQ ID NO: 442), which has a hairpin-like structure.

[0247] As used herein, the term "hsa-miR-760 gene" or "hsa-miR-760" encompasses the hsa-miR-760 gene set forth in SEQ ID NO: 166 (miRBase Accession No. MIMAT0004957) as well as homologs or orthologs from other biological species. The hsa-miR-760 gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, vol. 16, pp. 1289-1298. Furthermore, a known precursor of "hsa-miR-760" is "hsa-mir-760" (miRBase Accession No. MI0005567, SEQ ID NO: 443), which has a hairpin-like structure.

[0248] As used herein, the terms "hsa-miR-1199-5p gene" or "hsa-miR-1199-5p" encompass the hsa-miR-1199-5p gene set forth in SEQ ID NO: 167 (miRBase Accession No. MIMAT0031119) as well as homologs or orthologs from other species. The hsa-miR-1199-5p gene can be obtained by the method described in Salvi A et al., 2013, Int J Oncol, vol. 42, pp. 391-402. Furthermore, "hsa-miR-1199-5p" is known to have a precursor, "hsa-mir-1199" (miRBase Accession No. MI0020340, SEQ ID NO: 444), which has a hairpin-like structure.

[0249] As used herein, the term "hsa-miR-6813-5p gene" or "hsa-miR-6813-5p" encompasses the hsa-miR-6813-5p gene set forth in SEQ ID NO: 168 (miRBase Accession No. MIMAT0027526) and homologs or orthologs from other biological species. The hsa-miR-6813-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6813-5p" is known to be "hsa-mir-6813" (miRBase Accession No. MI0022658, SEQ ID NO: 445), which has a hairpin-like structure.

[0250] As used herein, the term "hsa-miR-6769a-5p gene" or "hsa-miR-6769a-5p" encompasses the hsa-miR-6769a-5p gene set forth in SEQ ID NO: 169 (miRBase Accession No. MIMAT0027438) and homologs or orthologs from other biological species. The hsa-miR-6769a-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6769a-5p" is known to be "hsa-mir-6769a" (miRBase Accession No. MI0022614, SEQ ID NO: 446), which has a hairpin-like structure.

[0251] As used herein, the term "hsa-miR-1193 gene" or "hsa-miR-1193" encompasses the hsa-miR-1193 gene set forth in SEQ ID NO: 170 (miRBase Accession No. MIMAT0015049) as well as homologs or orthologs from other organisms. The hsa-miR-1193 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, vol. 5, e9685. Furthermore, a known precursor of "hsa-miR-1193" is "hsa-mir-1193" (miRBase Accession No. MI0014205, SEQ ID NO: 447), which has a hairpin-like structure.

[0252] As used herein, the terms "hsa-miR-7108-3p gene" or "hsa-miR-7108-3p" encompass the hsa-miR-7108-3p gene set forth in SEQ ID NO: 171 (miRBase Accession No. MIMAT0028114) and homologs or orthologs from other biological species. The hsa-miR-7108-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-7108-3p" is known to be "hsa-mir-7108" (miRBase Accession No. MI0022959, SEQ ID NO: 448), which has a hairpin-like structure.

[0253] As used herein, the term "hsa-miR-6741-5p gene" or "hsa-miR-6741-5p" encompasses the hsa-miR-6741-5p gene set forth in SEQ ID NO: 172 (miRBase Accession No. MIMAT0027383) and homologs or orthologs from other organisms. The hsa-miR-6741-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6741-5p" is known to be "hsa-mir-6741" (miRBase Accession No. MI0022586, SEQ ID NO: 449), which has a hairpin-like structure.

[0254] As used herein, the term "hsa-miR-4298 gene" or "hsa-miR-4298" encompasses the hsa-miR-4298 gene set forth in SEQ ID NO: 173 (miRBase Accession No. MIMAT0016852) and homologs or orthologs from other biological species. The hsa-miR-4298 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, vol. 4, e7192. Furthermore, a known precursor of "hsa-miR-4298" is "hsa-mir-4298" (miRBase Accession No. MI0015830, SEQ ID NO: 450), which has a hairpin-like structure.

[0255] As used herein, the term "hsa-miR-6796-3p gene" or "hsa-miR-6796-3p" encompasses the hsa-miR-6796-3p gene set forth in SEQ ID NO: 174 (miRBase Accession No. MIMAT0027493) and homologs or orthologs from other biological species. The hsa-miR-6796-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6796-3p" is known to be "hsa-mir-6796" (miRBase Accession No. MI0022641, SEQ ID NO: 451), which has a hairpin-like structure.

[0256] As used herein, the terms "hsa-miR-4750-5p gene" or "hsa-miR-4750-5p" encompass the hsa-miR-4750-5p gene set forth in SEQ ID NO: 175 (miRBase Accession No. MIMAT0019887) as well as homologs or orthologs from other biological species. The hsa-miR-4750-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4750-5p" is known to be "hsa-mir-4750" (miRBase Accession No. MI0017389, SEQ ID NO: 452), which has a hairpin-like structure.

[0257] As used herein, the term "hsa-miR-6785-5p gene" or "hsa-miR-6785-5p" encompasses the hsa-miR-6785-5p gene set forth in SEQ ID NO: 176 (miRBase Accession No. MIMAT0027470) and homologs or orthologs from other organisms. The hsa-miR-6785-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6785-5p" is known to be "hsa-mir-6785" (miRBase Accession No. MI0022630, SEQ ID NO: 453), which has a hairpin-like structure.

[0258] As used herein, the terms "hsa-miR-1292-3p gene" or "hsa-miR-1292-3p" encompass the hsa-miR-1292-3p gene set forth in SEQ ID NO: 177 (miRBase Accession No. MIMAT0022948) and homologs or orthologs from other organisms. The hsa-miR-1292-3p gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, vol. 18, pp. 610-621. Furthermore, the precursor of "hsa-miR-1292-3p" is known to be "hsa-mir-1292" (miRBase Accession No. MI0006433, SEQ ID NO: 454), which has a hairpin-like structure.

[0259] As used herein, the terms "hsa-miR-4749-3p gene" or "hsa-miR-4749-3p" encompass the hsa-miR-4749-3p gene set forth in SEQ ID NO: 178 (miRBase Accession No. MIMAT0019886) as well as homologs or orthologs from other organisms. The hsa-miR-4749-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4749-3p" is known to be "hsa-mir-4749" (miRBase Accession No. MI0017388, SEQ ID NO: 455), which has a hairpin-like structure.

[0260] As used herein, the terms "hsa-miR-6800-3p gene" or "hsa-miR-6800-3p" encompass the hsa-miR-6800-3p gene set forth in SEQ ID NO: 179 (miRBase Accession No. MIMAT0027501) and homologs or orthologs from other biological species. The hsa-miR-6800-3p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6800-3p" is known to be "hsa-mir-6800" (miRBase Accession No. MI0022645, SEQ ID NO: 293), which has a hairpin-like structure.

[0261] As used herein, the terms "hsa-miR-4722-5p gene" or "hsa-miR-4722-5p" encompass the hsa-miR-4722-5p gene set forth in SEQ ID NO: 180 (miRBase Accession No. MIMAT0019836) as well as homologs or orthologs from other biological species. The hsa-miR-4722-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4722-5p" is known to be "hsa-mir-4722" (miRBase Accession No. MI0017357, SEQ ID NO: 456), which has a hairpin-like structure.

[0262] As used herein, the terms "hsa-miR-4746-3p gene" or "hsa-miR-4746-3p" encompass the hsa-miR-4746-3p gene set forth in SEQ ID NO: 181 (miRBase Accession No. MIMAT0019881) and homologs or orthologs from other organisms. The hsa-miR-4746-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4746-3p" is known to be "hsa-mir-4746" (miRBase Accession No. MI0017385, SEQ ID NO: 457), which has a hairpin-like structure.

[0263] As used herein, the term "hsa-miR-4450 gene" or "hsa-miR-4450" encompasses the hsa-miR-4450 gene set forth in SEQ ID NO: 182 (miRBase Accession No. MIMAT0018971) and homologs or orthologs from other biological species. The hsa-miR-4450 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4450" is "hsa-mir-4450" (miRBase Accession No. MI0016795, SEQ ID NO: 458), which has a hairpin-like structure.

[0264] As used herein, the term "hsa-miR-6795-5p gene" or "hsa-miR-6795-5p" encompasses the hsa-miR-6795-5p gene set forth in SEQ ID NO: 183 (miRBase Accession No. MIMAT0027490) and homologs or orthologs from other biological species. The hsa-miR-6795-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6795-5p" is known to have a precursor, "hsa-mir-6795" (miRBase Accession No. MI0022640, SEQ ID NO: 459), which has a hairpin-like structure.

[0265] As used herein, the terms "hsa-miR-365a-5p gene" or "hsa-miR-365a-5p" encompass the hsa-miR-365a-5p gene set forth in SEQ ID NO: 184 (miRBase Accession No. MIMAT0009199) and homologs or orthologs from other biological species. The hsa-miR-365a-5p gene can be obtained by the method described in Xie X et al., 2005, Nature, Vol. 434, pp. 338-345. Furthermore, the precursor of "hsa-miR-365a-5p" is known to be "hsa-mir-365a" (miRBase Accession No. MI0000767, SEQ ID NO: 460), which has a hairpin-like structure.

[0266] As used herein, the term "hsa-miR-498 gene" or "hsa-miR-498" encompasses the hsa-miR-498 gene set forth in SEQ ID NO: 185 (miRBase Accession No. MIMAT0002824) as well as homologs or orthologs from other organisms. The hsa-miR-498 gene can be obtained by the method described in Bentwich I et al., 2005, Nat Genet, vol. 37, pp. 766-770. Furthermore, a known precursor of "hsa-miR-498" is "hsa-mir-498" (miRBase Accession No. MI0003142, SEQ ID NO: 461), which has a hairpin-like structure.

[0267] As used herein, the term "hsa-miR-6797-5p gene" or "hsa-miR-6797-5p" encompasses the hsa-miR-6797-5p gene set forth in SEQ ID NO: 186 (miRBase Accession No. MIMAT0027494) and homologs or orthologs from other biological species. The hsa-miR-6797-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6797-5p" is known to have a precursor, "hsa-mir-6797" (miRBase Accession No. MI0022642, SEQ ID NO: 462), which has a hairpin-like structure.

[0268] As used herein, the term "hsa-miR-1470 gene" or "hsa-miR-1470" encompasses the hsa-miR-1470 gene set forth in SEQ ID NO: 187 (miRBase Accession No. MIMAT0007348) as well as homologs or orthologs from other biological species. The hsa-miR-1470 gene can be obtained by the method described in Kawaji H et al., 2008, BMC Genomics, Vol. 9, p. 157. Furthermore, a known precursor of "hsa-miR-1470" is "hsa-mir-1470" (miRBase Accession No. MI0007075, SEQ ID NO: 463), which has a hairpin-like structure.

[0269] As used herein, the terms "hsa-miR-6851-5p gene" or "hsa-miR-6851-5p" encompass the hsa-miR-6851-5p gene set forth in SEQ ID NO: 188 (miRBase Accession No. MIMAT0027602) and homologs or orthologs from other biological species. The hsa-miR-6851-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6851-5p" is known to have a precursor, "hsa-mir-6851" (miRBase Accession No. MI0022697, SEQ ID NO: 464), which has a hairpin-like structure.

[0270] As used herein, the terms "hsa-miR-1247-3p gene" or "hsa-miR-1247-3p" encompass the hsa-miR-1247-3p gene set forth in SEQ ID NO: 189 (miRBase Accession No. MIMAT0022721) and homologs or orthologs from other organisms. The hsa-miR-1247-3p gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, vol. 18, pp. 610-621. Furthermore, the precursor of "hsa-miR-1247-3p" is known to be "hsa-mir-1247" (miRBase Accession No. MI0006382, SEQ ID NO: 465), which has a hairpin-like structure.

[0271] As used herein, the terms "hsa-miR-5196-5p gene" or "hsa-miR-5196-5p" encompass the hsa-miR-5196-5p gene set forth in SEQ ID NO: 190 (miRBase Accession No. MIMAT0021128) as well as homologs or orthologs from other organisms. The hsa-miR-5196-5p gene can be obtained by the method described in Schotte D et al., 2011, Leukemia, Vol. 25, pp. 1389-1399. Furthermore, the precursor of "hsa-miR-5196-5p" is known to be "hsa-mir-5196" (miRBase Accession No. MI0018175, SEQ ID NO: 466), which has a hairpin-like structure.

[0272] As used herein, the terms "hsa-miR-208a-5p gene" or "hsa-miR-208a-5p" encompass the hsa-miR-208a-5p gene set forth in SEQ ID NO: 191 (miRBase Accession No. MIMAT0026474) and homologs or orthologs from other organisms. The hsa-miR-208a-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2003, RNA, 9, pp. 175-179. Furthermore, the precursor of "hsa-miR-208a-5p" is known to be "hsa-mir-208a" (miRBase Accession No. MI0000251, SEQ ID NO: 467), which has a hairpin-like structure.

[0273] As used herein, the terms "hsa-miR-6842-5p gene" or "hsa-miR-6842-5p" encompass the hsa-miR-6842-5p gene set forth in SEQ ID NO: 192 (miRBase Accession No. MIMAT0027586) and homologs or orthologs from other biological species. The hsa-miR-6842-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-6842-5p" is known to have a precursor, "hsa-mir-6842" (miRBase Accession No. MI0022688, SEQ ID NO: 468), which has a hairpin-like structure.

[0274] As used herein, the terms "hsa-miR-150-3p gene" or "hsa-miR-150-3p" encompass the hsa-miR-150-3p gene set forth in SEQ ID NO: 193 (miRBase Accession No. MIMAT0004610) and homologs or orthologs from other organisms. The hsa-miR-150-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, vol. 12, pp. 735-739. Furthermore, the precursor of "hsa-miR-150-3p" is known to be "hsa-mir-150" (miRBase Accession No. MI0000479, SEQ ID NO: 469), which has a hairpin-like structure.

[0275] As used herein, the term "hsa-miR-4534 gene" or "hsa-miR-4534" encompasses the hsa-miR-4534 gene set forth in SEQ ID NO: 194 (miRBase Accession No. MIMAT0019073) and homologs or orthologs from other biological species. The hsa-miR-4534 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4534" is "hsa-mir-4534" (miRBase Accession No. MI0016901, SEQ ID NO: 470), which has a hairpin-like structure.

[0276] As used herein, the term "hsa-miR-3135b gene" or "hsa-miR-3135b" encompasses the hsa-miR-3135b gene set forth in SEQ ID NO: 195 (miRBase Accession No. MIMAT0018985) and homologs or orthologs from other biological species. The hsa-miR-3135b gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, "hsa-miR-3135b" is known to have a precursor, "hsa-mir-3135b" (miRBase Accession No. MI0016809, SEQ ID NO: 471), which has a hairpin-like structure.

[0277] As used herein, the term "hsa-miR-3131 gene" or "hsa-miR-3131" encompasses the hsa-miR-3131 gene set forth in SEQ ID NO: 196 (miRBase Accession No. MIMAT0014996) as well as homologs or orthologs from other biological species. The hsa-miR-3131 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, vol. 5, e9685. Furthermore, a known precursor of "hsa-miR-3131" is "hsa-mir-3131" (miRBase Accession No. MI0014151, SEQ ID NO: 472), which has a hairpin-like structure.

[0278] As used herein, the term "hsa-miR-4792 gene" or "hsa-miR-4792" encompasses the hsa-miR-4792 gene set forth in SEQ ID NO: 197 (miRBase Accession No. MIMAT0019964) as well as homologs or orthologs from other biological species. The hsa-miR-4792 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4792" is "hsa-mir-4792" (miRBase Accession No. MI0017439, SEQ ID NO: 473), which has a hairpin-like structure.

[0279] As used herein, the terms "hsa-miR-6510-5p gene" or "hsa-miR-6510-5p" encompass the hsa-miR-6510-5p gene set forth in SEQ ID NO: 198 (miRBase Accession No. MIMAT0025476) and homologs or orthologs from other biological species. The hsa-miR-6510-5p gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet, vol. 20, pp. 4025-4040. Furthermore, the precursor of "hsa-miR-6510-5p" is known to be "hsa-mir-6510" (miRBase Accession No. MI0022222, SEQ ID NO: 474), which has a hairpin-like structure.

[0280] As used herein, the terms "hsa-miR-504-3p gene" or "hsa-miR-504-3p" encompass the hsa-miR-504-3p gene set forth in SEQ ID NO: 199 (miRBase Accession No. MIMAT0026612) and homologs or orthologs from other organisms. The hsa-miR-504-3p gene can be obtained by the method described in Bentwich I et al., 2005, Nat Genet, vol. 37, pp. 766-770. Furthermore, the precursor of "hsa-miR-504-3p" is known to be "hsa-mir-504" (miRBase Accession No. MI0003189, SEQ ID NO: 475), which has a hairpin-like structure.

[0281] As used herein, the terms "hsa-miR-3619-3p gene" or "hsa-miR-3619-3p" encompass the hsa-miR-3619-3p gene set forth in SEQ ID NO: 200 (miRBase Accession No. MIMAT0019219) and homologs or orthologs from other organisms. The hsa-miR-3619-3p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, vol. 8, p. 58. Furthermore, the precursor of "hsa-miR-3619-3p" is known to be "hsa-mir-3619" (miRBase Accession No. MI0016009, SEQ ID NO: 476), which has a hairpin-like structure.

[0282] As used herein, the terms "hsa-miR-671-5p gene" or "hsa-miR-671-5p" encompass the hsa-miR-671-5p gene set forth in SEQ ID NO: 201 (miRBase Accession No. MIMAT0003880) and homologs or orthologs from other organisms. The hsa-miR-671-5p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, vol. 16, pp. 1289-1298. Furthermore, the precursor of "hsa-miR-671-5p" is known to be "hsa-mir-671" (miRBase Accession No. MI0003760, SEQ ID NO: 477), which has a hairpin-like structure.

[0283] As used herein, the terms "hsa-miR-4667-5p gene" or "hsa-miR-4667-5p" encompass the hsa-miR-4667-5p gene set forth in SEQ ID NO: 202 (miRBase Accession No. MIMAT0019743) as well as homologs or orthologs from other organisms. The hsa-miR-4667-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4667-5p" is known to be "hsa-mir-4667" (miRBase Accession No. MI0017297, SEQ ID NO: 478), which has a hairpin-like structure.

[0284] As used herein, the term "hsa-miR-4430 gene" or "hsa-miR-4430" encompasses the hsa-miR-4430 gene set forth in SEQ ID NO: 203 (miRBase Accession No. MIMAT0018945) as well as homologs or orthologs from other biological species. The hsa-miR-4430 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4430" is "hsa-mir-4430" (miRBase Accession No. MI0016769, SEQ ID NO: 479), which has a hairpin-like structure.

[0285] As used herein, the term "hsa-miR-3195 gene" or "hsa-miR-3195" encompasses the hsa-miR-3195 gene set forth in SEQ ID NO: 204 (miRBase Accession No. MIMAT0015079) as well as homologs or orthologs from other species. The hsa-miR-3195 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, vol. 5, e9685. Furthermore, a known precursor of "hsa-miR-3195" is "hsa-mir-3195" (miRBase Accession No. MI0014240, SEQ ID NO: 480), which has a hairpin-like structure.

[0286] As used herein, the terms "hsa-miR-3679-5p gene" or "hsa-miR-3679-5p" encompass the hsa-miR-3679-5p gene set forth in SEQ ID NO: 205 (miRBase Accession No. MIMAT0018104) and homologs or orthologs from other organisms. The hsa-miR-3679-5p gene can be obtained by the method described in Creighton CJ et al., 2010, PLoS One, vol. 5, e9637. Furthermore, "hsa-miR-3679-5p" is known to have a precursor, "hsa-mir-3679" (miRBase Accession No. MI0016080, SEQ ID NO: 358), which has a hairpin-like structure.

[0287] As used herein, the term "hsa-miR-6076 gene" or "hsa-miR-6076" encompasses the hsa-miR-6076 gene set forth in SEQ ID NO: 206 (miRBase Accession No. MIMAT0023701) and homologs or orthologs from other biological species. The hsa-miR-6076 gene can be obtained by the method described in Voellenkle C et al., 2012, RNA, Vol. 18, pp. 472-484. Furthermore, a known precursor of "hsa-miR-6076" is "hsa-mir-6076" (miRBase Accession No. MI0020353, SEQ ID NO: 481), which has a hairpin-like structure.

[0288] As used herein, the terms "hsa-miR-6515-5p gene" or "hsa-miR-6515-5p" encompass the hsa-miR-6515-5p gene set forth in SEQ ID NO: 207 (miRBase Accession No. MIMAT0025486) as well as homologs or orthologs from other biological species. The hsa-miR-6515-5p gene can be obtained by the method described in Joyce CE et al., 2011, Hum Mol Genet, vol. 20, pp. 4025-4040. Furthermore, the precursor of "hsa-miR-6515-5p" is known to be "hsa-mir-6515" (miRBase Accession No. MI0022227, SEQ ID NO: 340), which has a hairpin-like structure.

[0289] As used herein, the terms "hsa-miR-6820-5p gene" or "hsa-miR-6820-5p" encompass the hsa-miR-6820-5p gene set forth in SEQ ID NO: 208 (miRBase Accession No. MIMAT0027540) and homologs or orthologs from other organisms. The hsa-miR-6820-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6820-5p" is known to be "hsa-mir-6820" (miRBase Accession No. MI0022665, SEQ ID NO: 482), which has a hairpin-like structure.

[0290] As used herein, the term "hsa-miR-4634 gene" or "hsa-miR-4634" encompasses the hsa-miR-4634 gene set forth in SEQ ID NO: 209 (miRBase Accession No. MIMAT0019691) as well as homologs or orthologs from other biological species. The hsa-miR-4634 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4634" is "hsa-mir-4634" (miRBase Accession No. MI0017261, SEQ ID NO: 483), which has a hairpin-like structure.

[0291] As used herein, the terms "hsa-miR-187-5p gene" or "hsa-miR-187-5p" encompass the hsa-miR-187-5p gene set forth in SEQ ID NO: 210 (miRBase Accession No. MIMAT0004561) and homologs or orthologs from other organisms. The hsa-miR-187-5p gene can be obtained by the method described in Lim LP et al., 2003, Science, vol. 299, p. 1540. It is also known that the precursor of "hsa-miR-187-5p" is "hsa-mir-187" (miRBase Accession No. MI0000274, SEQ ID NO: 484), which has a hairpin-like structure.

[0292] As used herein, the term "hsa-miR-6763-5p gene" or "hsa-miR-6763-5p" encompasses the hsa-miR-6763-5p gene set forth in SEQ ID NO: 211 (miRBase Accession No. MIMAT0027426) and homologs or orthologs from other biological species. The hsa-miR-6763-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6763-5p" is known to be "hsa-mir-6763" (miRBase Accession No. MI0022608, SEQ ID NO: 434), which has a hairpin-like structure.

[0293] As used herein, the terms "hsa-miR-1908-3p gene" or "hsa-miR-1908-3p" encompass the hsa-miR-1908-3p gene set forth in SEQ ID NO: 212 (miRBase Accession No. MIMAT0026916) and homologs or orthologs from other organisms. The hsa-miR-1908-3p gene can be obtained by the method described in Bar M et al., 2008, Stem Cells, Vol. 26, pp. 2496-2505. Furthermore, the precursor of "hsa-miR-1908-3p" is known to be "hsa-mir-1908" (miRBase Accession No. MI0008329, SEQ ID NO: 393), which has a hairpin-like structure.

[0294] As used herein, the term "hsa-miR-1181 gene" or "hsa-miR-1181" encompasses the hsa-miR-1181 gene set forth in SEQ ID NO: 213 (miRBase Accession No. MIMAT0005826) and homologs or orthologs from other species. The hsa-miR-1181 gene can be obtained by the method described in Subramanian S et al., 2008, Oncogene, Vol. 27, pp. 2015-2026. Furthermore, a known precursor of "hsa-miR-1181" is "hsa-mir-1181" (miRBase Accession No. MI0006274, SEQ ID NO: 485), which has a hairpin-like structure.

[0295] As used herein, the term "hsa-miR-6782-5p gene" or "hsa-miR-6782-5p" encompasses the hsa-miR-6782-5p gene set forth in SEQ ID NO: 214 (miRBase Accession No. MIMAT0027464) and homologs or orthologs from other biological species. The hsa-miR-6782-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6782-5p" is known to be "hsa-mir-6782" (miRBase Accession No. MI0022627, SEQ ID NO: 486), which has a hairpin-like structure.

[0296] As used herein, the terms "hsa-miR-5010-5p gene" or "hsa-miR-5010-5p" encompass the hsa-miR-5010-5p gene set forth in SEQ ID NO: 215 (miRBase Accession No. MIMAT0021043) and homologs or orthologs from other organisms. The hsa-miR-5010-5p gene can be obtained by the method described in Hansen TB et al., 2011, RNA Biol, Vol. 8, pp. 378-383. Furthermore, "hsa-miR-5010-5p" is known to have a precursor, "hsa-mir-5010" (miRBase Accession No. MI0017878, SEQ ID NO: 487), which has a hairpin-like structure.

[0297] As used herein, the term "hsa-miR-6870-5p gene" or "hsa-miR-6870-5p" encompasses the hsa-miR-6870-5p gene set forth in SEQ ID NO: 216 (miRBase Accession No. MIMAT0027640) and homologs or orthologs from other organisms. The hsa-miR-6870-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6870-5p" is known to be "hsa-mir-6870" (miRBase Accession No. MI0022717, SEQ ID NO: 488), which has a hairpin-like structure.

[0298] As used herein, the term "hsa-miR-6124 gene" or "hsa-miR-6124" encompasses the hsa-miR-6124 gene set forth in SEQ ID NO: 217 (miRBase Accession No. MIMAT0024597) as well as homologs or orthologs from other biological species. The hsa-miR-6124 gene can be obtained by the method described in Smith JL et al., 2012, J Virol, vol. 86, pp. 5278-5287. Furthermore, a known precursor of "hsa-miR-6124" is "hsa-mir-6124" (miRBase Accession No. MI0021258, SEQ ID NO: 489), which has a hairpin-like structure.

[0299] As used herein, the terms "hsa-miR-1249-5p gene" or "hsa-miR-1249-5p" encompass the hsa-miR-1249-5p gene set forth in SEQ ID NO: 218 (miRBase Accession No. MIMAT0032029) and homologs or orthologs from other organisms. The hsa-miR-1249-5p gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, vol. 18, pp. 610-621. It is also known that the precursor of "hsa-miR-1249-5p" is "hsa-mir-1249" (miRBase Accession No. MI0006384, SEQ ID NO: 321), which has a hairpin-like structure.

[0300] As used herein, the terms "hsa-miR-6511b-5p gene" or "hsa-miR-6511b-5p" encompass the hsa-miR-6511b-5p gene set forth in SEQ ID NO: 219 (miRBase Accession No. MIMAT0025847) as well as homologs or orthologs from other biological species. The hsa-miR-6511b-5p gene can be obtained by the method described in Li Y et al., 2012, Gene, vol. 497, pp. 330-335. Furthermore, "hsa-miR-6511b-5p" is known to have precursors, "hsa-mir-6511b-1 and hsa-mir-6511b-2," which have a hairpin-like structure (miRBase Accession Nos. MI0022552 and MI0023431, SEQ ID NOs: 490 and 491).

[0301] As used herein, the term "hsa-miR-1254 gene" or "hsa-miR-1254" encompasses the hsa-miR-1254 gene set forth in SEQ ID NO: 220 (miRBase Accession No. MIMAT0005905) as well as homologs or orthologs from other biological species. The hsa-miR-1254 gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, vol. 18, pp. 610-621. Furthermore, "hsa-miR-1254" is known to have precursors with hairpin-like structures, "hsa-mir-1254-1" and "hsa-mir-1254-2" (miRBase Accession Nos. MI0006388 and MI0016747, SEQ ID NOs: 492 and 493).

[0302] As used herein, the terms "hsa-miR-4727-3p gene" or "hsa-miR-4727-3p" encompass the hsa-miR-4727-3p gene set forth in SEQ ID NO: 221 (miRBase Accession No. MIMAT0019848) and homologs or orthologs from other biological species. The hsa-miR-4727-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4727-3p" is known to be "hsa-mir-4727" (miRBase Accession No. MI0017364, SEQ ID NO: 494), which has a hairpin-like structure.

[0303] As used herein, the term "hsa-miR-4259 gene" or "hsa-miR-4259" encompasses the hsa-miR-4259 gene set forth in SEQ ID NO: 222 (miRBase Accession No. MIMAT0016880) and homologs or orthologs from other biological species. The hsa-miR-4259 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, vol. 4, e7192. Furthermore, a known precursor of "hsa-miR-4259" is "hsa-mir-4259" (miRBase Accession No. MI0015858, SEQ ID NO: 495), which has a hairpin-like structure.

[0304] As used herein, the term "hsa-miR-4771 gene" or "hsa-miR-4771" encompasses the hsa-miR-4771 gene set forth in SEQ ID NO: 223 (miRBase Accession No. MIMAT0019925) as well as homologs or orthologs from other biological species. The hsa-miR-4771 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, "hsa-miR-4771" is known to have precursors with hairpin-like structures, "hsa-mir-4771-1" and "hsa-mir-4771-2" (miRBase Accession Nos. MI0017412 and MI0017413, SEQ ID NOs: 496 and 497).

[0305] As used herein, the terms "hsa-miR-3622a-5p gene" or "hsa-miR-3622a-5p" encompass the hsa-miR-3622a-5p gene set forth in SEQ ID NO: 224 (miRBase Accession No. MIMAT0018003) and homologs or orthologs from other biological species. The hsa-miR-3622a-5p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, vol. 8, p. 58. Furthermore, the precursor of "hsa-miR-3622a-5p" is known to be "hsa-mir-3622a" (miRBase Accession No. MI0016013, SEQ ID NO: 498), which has a hairpin-like structure.

[0306] As used herein, the term "hsa-miR-4480 gene" or "hsa-miR-4480" encompasses the hsa-miR-4480 gene set forth in SEQ ID NO: 225 (miRBase Accession No. MIMAT0019014) and homologs or orthologs from other biological species. The hsa-miR-4480 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4480" is "hsa-mir-4480" (miRBase Accession No. MI0016841, SEQ ID NO: 499), which has a hairpin-like structure.

[0307] As used herein, the terms "hsa-miR-4740-5p gene" or "hsa-miR-4740-5p" encompass the hsa-miR-4740-5p gene set forth in SEQ ID NO: 226 (miRBase Accession No. MIMAT0019869) as well as homologs or orthologs from other organisms. The hsa-miR-4740-5p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4740-5p" is known to be "hsa-mir-4740" (miRBase Accession No. MI0017378, SEQ ID NO: 500), which has a hairpin-like structure.

[0308] As used herein, the term "hsa-miR-6777-5p gene" or "hsa-miR-6777-5p" encompasses the hsa-miR-6777-5p gene set forth in SEQ ID NO: 227 (miRBase Accession No. MIMAT0027454) and homologs or orthologs from other biological species. The hsa-miR-6777-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6777-5p" is known to be "hsa-mir-6777" (miRBase Accession No. MI0022622, SEQ ID NO: 501), which has a hairpin-like structure.

[0309] As used herein, the term "hsa-miR-6794-5p gene" or "hsa-miR-6794-5p" encompasses the hsa-miR-6794-5p gene set forth in SEQ ID NO: 228 (miRBase Accession No. MIMAT0027488) and homologs or orthologs from other organisms. The hsa-miR-6794-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6794-5p" is known to be "hsa-mir-6794" (miRBase Accession No. MI0022639, SEQ ID NO: 502), which has a hairpin-like structure.

[0310] As used herein, the terms "hsa-miR-4687-3p gene" or "hsa-miR-4687-3p" encompass the hsa-miR-4687-3p gene set forth in SEQ ID NO: 229 (miRBase Accession No. MIMAT0019775) as well as homologs or orthologs from other biological species. The hsa-miR-4687-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4687-3p" is known to be "hsa-mir-4687" (miRBase Accession No. MI0017319, SEQ ID NO: 341), which has a hairpin-like structure.

[0311] As used herein, the term "hsa-miR-6743-5p gene" or "hsa-miR-6743-5p" encompasses the hsa-miR-6743-5p gene set forth in SEQ ID NO: 230 (miRBase Accession No. MIMAT0027387) and homologs or orthologs from other biological species. The hsa-miR-6743-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6743-5p" is known to be "hsa-mir-6743" (miRBase Accession No. MI0022588, SEQ ID NO: 503), which has a hairpin-like structure.

[0312] As used herein, the terms "hsa-miR-6771-5p gene" or "hsa-miR-6771-5p" encompass the hsa-miR-6771-5p gene set forth in SEQ ID NO: 231 (miRBase Accession No. MIMAT0027442) and homologs or orthologs from other biological species. The hsa-miR-6771-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6771-5p" is known to be "hsa-mir-6771" (miRBase Accession No. MI0022616, SEQ ID NO: 504), which has a hairpin-like structure.

[0313] As used herein, the term "hsa-miR-3141 gene" or "hsa-miR-3141" encompasses the hsa-miR-3141 gene set forth in SEQ ID NO: 232 (miRBase Accession No. MIMAT0015010) and homologs or orthologs from other species. The hsa-miR-3141 gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, vol. 5, e9685. Furthermore, a known precursor of "hsa-miR-3141" is "hsa-mir-3141" (miRBase Accession No. MI0014165, SEQ ID NO: 505), which has a hairpin-like structure.

[0314] As used herein, the terms "hsa-miR-3162-5p gene" or "hsa-miR-3162-5p" encompass the hsa-miR-3162-5p gene set forth in SEQ ID NO: 233 (miRBase Accession No. MIMAT0015036) and homologs or orthologs from other biological species. The hsa-miR-3162-5p gene can be obtained by the method described in Stark MS et al., 2010, PLoS One, vol. 5, e9685. Furthermore, the precursor of "hsa-miR-3162-5p" is known to be "hsa-mir-3162" (miRBase Accession No. MI0014192, SEQ ID NO: 506), which has a hairpin-like structure.

[0315] As used herein, the term "hsa-miR-4271 gene" or "hsa-miR-4271" encompasses the hsa-miR-4271 gene set forth in SEQ ID NO: 234 (miRBase Accession No. MIMAT0016901) and homologs or orthologs from other biological species. The hsa-miR-4271 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, vol. 4, e7192. Furthermore, a known precursor of "hsa-miR-4271" is "hsa-mir-4271" (miRBase Accession No. MI0015879, SEQ ID NO: 507), which has a hairpin-like structure.

[0316] As used herein, the terms "hsa-miR-1227-5p gene" or "hsa-miR-1227-5p" encompass the hsa-miR-1227-5p gene set forth in SEQ ID NO: 235 (miRBase Accession No. MIMAT0022941) and homologs or orthologs from other organisms. The hsa-miR-1227-5p gene can be obtained by the method described in Berezikov E et al., 2007, Mol Cell, vol. 28, pp. 328-336. Furthermore, the precursor of "hsa-miR-1227-5p" is known to be "hsa-mir-1227" (miRBase Accession No. MI0006316, SEQ ID NO: 508), which has a hairpin-like structure.

[0317] As used herein, the term "hsa-miR-4257 gene" or "hsa-miR-4257" encompasses the hsa-miR-4257 gene set forth in SEQ ID NO: 236 (miRBase Accession No. MIMAT0016878) as well as homologs or orthologs from other biological species. The hsa-miR-4257 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, vol. 4, e7192. Furthermore, a known precursor of "hsa-miR-4257" is "hsa-mir-4257" (miRBase Accession No. MI0015856, SEQ ID NO: 509), which has a hairpin-like structure.

[0318] As used herein, the term "hsa-miR-4270 gene" or "hsa-miR-4270" encompasses the hsa-miR-4270 gene set forth in SEQ ID NO: 237 (miRBase Accession No. MIMAT0016900) as well as homologs or orthologs from other species. The hsa-miR-4270 gene can be obtained by the method described in Goff LA et al., 2009, PLoS One, vol. 4, e7192. Furthermore, a known precursor of "hsa-miR-4270" is "hsa-mir-4270" (miRBase Accession No. MI0015878, SEQ ID NO: 510), which has a hairpin-like structure.

[0319] As used herein, the term "hsa-miR-4516 gene" or "hsa-miR-4516" encompasses the hsa-miR-4516 gene set forth in SEQ ID NO: 238 (miRBase Accession No. MIMAT0019053) and homologs or orthologs from other biological species. The hsa-miR-4516 gene can be obtained by the method described in Jima DD et al., 2010, Blood, vol. 116, e118-e127. Furthermore, a known precursor of "hsa-miR-4516" is "hsa-mir-4516" (miRBase Accession No. MI0016882, SEQ ID NO: 511), which has a hairpin-like structure.

[0320] As used herein, the term "hsa-miR-4651 gene" or "hsa-miR-4651" encompasses the hsa-miR-4651 gene set forth in SEQ ID NO: 239 (miRBase Accession No. MIMAT0019715) as well as homologs or orthologs from other biological species. The hsa-miR-4651 gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, a known precursor of "hsa-miR-4651" is "hsa-mir-4651" (miRBase Accession No. MI0017279, SEQ ID NO: 512), which has a hairpin-like structure.

[0321] As used herein, the terms "hsa-miR-4725-3p gene" or "hsa-miR-4725-3p" encompass the hsa-miR-4725-3p gene set forth in SEQ ID NO: 240 (miRBase Accession No. MIMAT0019844) as well as homologs or orthologs from other biological species. The hsa-miR-4725-3p gene can be obtained by the method described in Persson H et al., 2011, Cancer Res, Vol. 71, pp. 78-86. Furthermore, the precursor of "hsa-miR-4725-3p" is known to be "hsa-mir-4725" (miRBase Accession No. MI0017362, SEQ ID NO: 513), which has a hairpin-like structure.

[0322] As used herein, the term "hsa-miR-6125 gene" or "hsa-miR-6125" encompasses the hsa-miR-6125 gene set forth in SEQ ID NO: 241 (miRBase Accession No. MIMAT0024598) and homologs or orthologs from other biological species. The hsa-miR-6125 gene can be obtained by the method described in Smith JL et al., 2012, J Virol, vol. 86, pp. 5278-5287. Furthermore, a known precursor of "hsa-miR-6125" is "hsa-mir-6125" (miRBase Accession No. MI0021259, SEQ ID NO: 514), which has a hairpin-like structure.

[0323] As used herein, the terms "hsa-miR-6732-5p gene" or "hsa-miR-6732-5p" encompass the hsa-miR-6732-5p gene set forth in SEQ ID NO: 242 (miRBase Accession No. MIMAT0027365) and homologs or orthologs from other organisms. The hsa-miR-6732-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6732-5p" is known to be "hsa-mir-6732" (miRBase Accession No. MI0022577, SEQ ID NO: 515), which has a hairpin-like structure.

[0324] As used herein, the term "hsa-miR-6791-5p gene" or "hsa-miR-6791-5p" encompasses the hsa-miR-6791-5p gene set forth in SEQ ID NO: 243 (miRBase Accession No. MIMAT0027482) and homologs or orthologs from other organisms. The hsa-miR-6791-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6791-5p" is known to be "hsa-mir-6791" (miRBase Accession No. MI0022636, SEQ ID NO: 516), which has a hairpin-like structure.

[0325] As used herein, the term "hsa-miR-6819-5p gene" or "hsa-miR-6819-5p" encompasses the hsa-miR-6819-5p gene set forth in SEQ ID NO: 244 (miRBase Accession No. MIMAT0027538) and homologs or orthologs from other organisms. The hsa-miR-6819-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6819-5p" is known to be "hsa-mir-6819" (miRBase Accession No. MI0022664, SEQ ID NO: 517), which has a hairpin-like structure.

[0326] As used herein, the term "hsa-miR-6891-5p gene" or "hsa-miR-6891-5p" encompasses the hsa-miR-6891-5p gene set forth in SEQ ID NO: 245 (miRBase Accession No. MIMAT0027682) and homologs or orthologs from other organisms. The hsa-miR-6891-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-6891-5p" is known to be "hsa-mir-6891" (miRBase Accession No. MI0022738, SEQ ID NO: 518), which has a hairpin-like structure.

[0327] As used herein, the terms "hsa-miR-7108-5p gene" or "hsa-miR-7108-5p" encompass the hsa-miR-7108-5p gene set forth in SEQ ID NO: 246 (miRBase Accession No. MIMAT0028113) and homologs or orthologs from other organisms. The hsa-miR-7108-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, "hsa-miR-7108-5p" is known to have a precursor, "hsa-mir-7108" (miRBase Accession No. MI0022959, SEQ ID NO: 448), which has a hairpin-like structure.

[0328] As used herein, the term "hsa-miR-7109-5p gene" or "hsa-miR-7109-5p" encompasses the hsa-miR-7109-5p gene set forth in SEQ ID NO: 247 (miRBase Accession No. MIMAT0028115) and homologs or orthologs from other biological species. The hsa-miR-7109-5p gene can be obtained by the method described in Ladewig E et al., 2012, Genome Res, vol. 22, pp. 1634-1645. Furthermore, the precursor of "hsa-miR-7109-5p" is known to be "hsa-mir-7109" (miRBase Accession No. MI0022960, SEQ ID NO: 519), which has a hairpin-like structure.

[0329] As used herein, the term "hsa-miR-320a gene" or "hsa-miR-320a" encompasses the hsa-miR-320a gene set forth in SEQ ID NO: 248 (miRBase Accession No. MIMAT0000510) and homologs or orthologs from other organisms. The hsa-miR-320a gene can be obtained by the method described in Michael MZ et al., 2003, Mol Cancer Res, Vol. 1, pp. 882-891. Furthermore, a known precursor of "hsa-miR-320a" is "hsa-mir-320a" (miRBase Accession No. MI0000542, SEQ ID NO: 520), which has a hairpin-like structure.

[0330] As used herein, the term "hsa-miR-663a gene" or "hsa-miR-663a" encompasses the hsa-miR-663a gene set forth in SEQ ID NO: 249 (miRBase Accession No. MIMAT0003326) and homologs or orthologs from other organisms. The hsa-miR-663a gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, pp. 3687-3692. Furthermore, a known precursor of "hsa-miR-663a" is "hsa-mir-663a" (miRBase Accession No. MI0003672, SEQ ID NO: 521), which has a hairpin-like structure.

[0331] As used herein, the terms "hsa-miR-328-5p gene" or "hsa-miR-328-5p" encompass the hsa-miR-328-5p gene set forth in SEQ ID NO: 250 (miRBase Accession No. MIMAT0026486) and homologs or orthologs from other organisms. The hsa-miR-328-5p gene can be obtained by the method described in Kim J et al., 2004, Proc Natl Acad Sci USA, vol. 101, pp. 360-365. Furthermore, the precursor of "hsa-miR-328-5p" is known to be "hsa-mir-328" (miRBase Accession No. MI0000804, SEQ ID NO: 522), which has a hairpin-like structure.

[0332] As used herein, the terms "hsa-miR-642b-3p gene" or "hsa-miR-642b-3p" encompass the hsa-miR-642b-3p gene set forth in SEQ ID NO: 251 (miRBase Accession No. MIMAT0018444) and homologs or orthologs from other organisms. The hsa-miR-642b-3p gene can be obtained by the method described in Witten D et al., 2010, BMC Biol, vol. 8, p. 58. Furthermore, the precursor of "hsa-miR-642b-3p" is known to be "hsa-mir-642b" (miRBase Accession No. MI0016685, SEQ ID NO: 523), which has a hairpin-like structure.

[0333] As used herein, the terms "hsa-miR-128-2-5p gene" or "hsa-miR-128-2-5p" encompass the hsa-miR-128-2-5p gene set forth in SEQ ID NO: 252 (miRBase Accession No. MIMAT0031095) and homologs or orthologs from other organisms. The hsa-miR-128-2-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, vol. 12, pp. 735-739. Furthermore, the precursor of "hsa-miR-128-2-5p" is known to be "hsa-mir-128-2" (miRBase Accession No. MI0000727, SEQ ID NO: 524), which has a hairpin-like structure.

[0334] As used herein, the terms "hsa-miR-125a-3p gene" or "hsa-miR-125a-3p" encompass the hsa-miR-125a-3p gene set forth in SEQ ID NO: 253 (miRBase Accession No. MIMAT0004602) and homologs or orthologs from other organisms. The hsa-miR-125a-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, vol. 12, pp. 735-739. Furthermore, the precursor of "hsa-miR-125a-3p" is known to be "hsa-mir-125a" (miRBase Accession No. MI0000469, SEQ ID NO: 525), which has a hairpin-like structure.

[0335] As used herein, the terms "hsa-miR-191-5p gene" or "hsa-miR-191-5p" encompass the hsa-miR-191-5p gene set forth in SEQ ID NO: 254 (miRBase Accession No. MIMAT0000440) and homologs or orthologs from other organisms. The hsa-miR-191-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2003, RNA, 9, pp. 175-179. Furthermore, the precursor of "hsa-miR-191-5p" is known to be "hsa-mir-191" (miRBase Accession No. MI0000465, SEQ ID NO: 526), which has a hairpin-like structure.

[0336] As used herein, the term "hsa-miR-92b-5p gene" or "hsa-miR-92b-5p" encompasses the hsa-miR-92b-5p gene set forth in SEQ ID NO: 255 (miRBase Accession No. MIMAT0004792) and homologs or orthologs from other biological species. The hsa-miR-92b-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, pp. 3687-3692. Furthermore, the precursor of "hsa-miR-92b-5p" is known to be "hsa-mir-92b" (miRBase Accession No. MI0003560, SEQ ID NO: 527), which has a hairpin-like structure.

[0337] As used herein, the terms "hsa-miR-296-5p gene" or "hsa-miR-296-5p" encompass the hsa-miR-296-5p gene set forth in SEQ ID NO: 256 (miRBase Accession No. MIMAT0000690) and homologs or orthologs from other organisms. The hsa-miR-296-5p gene can be obtained by the method described in Houbaviy HB et al., 2003, Dev Cell, vol. 5, pp. 351-358. Furthermore, "hsa-miR-296-5p" is known to have a precursor, "hsa-mir-296" (miRBase Accession No. MI0000747, SEQ ID NO: 336), which has a hairpin-like structure.

[0338] As used herein, the term "hsa-miR-1246 gene" or "hsa-miR-1246" encompasses the hsa-miR-1246 gene set forth in SEQ ID NO: 257 (miRBase Accession No. MIMAT0005898) as well as homologs or orthologs from other organisms. The hsa-miR-1246 gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, vol. 18, pp. 610-621. Furthermore, a known precursor of "hsa-miR-1246" is "hsa-mir-1246" (miRBase Accession No. MI0006381, SEQ ID NO: 528), which has a hairpin-like structure.

[0339] As used herein, the term "hsa-miR-92a-2-5p gene" or "hsa-miR-92a-2-5p" encompasses the hsa-miR-92a-2-5p gene set forth in SEQ ID NO: 258 (miRBase Accession No. MIMAT0004508) and homologs or orthologs from other organisms. The hsa-miR-92a-2-5p gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes Dev, vol. 16, pp. 720-728. Furthermore, the precursor of "hsa-miR-92a-2-5p" is known to be "hsa-mir-92a-2" (miRBase Accession No. MI0000094, SEQ ID NO: 529), which has a hairpin-like structure.

[0340] As used herein, the terms "hsa-miR-128-1-5p gene" or "hsa-miR-128-1-5p" encompass the hsa-miR-128-1-5p gene set forth in SEQ ID NO: 259 (miRBase Accession No. MIMAT0026477) and homologs or orthologs from other organisms. The hsa-miR-128-1-5p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, vol. 12, pp. 735-739. Furthermore, "hsa-miR-128-1-5p" is known to have a precursor, "hsa-mir-128-1" (miRBase Accession No. MI0000447, SEQ ID NO: 530), which has a hairpin-like structure.

[0341] As used herein, the term "hsa-miR-1290 gene" or "hsa-miR-1290" encompasses the hsa-miR-1290 gene set forth in SEQ ID NO: 260 (miRBase Accession No. MIMAT0005880) as well as homologs or orthologs from other biological species. The hsa-miR-1290 gene can be obtained by the method described in Morin RD et al., 2008, Genome Res, vol. 18, pp. 610-621. Furthermore, a known precursor of "hsa-miR-1290" is "hsa-mir-1290" (miRBase Accession No. MI0006352, SEQ ID NO: 531), which has a hairpin-like structure.

[0342] As used herein, the terms "hsa-miR-211-3p gene" or "hsa-miR-211-3p" encompass the hsa-miR-211-3p gene set forth in SEQ ID NO: 261 (miRBase Accession No. MIMAT0022694) and homologs or orthologs from other organisms. The hsa-miR-211-3p gene can be obtained by the method described in Lim LP et al., 2003, Science, vol. 299, p. 1540. Furthermore, the precursor of "hsa-miR-211-3p" is known to be "hsa-mir-211" (miRBase Accession No. MI0000287, SEQ ID NO: 532), which has a hairpin-like structure.

[0343] As used herein, the terms "hsa-miR-744-5p gene" or "hsa-miR-744-5p" encompass the hsa-miR-744-5p gene set forth in SEQ ID NO: 262 (miRBase Accession No. MIMAT0004945) and homologs or orthologs from other organisms. The hsa-miR-744-5p gene can be obtained by the method described in Berezikov E et al., 2006, Genome Res, vol. 16, pp. 1289-1298. Furthermore, the precursor of "hsa-miR-744-5p" is known to be "hsa-mir-744" (miRBase Accession No. MI0005559, SEQ ID NO: 533), which has a hairpin-like structure.

[0344] As used herein, the terms "hsa-miR-135a-3p gene" or "hsa-miR-135a-3p" encompass the hsa-miR-135a-3p gene set forth in SEQ ID NO: 263 (miRBase Accession No. MIMAT0004595) and homologs or orthologs from other organisms. The hsa-miR-135a-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, vol. 12, pp. 735-739. Furthermore, "hsa-miR-135a-3p" is known to have a precursor, "hsa-mir-135a-1" (miRBase Accession No. MI0000452, SEQ ID NO: 534), which has a hairpin-like structure.

[0345] As used herein, the term "hsa-miR-451a gene" or "hsa-miR-451a" encompasses the hsa-miR-451a gene set forth in SEQ ID NO: 264 (miRBase Accession No. MIMAT0001631) and homologs or orthologs from other organisms. The hsa-miR-451a gene can be obtained by the method described in Altuvia Y et al., 2005, Nucleic Acids Res, 33, pp. 2697-2706. Furthermore, "hsa-miR-451a" is known to have a precursor, "hsa-mir-451a" (miRBase Accession No. MI0001729, SEQ ID NO: 535), which has a hairpin-like structure.

[0346] As used herein, the terms "hsa-miR-625-3p gene" or "hsa-miR-625-3p" encompass the hsa-miR-625-3p gene set forth in SEQ ID NO: 265 (miRBase Accession No. MIMAT0004808) and homologs or orthologs from other organisms. The hsa-miR-625-3p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, pp. 3687-3692. Furthermore, the precursor of "hsa-miR-625-3p" is known to be "hsa-mir-625" (miRBase Accession No. MI0003639, SEQ ID NO: 536), which has a hairpin-like structure.

[0347] As used herein, the term "hsa-miR-92a-3p gene" or "hsa-miR-92a-3p" encompasses the hsa-miR-92a-3p gene set forth in SEQ ID NO: 266 (miRBase Accession No. MIMAT0000092) and homologs or orthologs from other biological species. The hsa-miR-92a-3p gene can be obtained by the method described in Mourelatos Z et al., 2002, Genes Dev, vol. 16, pp. 720-728. Furthermore, "hsa-miR-92a-3p" is known to have precursors, "hsa-mir-92a-1" and "hsa-mir-92a-2," which have a hairpin-like structure (miRBase Accession Nos. MI0000093 and MI0000094, SEQ ID NOs: 537 and 529).

[0348] As used herein, the term "hsa-miR-422a gene" or "hsa-miR-422a" encompasses the hsa-miR-422a gene set forth in SEQ ID NO: 267 (miRBase Accession No. MIMAT0001339) as well as homologs or orthologs from other organisms. The hsa-miR-422a gene can be obtained by the method described in Kasashima K et al., 2004, Biochem Biophys Res Commun, vol. 322, pp. 403-410. Furthermore, a known precursor of "hsa-miR-422a" is "hsa-mir-422a" (miRBase Accession No. MI0001444, SEQ ID NO: 538), which has a hairpin-like structure.

[0349] As used herein, the terms "hsa-miR-642a-3p gene" or "hsa-miR-642a-3p" encompass the hsa-miR-642a-3p gene set forth in SEQ ID NO: 268 (miRBase Accession No. MIMAT0020924) and homologs or orthologs from other organisms. The hsa-miR-642a-3p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, pp. 3687-3692. Furthermore, the precursor of "hsa-miR-642a-3p" is known to be "hsa-mir-642a" (miRBase Accession No. MI0003657, SEQ ID NO: 539), which has a hairpin-like structure.

[0350] As used herein, the terms "hsa-miR-483-5p gene" or "hsa-miR-483-5p" encompass the hsa-miR-483-5p gene set forth in SEQ ID NO: 269 (miRBase Accession No. MIMAT0004761) and homologs or orthologs from other organisms. The hsa-miR-483-5p gene can be obtained by the method described in Fu H et al., 2005, FEBS Lett., vol. 579, pp. 3849-3854. Furthermore, the precursor of "hsa-miR-483-5p" is known to be "hsa-mir-483" (miRBase Accession No. MI0002467, SEQ ID NO: 540), which has a hairpin-like structure.

[0351] As used herein, the terms "hsa-miR-652-5p gene" or "hsa-miR-652-5p" encompass the hsa-miR-652-5p gene set forth in SEQ ID NO: 270 (miRBase Accession No. MIMAT0022709) and homologs or orthologs from other biological species. The hsa-miR-652-5p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, pp. 3687-3692. Furthermore, the precursor of "hsa-miR-652-5p" is known to be "hsa-mir-652" (miRBase Accession No. MI0003667, SEQ ID NO: 541), which has a hairpin-like structure.

[0352] As used herein, the terms "hsa-miR-24-3p gene" or "hsa-miR-24-3p" encompass the hsa-miR-24-3p gene set forth in SEQ ID NO: 271 (miRBase Accession No. MIMAT0000080) and homologs or orthologs from other organisms. The hsa-miR-24-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science, vol. 294, pp. 853-858. Furthermore, "hsa-miR-24-3p" is known to have precursors, "hsa-mir-24-1" and "hsa-mir-24-2," which have a hairpin-like structure (miRBase Accession Nos. MI0000080 and MI0000081, SEQ ID NOs: 542 and 543).

[0353] As used herein, the terms "hsa-miR-23b-3p gene" or "hsa-miR-23b-3p" encompass the hsa-miR-23b-3p gene set forth in SEQ ID NO: 272 (miRBase Accession No. MIMAT0000418) and homologs or orthologs from other organisms. The hsa-miR-23b-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2002, Curr Biol, vol. 12, pp. 735-739. Furthermore, the precursor of "hsa-miR-23b-3p" is known to be "hsa-mir-23b" (miRBase Accession No. MI0000439, SEQ ID NO: 544), which has a hairpin-like structure.

[0354] As used herein, the terms "hsa-miR-23a-3p gene" or "hsa-miR-23a-3p" encompass the hsa-miR-23a-3p gene set forth in SEQ ID NO: 273 (miRBase Accession No. MIMAT0000078) and homologs or orthologs from other biological species. The hsa-miR-23a-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science, Vol. 294, pp. 853-858. Furthermore, the precursor of "hsa-miR-23a-3p" is known to be "hsa-mir-23a" (miRBase Accession No. MI0000079, SEQ ID NO: 545), which has a hairpin-like structure.

[0355] As used herein, the terms "hsa-miR-92b-3p gene" or "hsa-miR-92b-3p" encompass the hsa-miR-92b-3p gene set forth in SEQ ID NO: 274 (miRBase Accession No. MIMAT0003218) and homologs or orthologs from other organisms. The hsa-miR-92b-3p gene can be obtained by the method described in Cummins JM et al., 2006, Proc Natl Acad Sci USA, vol. 103, pp. 3687-3692. Furthermore, the precursor of "hsa-miR-92b-3p" is known to be "hsa-mir-92b" (miRBase Accession No. MI0003560, SEQ ID NO: 527), which has a hairpin-like structure.

[0356] As used herein, the terms "hsa-miR-22-3p gene" or "hsa-miR-22-3p" encompass the hsa-miR-22-3p gene set forth in SEQ ID NO: 275 (miRBase Accession No. MIMAT0000077) and homologs or orthologs from other organisms. The hsa-miR-22-3p gene can be obtained by the method described in Lagos-Quintana M et al., 2001, Science, vol. 294, pp. 853-858. Furthermore, the precursor of "hsa-miR-22-3p" is known to be "hsa-mir-22" (miRBase Accession No. MI0000078, SEQ ID NO: 546), which has a hairpin-like structure.

[0357] Furthermore, when mature miRNAs are excised from RNA precursors with hairpin-like structures, one to several bases before or after the sequence may be shortened or lengthened, or base substitutions may occur, resulting in mutants called isomiRs (Morin RD. et al., 2008, Genome Res., Vol. 18, pp. 610-621). In addition to the nucleotide sequences represented by SEQ ID NOs: 1 to 275, miRBase Release 21 also lists numerous mutants and fragments of the nucleotide sequences represented by SEQ ID NOs: 547 to 842, known as isomiRs. These mutants can also be obtained as miRNAs with the nucleotide sequences represented by SEQ ID NOs: 1 to 275. That is, SEQ ID NOs: 2, 3, 4, 8, 11, 14, 17, 18, 20, 24, 25, 29, 34, 36, 39, 40, 41, 42, 43, 44, 45, 51, 53, 55, 57, 59, 62, 63, 66, 67, 69, 70, 71, 72, 73, 75, 76, 78, 79, 84, 87, 88, 90, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 6, 98, 101, 102, 103, 104, 105, 110, 112, 113, 117, 119, 121, 122, 123, 124, 125, 127, 130, 136, 140, 141, 146, 148, 151, 153, 154, 159, 164, 166, 170, 175, 180, 184, 185, 189, 1 90, 193, 195, 196, 197, 198, 199, 201, 202, 203, 204, 205, 207, 210, 212, 213, 215, 217, 218, 219, 220, 221, 223, 224, 229, 232, 233, 238, 239, 240, 241, 248, 249, 250, 251, 252 , 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 269, 270, 271, 272, 274, and 275, or variants of polynucleotides consisting of the nucleotide sequences in which u is t in the nucleotide sequences, for example, the longest variants registered in miRBase Release 21 are SEQ ID NOs: 547, 549, 551, 554, 556, 560, 563, 565, 567, 570, 572, 574, 576, 578, 580, 582, 584, 586, 588, 590,592, 594, 596, 598, 600, 602, 604, 606, 608, 610, 612, 614, 616, 618, 620, 623, 625, 627, 629, 632, 634, 636, 638, 641, 644, 646, 649, 651, 653, 655, 657, 661, 663, 665, 668, 670, 672, 674, 676, 678, 680, 682, 685, 687, 689, 691, 694, 696, 698, 700, 702, 704, 707, 709, 711, 714, 717, 720, 722, 725, 72 7, 729, 731, 733, 735, 737, 739, 741, 743, 745, 747, 749, 751, 754, 756, 758, 760, 762, 764, 766, 768, 770, 772, 774, 776, 778, 780, 783, 785, 787, 789, 791, 793, 795, 797, 799, 801, 803, 805, 807, 809, 811, 813, 815, 817, 819, 821, 823, 825, 827, 830, 832, 834, 836, 839 and 841. Furthermore, SEQ ID NOs: 2, 3, 4, 8, 11, 14, 17, 18, 20, 24, 25, 29, 34, 36, 39, 40, 41, 42, 43, 44, 45, 51, 53, 55, 57, 59, 62, 63, 66, 67, 69, 70, 71, 72, 73, 75, 76, 78, 79, 84, 87, 88, 90, 94, 96, 98, 101, 102, 103, 104, 105, 110, 112, 113, 117, 119, 121, 122, 123, 124, 125, 127, 130, 136, 140, 141, 146, 148, 151, 153, 154, 159 , 164, 166, 170, 175, 180, 184, 185, 189, 190, 193, 195, 196, 197, 198, 199, 201, 202, 203, 204, 205, 207, 210, 212, 213, 215, 217, 218, 219, 220, 221, 223 , 224, 229, 232, 233, 238, 239, 240, 241, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263, 264, 265, 266, 269, 270, 271, 272,Among variants of the polynucleotides consisting of the nucleotide sequences represented by SEQ ID NOs: 274 and 275 or the nucleotide sequences in which u is replaced by t, for example, the shortest variants registered in miRBase Release 21 are those represented by SEQ ID NOs: 548, 550, 552, 555, 557, 561, 564, 566, 568, 571, 573, 575, 577, 579, 581, 583, 585, 587, 589, 591, 593, 595, 597, 599, 601, 603, 605, 607, 609, 611, 613, 615, 617, 619, 621, 624, 626, 628, 630, 633, 635, 637, 639, 642, 645, 647, 650, 652, 654, 656, 658, 662, 664, 666, 669, 671, 673, 675, 677, 679, 681, 683, 686, 688, 690, 692, 695, 6 97, 699, 701, 703, 705, 708, 710, 712, 715, 718, 721, 723, 726, 728, 730, 732, 734, 736, 738, 740, 742, 744, 746, 748, 750, 752, 755, 757, 759, 761, 763, 765, 767, 769, 771, 773, 775, 77 Examples of polynucleotides containing the nucleotide sequences represented by SEQ ID NOs: 1 to 275 include polynucleotides having the sequences represented by SEQ ID NOs: 7, 779, 781, 784, 786, 788, 790, 792, 794, 796, 798, 800, 802, 804, 806, 808, 810, 812, 814, 816, 818, 820, 822, 824, 826, 828, 831, 833, 835, 837, 840, and 842. In addition to these variants and fragments, examples of polynucleotides containing the nucleotide sequences represented by SEQ ID NOs: 1 to 275 include the polynucleotides represented by SEQ ID NOs: 276 to 546, which are precursors of the respective polynucleotides.

[0358] The names of the genes represented by SEQ ID NOs: 1 to 842 and their miRBase Accession Nos. (registration numbers) are shown in Table 1.

[0359] As used herein, the term "capable of specifically binding" means that a nucleic acid such as a nucleic acid probe or primer used in the present invention binds to a specific target nucleic acid and is substantially incapable of binding to other nucleic acids.

[0360] [Table 1] TIFF2025118873000002.tif243129TIFF2025118873000003.tif243131TIFF20251188730 00004.tif243134TIFF2025118873000005.tif243132TIFF2025118873000006.tif243132 TIFF2025118873000007.tif242132TIFF2025118873000008.tif243132TIFF20251188730 00009.tif242130TIFF2025118873000010.tif242131TIFF2025118873000011.tif242130 TIFF2025118873000012.tif243131TIFF2025118873000013.tif243131TIFF20251188730 00014.tif243131TIFF2025118873000015.tif243131TIFF2025118873000016.tif244132 TIFF2025118873000017.tif243133TIFF2025118873000018.tif243132TIFF20251188730 00019.tif243131TIFF2025118873000020.tif243132TIFF2025118873000021.tif243131 TIFF2025118873000022.tif243135TIFF2025118873000023.tif204134 [Effects of the Invention]

[0361] The present invention makes it possible to easily and accurately detect ovarian tumors. For example, by using the measured expression levels of one to several miRNAs in the patient's blood, serum, and / or plasma, which can be collected minimally invasively, as an indicator, it is possible to easily detect whether a patient has ovarian tumors.

[0362] This specification includes the disclosure of Japanese Patent Application No. 2017-090799, from which the present application claims priority. [Brief explanation of the drawings]

[0363] [Figure 1] This figure shows the relationship between the base sequences of hsa-miR-4433a-5p, represented by sequence number 128, which is generated from its precursor hsa-mir-4433a, represented by sequence number 405, and hsa-miR-4433a-3p, represented by sequence number 151. [Figure 2] Left: The vertical axis shows the measured expression levels of hsa-miR-4675 (SEQ ID NO: 1) in the serum of healthy individuals (280 individuals) and ovarian tumor patients (303 individuals) selected as the training sample group. The horizontal line in the figure indicates the threshold (7.75) optimized by Fisher's discriminant analysis for discriminating between the two groups. Right: The vertical axis shows the measured expression levels of hsa-miR-4675 (SEQ ID NO: 1) in healthy individuals (120 individuals) and ovarian tumor patients (131 individuals) selected as the test sample group. The horizontal line in the figure indicates the threshold (7.75) set in the training sample group for discriminating between the two groups. [Figure 3]Upper panel: hsa-miR-296-5p (SEQ ID NO: 256), hsa-miR-3131 (SEQ ID NO: 196), hsa-miR-1290 (SEQ ID NO: 260), hsa-miR-642a-3p (SEQ ID NO: 268), and hsa-miR-1290 (SEQ ID NO: 260) in the serum of subjects without ovarian tumors (280 healthy subjects, 257 patients with benign bone and soft tissue tumors and benign breast diseases, and 280 patients with cancers other than ovarian cancer, a total of 817 subjects) and ovarian tumor patients (303 subjects) selected as the learning sample group. A discriminant equation was created using Fisher's discriminant analysis from the measured expression levels of R-128-2-5p (SEQ ID NO: 252) (1.390xhsa-miR-296-5p-1.095xhsa-miR-3131+0.201xhsa-miR-1290+0.695xhsa-miR-642a-3p+0.306xhsa-miR-128-2-5p-13.186), and the discriminant score obtained from the discriminant equation is plotted on the vertical axis and the sample group on the horizontal axis. The dotted line in the figure indicates the discriminant boundary for discriminating between the two groups where the discriminant score is 0. The figure below shows the levels of hsa-miR-296-5p (SEQ ID NO: 256), hsa-miR-3131 (SEQ ID NO: 196), hsa-miR-1290 (SEQ ID NO: 260), hsa-miR-642a-3p (SEQ ID NO: 268), and miR-3131 (SEQ ID NO: 196) in the serum of subjects without ovarian tumors (120 healthy subjects, 111 patients with benign bone and soft tissue tumors and benign breast diseases, and 120 patients with cancers other than ovarian cancer, a total of 351 subjects) and ovarian tumor patients (131 subjects) selected as the test sample group. The measured values of the expression levels of miR-128-2-5p (SEQ ID NO: 252) and miR-296-5p were substituted into the discriminant (1.390 x miR-296-5p - 1.095 x miR-3131 + 0.201 x miR-1290 + 0.695 x miR-642a-3p + 0.306 x miR-128-2-5p - 13.186) created for the training sample group. The discriminant score obtained is shown on the vertical axis, and the sample group is shown on the horizontal axis. The dotted line in the figure indicates the discriminant boundary for discriminating between the two groups, where the discriminant score is 0. DETAILED DESCRIPTION OF THE INVENTION

[0364] The present invention will be described in more detail below. 1. Targeted nucleic acids for ovarian tumorsThe main target nucleic acids as ovarian tumor markers for detecting the presence and / or absence of ovarian tumors or ovarian tumor cells using nucleic acids such as the nucleic acid probes or primers for detecting ovarian tumors defined above according to the present invention include hsa-miR-4675, hsa-miR-4783-3p, hsa-miR-1228-5p, hsa-miR-4532, hsa-miR-6802-5p, hsa-miR-6784-5p, hsa-miR-3940-5p, hsa-miR-1307-3p, hsa-miR-8073, hsa-miR-3184 ... a-miR-1233-5p, hsa-miR-6088, hsa-miR-5195-3p, hsa-miR-320b, hsa-miR-4649-5p, hsa-miR-6800-5p, hsa-miR-1343-3p, hsa-miR-4730, hsa-miR -6885-5p, hsa-miR-5100, hsa-miR-1203, hsa-miR-6756-5p, hsa-miR-373-5p, hsa-miR-1268a, hsa-miR-1260b, hsa-miR-4258, hsa-miR-4697-5p, h sa-miR-1469, hsa-miR-4515, hsa-miR-6861-5p, hsa-miR-6821-5p, hsa-miR-575, hsa-miR-6805-5p, hsa-miR-4758-5p, hsa-miR-3663-3p, hsa-miR -4530, hsa-miR-6798-5p, hsa-miR-6781-5p, hsa-miR-885-3p, hsa-miR-1273g-3p, hsa-miR-4787-3p, hsa-miR-4454, hsa-miR-4706, hsa-miR-1249 -3p, hsa-miR-887-3p, hsa-miR-6786-5p, hsa-miR-1238-5p, hsa-miR-6749-5p, hsa-miR-6729-5p, hsa-miR-6825-5p, hsa-miR-663b, hsa-miR-6858 -5p, hsa-miR-4690-5p, hsa-miR-6765-5p, hsa-miR-4710, hsa-miR-6775-5p, hsa-miR-371a-5p, hsa-miR-6816-5p, hsa-miR-296-3p, hsa-miR-7977,hsa-miR-8069, hsa-miR-6515-3p, hsa-miR-4687-5p, hsa-miR-1343-5p, hsa-miR-7110-5p, hsa-miR-4525, hsa-miR-3158-5p, hsa-miR-6787-5p, hs a-miR-614, hsa-miR-4689, hsa-miR-1185-2-3p, hsa-miR-1268b, hsa-miR-1228-3p, hsa-miR-1185-1-3p, hsa-miR-940, hsa-miR-939-5p, hsa-miR- 6757-5p、hsa-miR-1275、hsa-miR-5001-5p、hsa-miR-6826-5p、hsa-miR-6765-3p、hsa-miR-3679-3p、hsa-miR-4718、hsa-miR-4286、hsa-miR-8059、 hsa-miR-4447, hsa-miR-4448, hsa-miR-658, hsa-miR-6766-3p, hsa-miR-197-5p, hsa-miR-6887-5p, hsa-miR-6742-5p, hsa-miR-6729-3p, hsa-miR- 5090, hsa-miR-7975, hsa-miR-4505, hsa-miR-6889-5p, hsa-miR-4708-3p, hsa-miR-6131, hsa-miR-1225-3p, hsa-miR-6132, hsa-miR-4734, hsa-mi R-3194-3p, hsa-miR-638, hsa-miR-2467-3p, hsa-miR-4728-5p, hsa-miR-5572, hsa-miR-6789-5p, hsa-miR-8063, hsa-miR-4429, hsa-miR-6840-3p hsa-miR-4476, hsa-miR-675-5p, hsa-miR-711, hsa-miR-6875-5p, hsa-miR-3160-5p, hsa-miR-1908-5p, hsa-miR-6726-5p, hsa-miR-1913, hsa-mi R-8071, hsa-miR-3648, hsa-miR-4732-5p, hsa-miR-4787-5p, hsa-miR-3917, hsa-miR-619-5p, hsa-miR-1231, hsa-miR-342-5p, hsa-miR-4433a-5phsa-miR-6766-5p, hsa-miR-4707-5p, hsa-miR-7114-5p, hsa-miR-6872-3p, hsa-miR-6780b-5p, hsa-miR-7845-5p, hsa-miR-6798-3p, hsa-miR-665 hsa-miR-6848-5p, hsa-miR-5008-5p, hsa-miR-4294, hsa-miR-6511a-5p, hsa-miR-4435, hsa-miR-4747-3p, hsa-miR-6880-3p, hsa-miR-6869-5p, hs a-miR-7150, hsa-miR-1260a, hsa-miR-6877-5p, hsa-miR-6721-5p, hsa-miR-4656, hsa-miR-1229-5p, hsa-miR-4433a-3p, hsa-miR-4274, hsa-miR-4 419b, hsa-miR-4674, hsa-miR-6893-5p, hsa-miR-6763-3p, hsa-miR-6762-5p, hsa-miR-6738-5p, hsa-miR-4513, hsa-miR-6746-5p, hsa-miR-6880-5 p、hsa-miR-4736、hsa-miR-718、hsa-miR-6717-5p、hsa-miR-7847-3p、hsa-miR-760、hsa-miR-1199-5p、hsa-miR-6813-5p、hsa-miR-6769a-5p、hsa-m iR-1193, hsa-miR-7108-3p, hsa-miR-6741-5p, hsa-miR-4298, hsa-miR-6796-3p, hsa-miR-4750-5p, hsa-miR-6785-5p, hsa-miR-1292-3p, hsa-miR- 4749-3p、hsa-miR-6800-3p、hsa-miR-4722-5p、hsa-miR-4746-3p、hsa-miR-4450、hsa-miR-6795-5p、hsa-miR-365a-5p、hsa-miR-498、hsa-miR-6797 -5p、hsa-miR-1470、hsa-miR-6851-5p、hsa-miR-1247-3p、hsa-miR-5196-5p、hsa-miR-208a-5p、hsa-miR-6842-5p、hsa-miR-150-3p、hsa-miR-4534、hsa-miR-3135b, hsa-miR-3131, hsa-miR-4792, hsa-miR-6510-5p, hsa-miR-504-3p, hsa-miR-3619-3p, hsa-miR-671-5p, hsa- miR-4667-5p, hsa-miR-4430, hsa-miR-3195, hsa-miR-3679-5p, hsa-miR-6076, hsa-miR-6515-5p, hsa-miR-6820-5p, hsa-miR -4634, hsa-miR-187-5p, hsa-miR-6763-5p, hsa-miR-1908-3p, hsa-miR-1181, hsa-miR-6782-5p, hsa-miR-5010-5p, hsa-miR- 6870-5p, hsa-miR-6124, hsa-miR-1249-5p, hsa-miR-6511b-5p, hsa-miR-1254, hsa-miR-4727-3p, hsa-miR-4259, hsa-miR-477 1, hsa-miR-3622a-5p, hsa-miR-4480, hsa-miR-4740-5p, hsa-miR-6777-5p, hsa-miR-6794-5p, hsa-miR-4687-3p, hsa-miR-67 43-5p, hsa-miR-6771-5p, hsa-miR-3141, hsa-miR-3162-5p, hsa-miR-4271, hsa-miR-1227-5p, hsa-miR-4257, hsa-miR-4270, h The miR-1 and miR-2 include at least one miRNA selected from the group consisting of hsa-miR-4516, hsa-miR-4651, hsa-miR-4725-3p, hsa-miR-6125, hsa-miR-6732-5p, hsa-miR-6791-5p, hsa-miR-6819-5p, hsa-miR-6891-5p, hsa-miR-7108-5p, hsa-miR-7109-5p, hsa-miR-642b-3p, and hsa-miR-642a-3p. Furthermore, other ovarian tumor markers that can be combined with these miRNAs, namely, hsa-miR-320a, hsa-miR-663a, hsa-miR-328-5p, hsa-miR-128-2-5p, hsa-miR-125a-3p, hsa-miR-191-5p, hsa-miR-92b-5p,hsa-miR-296-5p, hsa-miR-1246, hsa-miR-92a-2-5p, hsa-miR-128-1-5p, hsa-miR-1290, hsa-mi R-211-3p, hsa-miR-744-5p, hsa-miR-135a-3p, hsa-miR-451a, hsa-miR-625-3p, hsa-miR-92a-3p At least one miRNA selected from the group consisting of hsa-miR-422a, hsa-miR-483-5p, hsa-miR-652-5p, hsa-miR-24-3p, hsa-miR-23b-3p, hsa-miR-23a-3p, hsa-miR-92b-3p, and hsa-miR-22-3p can also be preferably used as the target nucleic acid.

[0365] The above miRNAs include, for example, human genes containing the nucleotide sequences represented by any of SEQ ID NOs: 1 to 275 (i.e., hsa-miR-4675, hsa-miR-4783-3p, hsa-miR-1228-5p, hsa-miR-4532, hsa-miR-6802-5p, hsa-miR-6784-5p, hsa-miR-3940-5p, hsa-miR-1307-3p, hsa-miR-8073, hsa-miR-3184-5p, hsa-miR-1233-5p, hsa-miR-6088, hsa-miR-5195- 3p, hsa-miR-320b, hsa-miR-4649-5p, hsa-miR-6800-5p, hsa-miR-1343-3p, hsa-miR-4730, hsa-miR-6885-5p, hsa-miR-5100, hsa-miR-1203, hsa-mi R-6756-5p, hsa-miR-373-5p, hsa-miR-1268a, hsa-miR-1260b, hsa-miR-4258, hsa-miR-4697-5p, hsa-miR-1469, hsa-miR-4515, hsa-miR-6861-5p, h sa-miR-6821-5p, hsa-miR-575, hsa-miR-6805-5p, hsa-miR-4758-5p, hsa-miR-3663-3p, hsa-miR-4530, hsa-miR-6798-5p, hsa-miR-6781-5p, hsa-m iR-885-3p, hsa-miR-1273g-3p, hsa-miR-4787-3p, hsa-miR-4454, hsa-miR-4706, hsa-miR-1249-3p, hsa-miR-887-3p, hsa-miR-6786-5p, hsa-miR-1 238-5p, hsa-miR-6749-5p, hsa-miR-6729-5p, hsa-miR-6825-5p, hsa-miR-663b, hsa-miR-6858-5p, hsa-miR-4690-5p, hsa-miR-6765-5p, hsa-miR-4 710, hsa-miR-6775-5p, hsa-miR-371a-5p, hsa-miR-6816-5p, hsa-miR-296-3p, hsa-miR-7977, hsa-miR-8069, hsa-miR-6515-3p, hsa-miR-4687-5p,hsa-miR-1343-5p, hsa-miR-7110-5p, hsa-miR-4525, hsa-miR-3158-5p, hsa-miR-6787-5p, hsa-miR-614, hsa-miR-4689, hsa-miR-1185-2-3p, hsa- miR-1268b, hsa-miR-1228-3p, hsa-miR-1185-1-3p, hsa-miR-940, hsa-miR-939-5p, hsa-miR-6757-5p, hsa-miR-1275, hsa-miR-5001-5p, hsa-miR-6 826-5p、hsa-miR-6765-3p、hsa-miR-3679-3p、hsa-miR-4718、hsa-miR-4286、hsa-miR-8059、hsa-miR-4447、hsa-miR-4448、hsa-miR-658、hsa-miR- 6766-3p、hsa-miR-197-5p、hsa-miR-6887-5p、hsa-miR-6742-5p、hsa-miR-6729-3p、hsa-miR-5090、hsa-miR-7975、hsa-miR-4505、hsa-miR-6889-5p hsa-miR-4708-3p, hsa-miR-6131, hsa-miR-1225-3p, hsa-miR-6132, hsa-miR-4734, hsa-miR-3194-3p, hsa-miR-638, hsa-miR-2467-3p, hsa-miR- 4728-5p、hsa-miR-5572、hsa-miR-6789-5p、hsa-miR-8063、hsa-miR-4429、hsa-miR-6840-3p、hsa-miR-4476、hsa-miR-675-5p、hsa-miR-711、hsa-mi R-6875-5p, hsa-miR-3160-5p, hsa-miR-1908-5p, hsa-miR-6726-5p, hsa-miR-1913, hsa-miR-8071, hsa-miR-3648, hsa-miR-4732-5p, hsa-miR-4787 -5p、hsa-miR-3917、hsa-miR-619-5p、hsa-miR-1231、hsa-miR-342-5p、hsa-miR-4433a-5p、hsa-miR-6766-5p、hsa-miR-4707-5p、hsa-miR-7114-5p、hsa-miR-6872-3p, hsa-miR-6780b-5p, hsa-miR-7845-5p, hsa-miR-6798-3p, hsa-miR-665, hsa-miR-6848-5p, hsa-miR-5008-5p, hsa-miR-4294, hs a-miR-6511a-5p, hsa-miR-4435, hsa-miR-4747-3p, hsa-miR-6880-3p, hsa-miR-6869-5p, hsa-miR-7150, hsa-miR-1260a, hsa-miR-6877-5p, hsa-m iR-6721-5p, hsa-miR-4656, hsa-miR-1229-5p, hsa-miR-4433a-3p, hsa-miR-4274, hsa-miR-4419b, hsa-miR-4674, hsa-miR-6893-5p, hsa-miR-676 3-3p、hsa-miR-6762-5p、hsa-miR-6738-5p、hsa-miR-4513、hsa-miR-6746-5p、hsa-miR-6880-5p、hsa-miR-4736、hsa-miR-718、hsa-miR-6717-5p、h sa-miR-7847-3p, hsa-miR-760, hsa-miR-1199-5p, hsa-miR-6813-5p, hsa-miR-6769a-5p, hsa-miR-1193, hsa-miR-7108-3p, hsa-miR-6741-5p, hsa -miR-4298、hsa-miR-6796-3p、hsa-miR-4750-5p、hsa-miR-6785-5p、hsa-miR-1292-3p、hsa-miR-4749-3p、hsa-miR-6800-3p、hsa-miR-4722-5p、hs a-miR-4746-3p、hsa-miR-4450、hsa-miR-6795-5p、hsa-miR-365a-5p、hsa-miR-498、hsa-miR-6797-5p、hsa-miR-1470、hsa-miR-6851-5p、hsa-miR- 1247-3p、hsa-miR-5196-5p、hsa-miR-208a-5p、hsa-miR-6842-5p、hsa-miR-150-3p、hsa-miR-4534、hsa-miR-3135b、hsa-miR-3131、hsa-miR-4792、hsa-miR-6510-5p、hsa-miR-504-3p、hsa-miR-3619-3p、hsa-miR-671-5p、hsa-miR-4667-5p、hsa-miR-4430、hsa-miR-3195、hsa-miR-3679-5p、hsa -miR-6076, hsa-miR-6515-5p, hsa-miR-6820-5p, hsa-miR-4634, hsa-miR-187-5p, hsa-miR-6763-5p, hsa-miR-1908-3p, hsa-miR-1181, hsa-miR-6 782-5p、hsa-miR-5010-5p、hsa-miR-6870-5p、hsa-miR-6124、hsa-miR-1249-5p、hsa-miR-6511b-5p、hsa-miR-1254、hsa-miR-4727-3p、hsa-miR-4 259, hsa-miR-4771, hsa-miR-3622a-5p, hsa-miR-4480, hsa-miR-4740-5p, hsa-miR-6777-5p, hsa-miR-6794-5p, hsa-miR-4687-3p, hsa-miR-6743- 5p, hsa-miR-6771-5p, hsa-miR-3141, hsa-miR-3162-5p, hsa-miR-4271, hsa-miR-1227-5p, hsa-miR-4257, hsa-miR-4270, hsa-miR-4516, hsa-miR -4651、hsa-miR-4725-3p、hsa-miR-6125、hsa-miR-6732-5p、hsa-miR-6791-5p、hsa-miR-6819-5p、hsa-miR-6891-5p、hsa-miR-7108-5p、hsa-miR-6 42b-3p、hsa-miR-642a-3p、hsa-miR-7109-5p、hsa-miR-320a、hsa-miR-66 3a、hsa-miR-328-5p、hsa-miR-128-2-5p、hsa-miR-125a-3p、hsa-miR-191 -5p、hsa-miR-92b-5p、hsa-miR-296-5p、hsa-miR-1246、hsa-miR-92a-2-5p、hsa-miR-128-1-5p、hsa-miR-1290、hsa-miR-211-3p、hsa-miR-744-5p、These include miR-135a-3p, hsa-miR-451a, hsa-miR-625-3p, hsa-miR-92a-3p, hsa-miR-422a, hsa-miR-483-5p, hsa-miR-652-5p, hsa-miR-24-3p, hsa-miR-23b-3p, hsa-miR-23a-3p, hsa-miR-92b-3p, and hsa-miR-22-3p), their homologs, their transcription products, and / or their mutants or derivatives, where gene, homolog, transcription product, mutant, and derivative are as defined above.

[0366] Preferred target nucleic acids are human genes comprising the nucleotide sequence shown in any of SEQ ID NOs: 1 to 842, or transcription products thereof, more preferably such transcription products, ie, miRNAs, or their precursor RNAs, pri-miRNAs or pre-miRNAs.

[0367] The first target gene is the hsa-miR-4675 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0368] The second target gene is the hsa-miR-4783-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0369] The third target gene is the hsa-miR-1228-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products could be markers for ovarian tumors.

[0370] The fourth target gene is the hsa-miR-4532 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0371] The fifth target gene is the hsa-miR-6802-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0372] The sixth target gene is the hsa-miR-6784-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0373] The seventh target gene is the hsa-miR-3940-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0374] The eighth target gene is the hsa-miR-1307-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0375] The ninth target gene is the hsa-miR-8073 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0376] The tenth target gene is the hsa-miR-3184-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0377] The eleventh target gene is the hsa-miR-1233-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0378] The twelfth target gene is the hsa-miR-6088 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0379] The thirteenth target gene is the hsa-miR-5195-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0380] The 14th target gene is the hsa-miR-320b gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0381] The 15th target gene is the hsa-miR-4649-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0382] The 16th target gene is the hsa-miR-6800-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0383] The 17th target gene is the hsa-miR-1343-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0384] The 18th target gene is the hsa-miR-4730 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0385] The 19th target gene is the hsa-miR-6885-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0386] The 20th target gene is the hsa-miR-5100 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0387] The 21st target gene is the hsa-miR-1203 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products can be markers for ovarian tumors.

[0388] The 22nd target gene is the hsa-miR-6756-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0389] The 23rd target gene is the hsa-miR-373-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0390] The 24th target gene is the hsa-miR-1268a gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0391] The 25th target gene is the hsa-miR-1260b gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0392] The 26th target gene is the hsa-miR-4258 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0393] The 27th target gene is the hsa-miR-4697-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0394] The 28th target gene is the hsa-miR-1469 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0395] The 29th target gene is the hsa-miR-4515 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0396] The 30th target gene is the hsa-miR-6861-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0397] The 31st target gene is the hsa-miR-6821-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0398] The 32nd target gene is the hsa-miR-575 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0399] The 33rd target gene is the hsa-miR-6805-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0400] The 34th target gene is the hsa-miR-4758-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0401] The 35th target gene is the hsa-miR-3663-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0402] The 36th target gene is the hsa-miR-4530 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0403] The 37th target gene is the hsa-miR-6798-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0404] The 38th target gene is the hsa-miR-6781-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0405] The 39th target gene is the hsa-miR-885-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0406] The 40th target gene is the hsa-miR-1273g-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0407] The 41st target gene is the hsa-miR-4787-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0408] The 42nd target gene is the hsa-miR-4454 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0409] The 43rd target gene is the hsa-miR-4706 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0410] The 44th target gene is the hsa-miR-1249-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0411] The 45th target gene is the hsa-miR-887-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0412] The 46th target gene is the hsa-miR-6786-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0413] The 47th target gene is the hsa-miR-1238-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0414] The 48th target gene is the hsa-miR-6749-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0415] The 49th target gene is the hsa-miR-6729-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0416] The 50th target gene is the hsa-miR-6825-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0417] The 51st target gene is the hsa-miR-663b gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0418] The 52nd target gene is the hsa-miR-6858-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0419] The 53rd target gene is the hsa-miR-4690-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0420] The 54th target gene is the hsa-miR-6765-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0421] The 55th target gene is the hsa-miR-4710 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0422] The 56th target gene is the hsa-miR-6775-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0423] The 57th target gene is the hsa-miR-371a-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0424] The 58 target genes are the hsa-miR-6816-5p gene, its homologs, its transcripts, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcripts could be markers for ovarian tumors.

[0425] The 59th target gene is the hsa-miR-296-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0426] The 60th target gene is the hsa-miR-7977 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0427] The 61st target gene is the hsa-miR-8069 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0428] The 62nd target gene is the hsa-miR-6515-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0429] The 63rd target gene is the hsa-miR-4687-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0430] The 64th target gene is the hsa-miR-1343-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0431] The 65th target gene is the hsa-miR-7110-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0432] The 66th target gene is the hsa-miR-4525 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0433] The 67th target gene is the hsa-miR-3158-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0434] The 68th target gene is the hsa-miR-6787-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0435] The 69th target gene is the hsa-miR-614 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0436] The 70th target gene is the hsa-miR-4689 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0437] The 71st target gene is the hsa-miR-1185-2-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0438] The 72nd target gene is the hsa-miR-1268b gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0439] The 73rd target gene is the hsa-miR-1228-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0440] The 74th target gene is the hsa-miR-1185-1-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0441] The 75th target gene is the hsa-miR-940 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0442] The 76th target gene is the hsa-miR-939-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0443] The 77th target gene is the hsa-miR-6757-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0444] The 78th target gene is the hsa-miR-1275 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0445] The 79th target gene is the hsa-miR-5001-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0446] The 80th target gene is the hsa-miR-6826-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products could be markers for ovarian tumors.

[0447] The 81st target gene is the hsa-miR-6765-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0448] The 82nd target gene is the hsa-miR-3679-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0449] The 83rd target gene is the hsa-miR-4718 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0450] The 84th target gene is the hsa-miR-4286 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0451] The 85th target gene is the hsa-miR-8059 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0452] The 86th target gene is the hsa-miR-4447 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0453] The 87th target gene is the hsa-miR-4448 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0454] The 88th target gene is the hsa-miR-658 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0455] The 89th target gene is the hsa-miR-6766-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0456] The 90th target gene is the hsa-miR-197-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0457] The 91st target gene is the hsa-miR-6887-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0458] The 92nd target gene is the hsa-miR-6742-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0459] The 93rd target gene is the hsa-miR-6729-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0460] The 94th target gene is the hsa-miR-5090 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0461] The 95th target gene is the hsa-miR-7975 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0462] The 96th target gene is the hsa-miR-4505 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0463] The 97th target gene is the hsa-miR-6889-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0464] The 98th target gene is the hsa-miR-4708-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products could be a marker for ovarian tumors.

[0465] The 99th target gene is the hsa-miR-6131 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0466] The 100th target gene is the hsa-miR-1225-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0467] The 101st target gene is the hsa-miR-6132 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0468] The 102nd target gene is the hsa-miR-4734 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0469] The 103rd target gene is the hsa-miR-3194-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0470] The 104th target gene is the hsa-miR-638 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0471] The 105th target gene is the hsa-miR-2467-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0472] The 106th target gene is the hsa-miR-4728-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0473] The 107th target gene is the hsa-miR-5572 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0474] The 108th target gene is the hsa-miR-6789-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0475] The 109th target gene is the hsa-miR-8063 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products can be markers for ovarian tumors.

[0476] The 110th target gene is the hsa-miR-4429 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0477] The 111th target gene is the hsa-miR-6840-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0478] The 112th target gene is the hsa-miR-4476 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0479] The 113th target gene is the hsa-miR-675-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0480] The 114th target gene is the hsa-miR-711 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0481] The 115th target gene is the hsa-miR-6875-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0482] The 116th target gene is the hsa-miR-3160-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0483] The 117th target gene is the hsa-miR-1908-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products can be markers for ovarian tumors.

[0484] The 118th target gene is the hsa-miR-6726-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0485] The 119th target gene is the hsa-miR-1913 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products can be markers for ovarian tumors.

[0486] The 120th target gene is the hsa-miR-8071 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products can be markers for ovarian tumors.

[0487] The 121st target gene is the hsa-miR-3648 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0488] The 122nd target gene is the hsa-miR-4732-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0489] The 123rd target gene is the hsa-miR-4787-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0490] The 124th target gene is the hsa-miR-3917 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0491] The 125th target gene is the hsa-miR-619-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0492] The 126th target gene is the hsa-miR-1231 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0493] The 127th target gene is the hsa-miR-342-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0494] The 128th target gene is the hsa-miR-4433a-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0495] The 129th target gene is the hsa-miR-6766-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0496] The 130th target gene is the hsa-miR-4707-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0497] The 131st target gene is the hsa-miR-7114-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0498] The 132nd target gene is the hsa-miR-6872-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0499] The 133rd target gene is the hsa-miR-6780b-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0500] The 134th target gene is the hsa-miR-7845-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0501] The 135th target gene is the hsa-miR-6798-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0502] The 136th target gene is the hsa-miR-665 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0503] The 137th target gene is the hsa-miR-6848-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0504] The 138th target gene is the hsa-miR-5008-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0505] The 139th target gene is the hsa-miR-4294 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0506] The 140th target gene is the hsa-miR-6511a-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0507] The 141st target gene is the hsa-miR-4435 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0508] The 142nd target gene is the hsa-miR-4747-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0509] The 143rd target gene is the hsa-miR-6880-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0510] The 144th target gene is the hsa-miR-6869-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0511] The 145th target gene is the hsa-miR-7150 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0512] The 146th target gene is the hsa-miR-1260a gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0513] The 147th target gene is the hsa-miR-6877-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0514] The 148th target gene is the hsa-miR-6721-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0515] The 149th target gene is the hsa-miR-4656 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0516] The 150th target gene is the hsa-miR-1229-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0517] The 151st target gene is the hsa-miR-4433a-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0518] The 152nd target gene is the hsa-miR-4274 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0519] The 153rd target gene is the hsa-miR-4419b gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0520] The 154th target gene is the hsa-miR-4674 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0521] The 155th target gene is the hsa-miR-6893-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0522] The 156th target gene is the hsa-miR-6763-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0523] The 157th target gene is the hsa-miR-6762-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0524] The 158th target gene is the hsa-miR-6738-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0525] The 159th target gene is the hsa-miR-4513 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0526] The 160th target gene is the hsa-miR-6746-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0527] The 161st target gene is the hsa-miR-6880-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0528] The 162nd target gene is the hsa-miR-4736 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0529] The 163rd target gene is the hsa-miR-718 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products can be markers for ovarian tumors.

[0530] The 164th target gene is the hsa-miR-6717-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0531] The 165th target gene is the hsa-miR-7847-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0532] The 166th target gene is the hsa-miR-760 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0533] The 167th target gene is the hsa-miR-1199-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0534] The 168th target gene is the hsa-miR-6813-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0535] The 169th target gene is the hsa-miR-6769a-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0536] The 170th target gene is the hsa-miR-1193 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products can be markers for ovarian tumors.

[0537] The 171st target gene is the hsa-miR-7108-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products can be markers for ovarian tumors.

[0538] The 172nd target gene is the hsa-miR-6741-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0539] The 173rd target gene is the hsa-miR-4298 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0540] The 174th target gene is the hsa-miR-6796-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0541] The 175th target gene is the hsa-miR-4750-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0542] The 176th target gene is the hsa-miR-6785-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0543] The 177th target gene is the hsa-miR-1292-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0544] The 178th target gene is the hsa-miR-4749-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0545] The 179th target gene is the hsa-miR-6800-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0546] The 180th target gene is the hsa-miR-4722-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0547] The 181st target gene is the hsa-miR-4746-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0548] The 182nd target gene is the hsa-miR-4450 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0549] The 183rd target gene is the hsa-miR-6795-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0550] The 184th target gene is the hsa-miR-365a-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0551] The 185th target gene is the hsa-miR-498 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0552] The 186th target gene is the hsa-miR-6797-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0553] The 187th target gene is the hsa-miR-1470 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0554] The 188th target gene is the hsa-miR-6851-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0555] The 189th target gene is the hsa-miR-1247-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0556] The 190th target gene is the hsa-miR-5196-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0557] The 191st target gene is the hsa-miR-208a-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products can be markers for ovarian tumors.

[0558] The 192nd target gene is the hsa-miR-6842-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0559] The 193rd target gene is the hsa-miR-150-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0560] The 194th target gene is the hsa-miR-4534 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0561] The 195th target gene is the hsa-miR-3135b gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0562] The 196th target gene is the hsa-miR-3131 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0563] The 197th target gene is the hsa-miR-4792 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of genes or their transcription products can be markers for ovarian tumors.

[0564] The 198th target gene is the hsa-miR-6510-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0565] The 199th target gene is the hsa-miR-504-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0566] The 200th target gene is the hsa-miR-3619-3p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0567] The 201st target gene is the hsa-miR-671-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0568] The 202nd target gene is the hsa-miR-4667-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0569] The 203rd target gene is the hsa-miR-4430 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0570] The 204th target gene is the hsa-miR-3195 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0571] The 205th target gene is the hsa-miR-3679-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0572] The 206th target gene is the hsa-miR-6076 gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0573] The 207th target gene is the hsa-miR-6515-5p gene, its homologs, its transcription products, or their mutants or derivatives. There have been no reports to date that altered expression of the gene or its transcription products can be a marker for ovarian tumors.

[0574] The 208th target gene is the hsa-miR-6820-5p gene, its homologs, its transcr...

Claims

1. A kit for detecting ovarian tumors, comprising a nucleic acid capable of specifically binding to a polynucleotide of miR-675-5p, an ovarian tumor marker, or a polynucleotide consisting of a strand complementary to said polynucleotide.

2. The kit according to claim 1, wherein the nucleic acid is selected from the group consisting of the polynucleotides (a) to (e) below or fragments thereof: (a) (1) A polynucleotide consisting of the base sequence represented by SEQ ID NO: 113 or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; (2) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof of (1), (3) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (1), (4) A polynucleotide or a fragment thereof according to any one of (1) to (3) containing a modified nucleic acid and / or a modified nucleotide. (b) a polynucleotide containing the base sequence represented by SEQ ID NO: 113 or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; (c) (5) A polynucleotide consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 113 or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; (6) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof of (5). (7) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (5). (8) A polynucleotide or a fragment thereof according to any one of (5) to (7) containing a modified nucleic acid and / or a modified nucleotide. (d) a polynucleotide containing a base sequence complementary to the base sequence represented by SEQ ID NO: 113 or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; and (e) A polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (a) to (d) or a fragment thereof.

3. The kit includes another ovarian tumor marker, miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, miR-6887-5p, miR-6742-5p, miR-6729-3pmiR-5090、miR-7975、miR-4505、miR-6889-5p、miR-4708-3p、miR-6131、mi R-1225-3p、miR-6132、miR-4734、miR-3194-3p、miR-638、miR-2467-3p、miR -4728-5p、miR-5572、miR-6789-5p、miR-8063、miR-4429、miR-6840-3p、mi R-4476、miR-711、miR-6875-5p、miR-3160-5p、miR-1908-5p、miR-6726-5p、 miR-1913、miR-8071、miR-3648、miR-4732-5p、miR-4787-5p、miR-3917、mi R-619-5p、miR-1231、miR-342-5p、miR-4433a-5p、miR-6766-5p、miR-4707- 5p、miR-7114-5p、miR-6872-3p、miR-6780b-5p、miR-7845-5p、miR-6798-3 p、miR-665、miR-6848-5p、miR-5008-5p、miR-4294、miR-6511a-5p、miR-443 5、miR-4747-3p、miR-6880-3p、miR-6869-5p、miR-7150、miR-1260a、miR-6 877-5p、miR-6721-5p、miR-4656、miR-1229-5p、miR-4433a-3p、miR-4274、m iR-4419b、miR-4674、miR-6893-5p、miR-6763-3p、miR-6762-5p、miR-6738 -5p、miR-4513、miR-6746-5p、miR-6880-5p、miR-4736、miR-718、miR-6717- 5p、miR-7847-3p、miR-760、miR-1199-5p、miR-6813-5p、miR-6769a-5p、mi R-1193、miR-7108-3p、miR-6741-5p、miR-4298、miR-6796-3p、miR-4750-5p 、miR-6785-5p、miR-1292-3p、miR-4749-3p、miR-6800-3p、miR-4722-5p、mi R-4746-3p、miR-4450、miR-6795-5p、miR-365a-5p、miR-498、miR-6797-5p、a group consisting of miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR-208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619-3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR-6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-6794-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p; and / or miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3p, miR-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3pand miR-22-3p, or a polynucleotide consisting of a complementary strand of said polynucleotide.

4. The kit according to claim 3, wherein the nucleic acid is selected from the group consisting of the polynucleotides (f) to (j) below or fragments thereof: (f) (9) A polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (10) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof according to (9). (11) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (9). (12) A polynucleotide or a fragment thereof according to any one of (9) to (11) containing a modified nucleic acid and / or a modified nucleotide. (g) a polynucleotide containing a base sequence represented by any one of SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (h) (13) A polynucleotide consisting of a base sequence complementary to any of SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (14) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof according to (13). (15) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (13). (16) A polynucleotide or a fragment thereof according to any one of (13) to (15) containing a modified nucleic acid and / or a modified nucleotide. (i) A polynucleotide containing a base sequence complementary to any of the base sequences represented by SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; (j) A polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (f) to (i) above or a fragment thereof.

5. A device for detecting ovarian tumors, comprising a nucleic acid capable of specifically binding to a polynucleotide of miR-675-5p, an ovarian tumor marker, or a polynucleotide consisting of a complementary strand of said polynucleotide.

6. The device according to claim 5, wherein the nucleic acid is selected from the group consisting of the polynucleotides (a) to (e) below or fragments thereof: (a) (1) A polynucleotide consisting of the base sequence represented by SEQ ID NO: 113 or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; (2) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof of (1), (3) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (1), (4) A polynucleotide or a fragment thereof according to any one of (1) to (3) containing a modified nucleic acid and / or a modified nucleotide. (b) a polynucleotide containing the base sequence represented by SEQ ID NO: 113 or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; (c) (5) A polynucleotide consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 113 or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; (6) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof of (5). (7) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (5). (8) A polynucleotide or a fragment thereof according to any one of (5) to (7) containing a modified nucleic acid and / or a modified nucleotide. (d) a polynucleotide containing a base sequence complementary to the base sequence represented by SEQ ID NO: 113 or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; and (e) A polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (a) to (d) or a fragment thereof.

7. The device is another ovarian tumor marker, miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, miR-6887-5p, miR-6742-5p, miR-6729-3pmiR-5090、miR-7975、miR-4505、miR-6889-5p、miR-4708-3p、miR-6131、mi R-1225-3p、miR-6132、miR-4734、miR-3194-3p、miR-638、miR-2467-3p、miR -4728-5p、miR-5572、miR-6789-5p、miR-8063、miR-4429、miR-6840-3p、mi R-4476、miR-711、miR-6875-5p、miR-3160-5p、miR-1908-5p、miR-6726-5p、 miR-1913、miR-8071、miR-3648、miR-4732-5p、miR-4787-5p、miR-3917、mi R-619-5p、miR-1231、miR-342-5p、miR-4433a-5p、miR-6766-5p、miR-4707- 5p、miR-7114-5p、miR-6872-3p、miR-6780b-5p、miR-7845-5p、miR-6798-3 p、miR-665、miR-6848-5p、miR-5008-5p、miR-4294、miR-6511a-5p、miR-443 5、miR-4747-3p、miR-6880-3p、miR-6869-5p、miR-7150、miR-1260a、miR-6 877-5p、miR-6721-5p、miR-4656、miR-1229-5p、miR-4433a-3p、miR-4274、m iR-4419b、miR-4674、miR-6893-5p、miR-6763-3p、miR-6762-5p、miR-6738 -5p、miR-4513、miR-6746-5p、miR-6880-5p、miR-4736、miR-718、miR-6717- 5p、miR-7847-3p、miR-760、miR-1199-5p、miR-6813-5p、miR-6769a-5p、mi R-1193、miR-7108-3p、miR-6741-5p、miR-4298、miR-6796-3p、miR-4750-5p 、miR-6785-5p、miR-1292-3p、miR-4749-3p、miR-6800-3p、miR-4722-5p、mi R-4746-3p、miR-4450、miR-6795-5p、miR-365a-5p、miR-498、miR-6797-5p、a group consisting of miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR-208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619-3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR-6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-6794-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p; and / or miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3p, miR-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3pand miR-22-3p, or a polynucleotide consisting of a complementary strand of said polynucleotide.

8. The device according to claim 7, wherein the nucleic acid is selected from the group consisting of the polynucleotides (f) to (j) below or fragments thereof: (f) (9) A polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (10) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof according to (9). (11) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (9). (12) A polynucleotide or a fragment thereof according to any one of (9) to (11) containing a modified nucleic acid and / or a modified nucleotide. (g) a polynucleotide containing a base sequence represented by any one of SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (h) (13) A polynucleotide consisting of a base sequence complementary to any of SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (14) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof according to (13). (15) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (13). (16) A polynucleotide or a fragment thereof according to any one of (13) to (15) containing a modified nucleic acid and / or a modified nucleotide. (i) A polynucleotide containing a base sequence complementary to any of the base sequences represented by SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; (j) A polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (f) to (i) above or a fragment thereof.

9. The device according to any one of claims 5 to 8, which is a device for measurement by hybridization technology.

10. The device of claim 9 , wherein the hybridization technology is a nucleic acid array technology.

11. A method for assisting in the detection of ovarian tumors, comprising measuring an expression level in a specimen from a subject of a polynucleotide of miR-675-5p, which is an ovarian tumor marker, and evaluating in vitro whether the subject is affected with an ovarian tumor or not using the measured expression level, A method in which the evaluation is an evaluation aid based on the results of an in vitro test, not a medical doctor's judgment.

12. A method for assisting in the detection of ovarian tumors, comprising measuring the expression level of target nucleic acid miR-675-5p in a specimen from a subject using a nucleic acid capable of specifically binding to a polynucleotide of miR-675-5p, an ovarian tumor marker, or a polynucleotide consisting of a complementary strand of said polynucleotide, or using the kit according to any one of claims 1 to 4 or the device according to any one of claims 5 to 10, which contains said nucleic acid, and evaluating in vitro whether the subject is affected with or not affected by an ovarian tumor using the measured expression level and a control expression level of a healthy subject similarly measured, A method in which the evaluation is an evaluation aid based on the results of an in vitro test, not a medical doctor's judgment.

13. A method for assisting in the detection of ovarian tumors, comprising: measuring the expression level of a target gene, which is the miR-675-5p gene, in a specimen from a subject using a nucleic acid capable of specifically binding to a polynucleotide of miR-675-5p, which is an ovarian tumor marker, or a polynucleotide consisting of a complementary strand of said polynucleotide, or using the kit according to any one of claims 1 to 4 or the device according to any one of claims 5 to 10, which contains said nucleic acid; and substituting the expression level of the target gene in the specimen from the subject into a discriminant that is capable of discriminating between the presence or absence of an ovarian tumor, the discriminant being prepared using the gene expression levels of specimens derived from subjects known to have an ovarian tumor and the gene expression levels of specimens derived from subjects not affected by ovarian tumors as teacher samples, and that is capable of discriminating between the presence or absence of an ovarian tumor, thereby evaluating the presence or absence of an ovarian tumor in vitro, A method in which the evaluation is an evaluation aid based on the results of an in vitro test, not a medical doctor's judgment.

14. The method according to claim 12 or 13, wherein the nucleic acid is selected from the group consisting of the polynucleotides (a) to (e) below or fragments thereof: (a) (1) A polynucleotide consisting of the base sequence represented by SEQ ID NO: 113, or the base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (2) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof of (1), (3) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (1), (4) A polynucleotide or a fragment thereof according to any one of (1) to (3) containing a modified nucleic acid and / or a modified nucleotide. (b) a polynucleotide containing the base sequence represented by SEQ ID NO: 113 or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; (c) (5) A polynucleotide consisting of a base sequence complementary to the base sequence represented by SEQ ID NO: 113, or the base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (6) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof of (5). (7) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (5). (8) A polynucleotide or a fragment thereof according to any one of (5) to (7) containing a modified nucleic acid and / or a modified nucleotide. (d) a polynucleotide containing a base sequence complementary to the base sequence represented by SEQ ID NO: 113, or the base sequence in which u is t, or a fragment thereof containing 15 or more consecutive bases; and (e) A polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (a) to (d) or a fragment thereof.

15. Other ovarian tumor markers, miR-4675, miR-4783-3p, miR-1228-5p, miR-4532, miR-6802-5p, miR-6784-5p, miR-3940-5p, miR-1307-3p, miR-8073, miR-3184-5p, miR-6088, miR-5195-3p, miR-320b, miR-4649-5p, miR-6800-5p, miR-1343-3p, miR-4730, miR-6885-5p, miR-5100, miR-1203, miR-6756-5p, miR-373-5p, miR-1268a, miR-1260b, miR-4258, miR-4697-5p, miR-1469, miR-4515, miR-6861-5p, miR-6821-5p, miR-575, miR-6805-5p, miR-4758-5p, miR-3663-3p, miR-4530, miR-6781-5p, miR-885-3p, miR-1273g-3p, miR-4787-3p, miR-4454, miR-4706, miR-1249-3p, miR-887-3p, miR-6786-5p, miR-1238-5p, miR-6749-5p, miR-6729-5p, miR-6825-5p, miR-663b, miR-6858-5p, miR-4690-5p, miR-6765-5p, miR-4710, miR-6775-5p, miR-371a-5p, miR-6816-5p, miR-296-3p, miR-7977, miR-8069, miR-6515-3p, miR-4687-5p, miR-1343-5p, miR-7110-5p, miR-4525, miR-3158-5p, miR-6787-5p, miR-614, miR-4689, miR-1185-2-3p, miR-1268b, miR-1228-3p, miR-1185-1-3p, miR-940, miR-939-5p, miR-6757-5p, miR-1275, miR-5001-5p, miR-6826-5p, miR-3679-3p, miR-4718, miR-4286, miR-8059, miR-4447, miR-4448, miR-658, miR-6766-3p, miR-197-5p, miR-6887-5p, miR-6742-5p, miR-6729-3pmiR-5090、miR-7975、miR-4505、miR-6889-5p、miR-4708-3p、miR-6131、mi R-1225-3p、miR-6132、miR-4734、miR-3194-3p、miR-638、miR-2467-3p、miR -4728-5p、miR-5572、miR-6789-5p、miR-8063、miR-4429、miR-6840-3p、mi R-4476、miR-711、miR-6875-5p、miR-3160-5p、miR-1908-5p、miR-6726-5p、 miR-1913、miR-8071、miR-3648、miR-4732-5p、miR-4787-5p、miR-3917、mi R-619-5p、miR-1231、miR-342-5p、miR-4433a-5p、miR-6766-5p、miR-4707- 5p、miR-7114-5p、miR-6872-3p、miR-6780b-5p、miR-7845-5p、miR-6798-3 p、miR-665、miR-6848-5p、miR-5008-5p、miR-4294、miR-6511a-5p、miR-443 5、miR-4747-3p、miR-6880-3p、miR-6869-5p、miR-7150、miR-1260a、miR-6 877-5p、miR-6721-5p、miR-4656、miR-1229-5p、miR-4433a-3p、miR-4274、m iR-4419b、miR-4674、miR-6893-5p、miR-6763-3p、miR-6762-5p、miR-6738 -5p、miR-4513、miR-6746-5p、miR-6880-5p、miR-4736、miR-718、miR-6717- 5p、miR-7847-3p、miR-760、miR-1199-5p、miR-6813-5p、miR-6769a-5p、mi R-1193、miR-7108-3p、miR-6741-5p、miR-4298、miR-6796-3p、miR-4750-5p 、miR-6785-5p、miR-1292-3p、miR-4749-3p、miR-6800-3p、miR-4722-5p、mi R-4746-3p、miR-4450、miR-6795-5p、miR-365a-5p、miR-498、miR-6797-5p、a group consisting of miR-1470, miR-6851-5p, miR-1247-3p, miR-5196-5p, miR-208a-5p, miR-6842-5p, miR-150-3p, miR-4534, miR-3135b, miR-3131, miR-4792, miR-6510-5p, miR-504-3p, miR-3619-3p, miR-671-5p, miR-4667-5p, miR-4430, miR-3195, miR-3679-5p, miR-6076, miR-6515-5p, miR-6820-5p, miR-4634, miR-187-5p, miR-6763-5p, miR-1908-3p, miR-1181, miR-6782-5p, miR-5010-5p, miR-6870-5p, miR-6124, miR-1249-5p, miR-6511b-5p, miR-1254, miR-4727-3p, miR-4259, miR-4771, miR-3622a-5p, miR-4480, miR-4740-5p, miR-6777-5p, miR-6794-5p, miR-4687-3p, miR-6743-5p, miR-6771-5p, miR-3141, miR-3162-5p, miR-4271, miR-1227-5p, miR-4257, miR-4270, miR-4516, miR-4651, miR-4725-3p, miR-6125, miR-6732-5p, miR-6791-5p, miR-6819-5p, miR-6891-5p, miR-7108-5p, miR-7109-5p, miR-642b-3p, and miR-642a-3p; and / or miR-320a, miR-663a, miR-328-5p, miR-128-2-5p, miR-125a-3p, miR-191-5p, miR-92b-5p, miR-296-5p, miR-1246, miR-92a-2-5p, miR-128-1-5p, miR-1290, miR-211-3p, miR-744-5p, miR-135a-3p, miR-451a, miR-625-3p, miR-92a-3p, miR-422a, miR-483-5p, miR-652-5p, miR-24-3p, miR-23b-3p, miR-23a-3p, miR-92b-3pand miR-22-3p, and performing the in vitro evaluation using the measured expression level in combination with the expression level of miR-675-5p in the subject's specimen; The evaluation is an evaluation support based on the results of an in vitro test, not a judgment by a doctor. The method according to any one of claims 11 to 14.

16. The method according to claim 15, wherein the expression level of the at least one polynucleotide in a specimen of a subject is measured using a nucleic acid capable of specifically binding to each of the at least one polynucleotide or a polynucleotide consisting of a complementary strand of the polynucleotide, and the nucleic acid is selected from the group consisting of polynucleotides shown in (f) to (j) below or fragments thereof: (f) (9) A polynucleotide consisting of a base sequence represented by any one of SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (10) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof according to (9). (11) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (9). (12) A polynucleotide or a fragment thereof according to (9) to (11) containing a modified nucleic acid and / or a modified nucleotide. (g) a polynucleotide containing a base sequence represented by any one of SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (h) (13) A polynucleotide consisting of a base sequence complementary to any of the base sequences represented by SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (14) A polynucleotide or a fragment thereof containing a deletion, substitution, addition, or insertion of one or two bases in the base sequence of the polynucleotide or a fragment thereof according to (13). (15) A polynucleotide or a fragment thereof showing 90% or more identity with the base sequence of the polynucleotide or a fragment thereof of (13). (16) A polynucleotide or a fragment thereof according to any one of (13) to (15) containing a modified nucleic acid and / or a modified nucleotide. (i) A polynucleotide containing a base sequence complementary to any of the base sequences represented by SEQ ID NOs: 1 to 10, 12 to 36, 38 to 80, 82 to 112, and 114 to 275, or a base sequence in which u is t in the base sequence, or a fragment thereof containing 15 or more consecutive bases; (j) A polynucleotide that hybridizes under stringent conditions with any one of the polynucleotides (f) to (i) above or a fragment thereof.

17. The method of any one of claims 11 to 16, wherein the subject is a human.

18. The method according to any one of claims 11 to 17, wherein the sample is blood, serum, or plasma.